Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists

ABSTRACT

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, 
                         
wherein L, X, R a , R b , R 1 , R 2  and R 3  are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

The present invention relates to amide derivatives, processes for theirpreparation, pharmaceutical compositions containing them and their usein therapy, particularly in the treatment or prevention of conditionshaving an association with the orexin sub-type 1 receptor.

The orexin peptides (orexin A and orexin B, OxA and OxB), also known ashypocretins, were discovered in 1998 bp two groups (Sakurai et al.,Cell, 1998, 92, 573 and De Lecea et al., Proc. Nat. Acad. Sci., 1998,95, 322). These neuropeptides are both derived from the common precursorpre-pro-orexin and are produced in the lateral hypothalamus. OxA is a 33amino acid residue which has similar potency at both the Ox1R (orexin 1receptors) and Ox2R (orexin 2 receptors) whereas OxB is made up of 28amino acids and binds selectively to the Ox2R.

Orexin receptors are believed to be implicated in both feeding behaviour(Sakurai et al., Cell, 1998, 92, 573) and also in regulating sleeparchitecture (Chemelli et al., Cell, 1999, 98, 437). More recently, ithas been shown that orexin receptors are implicated in arousal, reward,learning and memory (Harris et al., Trends Neurosci., 2006, 29, 571).

WO 2003/099276 describes a broad class of compounds, including certainamides, which are useful as factor Xa inhibitors for treatingthromboembolic disorders.

We have now discovered a class of compounds that are orexin receptorantagonists. Furthermore, certain compounds of the invention showselectivity for the orexin 1 receptor over the orexin 2 receptor.

In accordance with the present invention, there is therefore provided acompound of formula

wherein

R¹ represents a 5- or 6-membered heteroaryl group optionally substitutedby at least one substituent independently selected from halogen, cyano,hydroxyl, C₃-C₆ cycloalkyl, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃alkoxycarbonyl, C₁-C₃ alkoxycarbonylamino, C₁-C₃ haloalkyl, C₁-C₃haloalkoxy, —NR⁴R⁵, C₃-C₆ cycloalkylamino, C₁-C₃ alkylcarbonyloxy, C₁-C₃alkylcarbonylamino, sulphonamido (—SO₂NH₂), C₁-C₃ alkylsulphonyl, C₁-C₃alkylsulphonylamino and —C(O)NR⁶R⁷;

L represents a bond, CH₂, O or NR¹²;

R^(a) represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkylgroup;

R^(b) represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkylgroup;

X represents CH₂, CHF or CF₂;

R² represents a hydrogen atom or a C₁-C₆ alkyl or C₃-C₆ cycloalkylgroup;

R³ represents a phenyl group or a 5- or 6-membered heteroaryl group, alloptionally substituted by at least one substituent independentlyselected from halogen, hydroxyl, cyano, C₁-C₃ alkyl, C₁-C₃ haloalkyl,C₁-C₃ hydroxyalkyl, C₁-C₃ alkoxy, C₁-C₃ haloalkoxy, C₂-C₄ alkenyl, C₁-C₃alkylcarbonyloxy, C₁-C₃ alkoxycarbonyl, —NR⁸R⁹, —C(O)NR¹⁰R¹¹, C₃-C₆cycloalkyl, C₃-C₆ cycloalkyloxy, C₃-C₆ cycloalkylmethyl or a 5- or6-membered heteroaryl group, the heteroaryl group itself beingoptionally substituted by at least one substituent independentlyselected from C₁-C₆ alkyl, C₁-C₆ alkoxy and C₁-C₆ haloalkoxy;

R⁴ and R⁵ each independently represent a hydrogen atom or a C₁-C₃ alkylor C₃-C₆ cycloalkyl group, or R⁴ and R⁵ may together with the nitrogenatom to which they are attached form a 4- to 7-membered saturatedheterocyclic ring optionally substituted by at least one substituentindependently selected from halogen, hydroxyl and C₁-C₃ alkoxy;

R⁶ and R⁷ each independently represent a hydrogen atom or a C₁-C₃ alkylor C₃-C₆ cycloalkyl group, or R⁶ and R⁷ may together with the nitrogenatom to which they are attached form a 4- to 7-membered saturatedheterocyclic ring optionally substituted by at least one substituentindependently selected from halogen and hydroxyl;

R⁸ and R⁹ each independently represent a hydrogen atom or a C₁-C₃ alkylor C₃-C₆ cycloalkyl group, or R⁸ and R⁹ may together with the nitrogenatom to which they are attached form a 4- to 7-membered saturatedheterocyclic ring optionally substituted by at least one substituentindependently selected from halogen, hydroxyl and C₁-C₃ alkoxy;

R¹⁰ and R¹¹ each independently represent a hydrogen atom or a C₁-C₃alkyl or C₃-C₆ cycloalkyl group, or R¹⁰ and R¹¹ may together with thenitrogen atom to which they are attached form a 4- to 7-memberedsaturated heterocyclic ring optionally substituted by at least onesubstituent independently selected from halogen and hydroxyl; and

R¹² represents a hydrogen atom, methyl group or a C₂-C₃ alkylene chainthat links to R¹ to form a 5- or 6-membered ring;

or a pharmaceutically acceptable salt thereof.

In the context of the present specification, unless otherwise stated, an“alkyl” substituent group or an alkyl moiety in a substituent group maybe linear or branched. Examples of C₁-C₈ alkyl groups/moieties includemethyl, ethyl, propyl, 2-methyl-1-propyl, 2-methyl-2-propyl,2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl,2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl,4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl,4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl,2-ethyl-1-butyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl,neopentyl, n-hexyl, n-heptyl and n-octyl.

An “alkenyl” substituent group or an alkenyl moiety in a substituentgroup refers to an unsaturated alkyl group having one or more doublebonds. Examples of C₂-C₆ alkenyl groups/moieties include ethenyl,propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl,1,3-pentadienyl, 1,4-pentadienyl and 1,4-hexadienyl.

A “cycloalkyl” substituent group/moiety is a saturated hydrocarbyl ringcontaining, for example, from 3 to 8 carbon atoms, examples of whichinclude cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

A “haloalkyl” or “haloalkoxy” substituent group/moiety comprises atleast one halogen atom, e.g. one, two, three, four or five halogenatoms. Examples of C₁-C₆ haloalkyl and C₁-C₆ haloalkoxy groups/moietiesinclude fluoromethyl, difluoromethyl, trifluoromethyl,2,2,2-trifluoroethyl, pentafluoroethyl, fluoromethoxy, difluoromethoxyand trifluoromethoxy.

It will be understood that if R⁴ and R⁵ together with the nitrogen atomto which they are attached form a 4- to 7-membered saturatedheterocyclic ring, the heterocyclic ring may contain one or more (e.g.one or two) further ring heteroatoms (e.g. nitrogen, oxygen or sulphuratoms) in addition to the nitrogen atom to which R⁴ and R⁵ are attached.However, it will be appreciated that the invention does not encompassany unstable ring structures or any O—O, O—S or S—S bonds. If asubstituent is present on the ring, it may be attached to any suitablering atom. Examples of such heterocyclic rings include azetidinyl,pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazinyl,1,4-azathianyl, azepanyl and 1,4-oxaazepanyl moieties. Similar commentsapply with respect to R⁶ and R⁷, R⁸ and R⁹, and R¹⁰ and R¹¹ when theyform a 4- to 7-membered saturated heterocyclic ring.

A “heteroaryl” group is a 5- or 6-membered aryl group in which from 1 to4 ring carbon atoms are replaced by heteroatoms independently selectedfrom nitrogen, oxygen and sulphur. The heteroaryl group can be bonded atany suitable ring atom (i.e. at any carbon or heteroatom of theheteroaryl ring system).

When any chemical moiety or group in formula (I) is described as beingoptionally substituted, it will be appreciated that the moiety or groupmay be either unsubstituted or substituted by one or more of thespecified substituents. It will be appreciated that the number andnature of substituents will be selected so as to avoid stericallyundesirable combinations.

R¹ represents a 5- or 6-membered heteroaryl group optionally substitutedby at least one substituent, e.g. one, two, three or four substituents,independently selected from halogen (e.g. fluorine, chlorine, bromine oriodine), cyano, hydroxyl, C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl,cyclopentyl or cyclohexyl), C₁, C₂ or C₃ alkyl, C₁, C₂ or C₃ alkoxy, C₁,C₂ or C₃ alkoxycarbonyl, C₁, C₂ or C₃ alkoxycarbonylamino, C₁, C₂ or C₃haloalkyl, C₁, C₂ or C₃ haloalkoxy, —NR⁴R⁵, C₃-C₆ cycloalkylamino(cyclopropylamino, cyclobutylamino, cyclopentylamino orcyclohexylamino), C₁, C₂ or C₃ alkylcarbonyloxy, C₁, C₂ or C₃alkylcarbonylamino, sulphonamido, C₁, C₂ or C₃ alkylsulphonyl, C₁, C₂ orC₃ alkylsulphonylamino and —C(O)NR⁶R⁷.

R¹ represents a 5- or 6-membered heteroaryl group. This R¹ heteroarylgroup comprises one or more, e.g. one, two, three or four, ringheteroatoms independently selected from nitrogen, oxygen and sulphur.Examples of such 5- or 6-membered monocyclic heteroaromatic groupsinclude pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl,furyl, furazanyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl,isoxazolyl, thiadiazolyl and tetrazinyl.

In an embodiment of the invention, R¹ represents a 5- or 6-memberedheteroaryl group containing one or two ring heteroatoms independentlyselected from nitrogen, oxygen and sulphur (such as pyridinyl,pyrimidinyl and pyrazinyl), the heteroaryl group being optionallysubstituted by at least one substituent, e.g. one, two, three or foursubstituents, independently selected from halogen (e.g. fluorine,chlorine, bromine or iodine), cyano, hydroxyl, C₃-C₆ cycloalkyl(cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C₁, C₂ or C₃alkyl, C₁, C₂ or C₃ alkoxy, C₁, C₂ or C₃ alkoxycarbonyl, C₁, C₂ or C₃alkoxycarbonylamino, C₁, C₂ or C₃ haloalkyl, C₁, C₂ or C₃ haloalkoxy,—NR⁴R⁵, C₃-C₆ cycloalkylamino (cyclopropylamino, cyclobutylamino,cyclopentylamino or cyclohexylamino), C₁, C₂ or C₃ alkylcarbonyloxy, C₁,C₂ or C₃ alkylcarbonylamino, sulphonamido, C₁, C₂ or C₃ alkylsulphonyl,C₁, C₂ or C₃ alkylsulphonylamino and —C(O)NR⁶R⁷.

In another embodiment, R¹ represents a 5- or 6-membered heteroaryl groupcontaining one or two ring heteroatoms independently selected fromnitrogen and oxygen (such as pyridinyl, pyrimidinyl and pyrazinyl), theheteroaryl group being optionally substituted by one, two, three or foursubstituents independently selected from halogen (e.g. fluorine,chlorine, bromine or iodine), cyano, hydroxyl, C₃-C₆ cycloalkyl, C₁, C₂or C₃ alkyl, C₁, C₂ or C₃ alkoxy, C₁, C₂ or C₃ alkoxycarbonyl, C₁, C₂ orC₃ alkoxycarbonylamino, C₁, C₂ or C₃ haloalkyl, C₁, C₂ or C₃ haloalkoxy,—NR⁴R⁵, C₅-C₆ cycloalkylamino, C₁, C₂ or C₃ alkylcarbonyloxy, C₁, C₂ orC₃ alkylcarbonylamino, sulphonamido, C₁, C₂ or C₃ alkylsulphonyl, C₁, C₂or C₃ alkylsulphonylamino and —C(O)NR⁶R⁷.

In a further embodiment, R¹ represents a 6-membered heteroaryl groupcontaining as the only ring heteroatoms one or two ring nitrogen atoms(such as pyridinyl, pyrimidinyl and pyrazinyl), the heteroaryl groupbeing optionally substituted by one, two, three or four (particularlyone or two) substituents independently selected from halogen(particularly fluorine, chlorine and bromine), cyclopropyl, C₁, C₂ or C₃alkyl (particularly methyl, ethyl and isopropyl), C₁, C₂ or C₃ alkoxy(particularly methoxy), C₁, C₂ or C₃ haloalkyl (particularlytrifluoromethyl) and C₁, C₂ or C₃ haloalkoxy (particularlytrifluoromethoxy).

In a still further embodiment, R¹ represents any one of the followingmoieties or is selected from a group containing two or more of suchmoieties in any combination:

-   (i) 4-(trifluoromethyl)pyridin-2-yl,-   (ii) 5-(trifluoromethyl)pyridin-2-yl,-   (iii) 5-(trifluoromethoxy)pyridin-2-yl,-   (iv) 6-(trifluoromethyl)pyridin-2-yl,-   (v) 6-(trifluoromethyl)pyridin-3-yl,-   (vi) 5-chloropyridin-2-yl,-   (vii) 5-bromopyridin-2-yl,-   (viii) 3-fluoro-5-(trifluoromethyl)pyridin-2-yl,-   (ix) 3-chloro-5-(trifluoromethyl)pyridin-2-yl,-   (x) 3-bromo-5-(trifluoromethyl)pyridin-2-yl,-   (xi) 5-bromo-3-methoxypyridin-2-yl,-   (xii) 3-methyl-5-(trifluoromethyl)pyridin-2-yl,-   (xiii) 5-(trifluoromethyl)pyrimidin-2-yl,-   (xiv) 5-ethylpyrimidin-2-yl,-   (xv) 5-(trifluoromethyl)pyrazin-2-yl,-   (xvi) 5-chloropyrazin-2-yl,-   (xvii) 5-(ethyl)pyrazin-2-yl,-   (xviii) 5-(cyclopropyl)pyrazin-2-yl,-   (xix) 5-(isopropyl)pyrazin-2-yl,-   (xx) 3-methyl-5-(trifluoromethyl)pyrazin-2-yl,-   (xxi) 3-ethyl-5-(trifluoromethyl)pyrazin-2-yl,-   (xxii) 3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl, and-   (xxiii) 3-isopropyl-5-(trifluoromethyl)pyrazin-2-yl.

In one embodiment, R¹ represents a mono-substituted 6-memberedheteroaryl group, the substituent being preferably attached in thepara-position relative to the point of attachment of the moiety -L-, or,the five-membered ring in the case where the moiety -L- represents abond.

In an embodiment of the invention, L represents CH₂, O or NR¹².

In a further embodiment, L represents NR¹².

R^(a) and R^(b) each independently represent a hydrogen atom or a C₁, C₂or C₃ alkyl or C₁, C₂ or C₃ haloalkyl group.

In one embodiment, R^(a) and R^(b) each represent a hydrogen atom.

In another embodiment, one of R^(a) and R^(b) represents a hydrogen atomand the other of R^(a) and R^(b) represents a C₁ alkyl (i.e. methyl) orhaloalkyl (e.g. trifluoromethyl) group.

In a further embodiment, R^(a) represents a hydrogen atom or a methylgroup and R^(b) represents a hydrogen atom.

X represents CH₂, CHF or CF₂.

In one embodiment, X represents CH₂.

R² represents a hydrogen atom or a C₁-C₆, or C₁-C₄, or C₁-C₂ alkyl orC₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl)group.

In one embodiment, R² represents a hydrogen atom or C₃-C₆ cycloalkylgroup. In another embodiment, R² represents a hydrogen atom.

R³ represents a phenyl group or a 5- or 6-membered heteroaryl group, alloptionally substituted by at least one substituent, e.g. one, two, threeor four substituents, independently selected from halogen (e.g.fluorine, chlorine, bromine or iodine), hydroxyl, cyano, C₁, C₂ or C₃alkyl, C₁, C₂ or C₃ haloalkyl, C₁, C₂ or C₃ hydroxyalkyl, C₁, C₂ or C₃alkoxy, C₁, C₂ or C₃ haloalkoxy, C₂, C₃ or C₄ alkenyl, C₁, C₂ or C₃alkylcarbonyloxy, C₁, C₂ or C₃ alkoxycarbonyl, —NR⁸R⁹, —C(O)NR¹⁰R¹¹,C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl),C₃-C₆ cycloalkyloxy (cyclopropyloxy, cyclobutyloxy, cyclopentyloxy orcyclohexyloxy), C₃-C₆ cycloalkylmethyl (cyclopropylmethyl,cyclobutylmethyl, cyclopentylmethyl or cyclohexylmethyl) or a 5- or6-membered heteroaryl group, the heteroaryl group itself beingoptionally substituted by at least one substituent, e.g. one, two, threeor four substituents, independently selected from C₁-C₆, or C₁-C₄, orC₁-C₂ alkyl, C₁-C₆, or C₁-C₄, or C₁-C₂ alkoxy and C₁-C₆, or C₁-C₄, orC₁-C₂ haloalkoxy.

R³ represents a phenyl group or a 5- or 6-membered heteroaryl group.This R³ heteroaryl group comprises one or more, e.g. one, two, three orfour, ring heteroatoms independently selected from nitrogen, oxygen andsulphur. Examples of such 5- or 6-membered heteroaryl groups includepyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl,pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furyl,furazanyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl,thiadiazolyl and tetrazinyl.

The R³ phenyl or heteroaryl group may optionally be substituted with atleast one 5- or 6-membered heteroaryl substituent group. The“heteroaryl” substituent group, as used in this context, comprises atotal of 5 or 6 ring atoms, of which one, two, three or four ring atomsare heteroatoms independently selected from nitrogen, oxygen and sulphuratoms. Examples of such heteroaryl substituent groups include pyrrolyl,imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyrazinyl,pyrimidinyl, pyridazinyl, triazinyl, thienyl, furyl, furazanyl,oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyland tetrazinyl.

In an embodiment of the invention, R³ represents a phenyl group or a 5-or 6-membered heteroaryl group containing one or two ring heteroatomsindependently selected from nitrogen, oxygen and sulphur (such aspyridinyl, pyrimidinyl and pyrazinyl), all optionally substituted by atleast one substituent, e.g. one, two, three or four substituents,independently selected from halogen (e.g. fluorine, chlorine, bromine oriodine), hydroxyl, cyano, C₁, C₂ or C₃ alkyl, C₁, C₂ or C₃ haloalkyl,C₁, C₂ or C₃ hydroxyalkyl, C₁, C₂ or C₃ alkoxy, C₁, C₂ or C₃ haloalkoxy,C₂, C₃ or C₄ alkenyl, C₁, C₂ or C₃ alkylcarbonyloxy, C₁, C₂ or C₃alkoxycarbonyl, —NR⁸R⁹, —C(O)NR¹⁰R¹¹, C₃-C₅ cycloalkyl, C₃-C₅cycloalkyloxy, C₃-C₅ cycloalkylmethyl or a 5- or 6-membered heteroarylgroup (such as triazolyl, pyrazolyl, oxadiazolyl, pyrimidinyl andimidazolyl), the heteroaryl group itself being optionally substituted byat least one substituent, e.g. one, two, three or four substituents,independently selected from C₁-C₆, or C₁-C₄, or C₁-C₂ alkyl, C₁-C₆, orC₁-C₄, or C₁-C₂ alkoxy and C₁-C₆, or C₁-C₄, or C₁-C₂ haloalkoxy.

In another embodiment, R³ represents a phenyl group or a 5- or6-membered heteroaryl group containing one or two ring heteroatomsindependently selected from nitrogen, oxygen and sulphur (such aspyridinyl, pyrimidinyl and pyrazinyl), all optionally substituted by atleast one substituent, e.g. one, two, three or four substituents,independently selected from fluorine, chlorine, bromine, C₁, C₂ or C₃alkyl, C₁, C₂ or C₃ haloalkyl, C₁, C₂ or C₃ alkoxy, C₁, C₂ or C₃haloalkoxy, cyclopropyl, —NR⁸R⁹ (e.g. piperidinyl), or a 5- or6-membered heteroaryl group (such as triazolyl, pyrazolyl, oxadiazolyl,pyrimidinyl and imidazolyl), the heteroaryl group itself beingoptionally substituted by at least one substituent, e.g. one, two, threeor four substituents, independently selected from C₁-C₂ alkyl, C₁-C₂alkoxy and C₁-C₂ haloalkoxy.

In a further embodiment, R³ represents a phenyl group optionallysubstituted by one, two or three (particularly one or two) substituentsindependently selected from fluorine, chlorine, C₁, C₂ or C₃ alkyl, C₁,C₂ or C₃ alkoxy or a 5- or 6-membered heteroaryl group (such astriazolyl, pyrazolyl, oxadiazolyl and pyrimidinyl), the heteroaryl groupitself being optionally substituted by one or two substituentsindependently selected from C₁-C₂ alkyl, C₁-C₂ alkoxy and C₁-C₂haloalkoxy, preferably methyl.

In a still further embodiment, R³ represents any one of the followingmoieties or is selected from a group containing two or more of suchmoieties in any combination:

-   (i) 2-fluorophenyl,-   (ii) 2-chlorophenyl,-   (iii) 2-methylphenyl,-   (iv) 2-cyclopropylphenyl,-   (v) 2-methoxyphenyl,-   (vi) 2-ethoxyphenyl,-   (vii) 2-(difluoromethoxy)phenyl,-   (viii) 3-methylphenyl,-   (ix) 3-methoxyphenyl,-   (x) 2,6-difluorophenyl,-   (xi) 2,6-dichlorophenyl,-   (xii) 2,6-dimethoxyphenyl,-   (xiii) 2,6-diethoxyphenyl,-   (xiv) 2-ethoxy-5-methylphenyl,-   (xv) 2,5-dimethoxyphenyl,-   (xvi) 2-fluoro-6-methoxyphenyl,-   (xvii) 5-fluoro-2-methoxyphenyl,-   (xviii) 3-fluoro-2-methoxyphenyl,-   (xix) 2-(1H-1,2,4-triazol-1-yl)phenyl,-   (xx) 2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xxi) 5-methyl-2-(1H-1,2,3-triazol-1-yl)phenyl,-   (xxii) 5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xxiii) 5-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl,-   (xxiv) 5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xxv) 2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl,-   (xxvi) 2-(pyrimidin-2-yl)phenyl,-   (xxvii) 5-fluoro-2-(pyrimidin-2-yl)phenyl,-   (xxviii) 2-(1H-pyrazol-1-yl)phenyl,-   (xxix) 2-(1H-imidazol-1-yl)phenyl,-   (xxx) 2-(1H-1,2,3-triazol-1-yl)phenyl,-   (xxxi) 2-(pyrimidin-2-yl)-5-fluorophenyl,-   (xxxii) 2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl,-   (xxxiii) 2-methoxy-5-methylphenyl,-   (xxxiv) 2-chloro-6-(2H-1,2,3-triazol-2-yl)phenyl,-   (xxxv) 2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl,-   (xxxvi) 5-trifluoromethyl-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xxxvii) 2-fluoro-6-(pyrazol-1-yl)phenyl,-   (xxxviii) 5-fluoro-2-(pyrazol-1-yl)phenyl,-   (xxxix) 5-methyl-2-(pyrazol-1-yl)phenyl,-   (xl) 2-bromo-6-methoxyphenyl,-   (xli) 2-methoxy-6-(pyrazol-1-yl)phenyl,-   (xlii) 5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xliii) 3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xliv) 5-trifluoromethyl-2-(1H-1,2,3-triazol-1-yl)phenyl,-   (xlv) 5-chloro-2-(1H-1,2,3-triazol-1-yl)phenyl,-   (xlvi) 2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)phenyl,-   (xlvii) 5-cyclopropyl-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (xlviii) 5-chloro-2-(pyrazol-1-yl)phenyl,-   (xlix) 3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (l) 2-(difluoromethyl)phenyl,-   (li) 2-(trifluoromethyl)phenyl,-   (lii) 3,6-difluoro-2-(2H-1,2,3-triazol-2-yl)phenyl,-   (liii) 2-cyclopropyl-6-fluorophenyl,-   (liv) 2-(5-ethoxypyrimidin-2-yl)phenyl,-   (lv) 3-(pyrimidin-2-yl)pyridin-2-yl,-   (lvi) 3-ethoxy-6-methylpyridin-2-yl,-   (lvii) 3-(pyrazol-1-yl)pyridin-2-yl,-   (lviii) 3-(piperidin-1-yl)pyridin-2-yl,-   (lix) 3-(trifluoromethoxy)pyridin-2-yl,-   (lx) 3-(ethoxy)pyridin-2-yl,-   (lxi) 3-(cyclopropyl)pyridin-2-yl,-   (lxii) 3-chloropyridin-2-yl,-   (lxiii) 3-bromopyridin-2-yl,-   (lxiv) 3-methoxypyridin-2-yl,-   (lxv) 3-(propan-2-yloxy)pyridin-2-yl,-   (lxvi) 6-bromo-3-methoxypyridin-2-yl,-   (lxvii) 3-methoxy-6-methylpyridin-2-yl, and-   (lxviii) 3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl.

In a still further embodiment, when R³ represents a substituted phenylgroup or a substituted 5- or 6-membered heteroaryl group (such aspyridinyl, pyrimidinyl and pyrazinyl), the substituent(s) is/areindependently any one of the following moieties or is/are independentlyselected from a group containing two or more of such moieties in anycombination:

-   (i) methyl,-   (ii) methoxy,-   (iii) ethoxy,-   (iv) isopropyloxy,-   (v) difluoromethoxy,-   (vi) trifluoromethoxy,-   (vii) fluorine,-   (viii) chlorine,-   (ix) bromine,-   (x) difluoromethyl,-   (xi) trifluoromethyl,-   (xii) piperidinyl (e.g. piperidin-1-yl),-   (xiii) triazolyl (e.g. 1,2,3-triazol-2-yl, 1,2,3-triazol-1-yl or    1,2,4-triazol-1-yl),-   (xiv) pyrazolyl (e.g. pyrazol-1-yl),-   (xv) oxadiazolyl,-   (xvi) 3-methyl-1,2,4-oxadiazol-5-yl,-   (xvii) 5-methyl-1,3,4-oxadiazol-2-yl,-   (xviii) pyrimidinyl (e.g. pyrimidin-2-yl),-   (xix) 5-ethoxypyrimidin-2-yl,-   (xx) imidazolyl (e.g. imidazol-1-yl), and-   (xxi) cyclopropyl.

When R³ represents a substituted phenyl group or a substituted6-membered heteroaryl group, the substituent(s) is/are preferablyattached in the ortho- and/or meta-positions relative to the point ofattachment of the amide moiety, —NR²C(O)—.

R⁴ and R⁵ each independently represent a hydrogen atom or a C₁, C₂ or C₃alkyl or C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl orcyclohexyl) group, or R⁴ and R⁵ may together with the nitrogen atom towhich they are attached form a 4-, 5-, 6- or 7-membered saturatedheterocyclic ring optionally substituted by at least one substituent,e.g. one or two substituents independently, selected from halogen (e.g.fluorine, chlorine, bromine or iodine), hydroxyl and C₁, C₂ or C₃alkoxy.

In one aspect, the saturated heterocyclic ring may contain a single ringheteroatom (being the nitrogen atom to which R⁴ and R⁵ are attached).

In an alternative aspect, the saturated heterocyclic ring may contain asecond ring heteroatom selected from a nitrogen or oxygen atom.

In one embodiment, R⁴ and R⁵ each independently represent a hydrogenatom or a C₁, C₂ or C₃ alkyl or C₃-C₆ or C₃—O₅ or C₅-C₆ cycloalkyl,particularly cyclopropyl, group, or R⁴ and R⁵ may together with thenitrogen atom to which they are attached form a 4- or 5-memberedsaturated heterocyclic ring optionally substituted by one or twosubstituents independently selected from fluorine, chlorine, bromine,hydroxyl and methoxy.

In a second embodiment, R⁴ and R⁵ each represent a hydrogen atom.

In a third embodiment, R⁴ and R⁵ each represent a C₁-C₃ alkyl group.

In a fourth embodiment, one of R⁴ and R⁵ represents a hydrogen atom andthe other of R⁴ and R⁵ represents a C₁-C₃ alkyl group.

In a fifth embodiment, one of R⁴ and R⁵ represents a cyclopropyl groupand the other of R⁴ and R⁵ represents a C₁-C₃ alkyl group.

In a sixth embodiment, R⁴ and R⁵ together with the nitrogen atom towhich they are attached form an azetidinyl or pyrrolidinyl ringoptionally substituted by one or two substituents independently selectedfrom fluorine, hydroxyl and methoxy.

R⁶ and R⁷ each independently represent a hydrogen atom or a C₁, C₂ or C₃alkyl or C₃-C₆ cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl orcyclohexyl) group, or R⁶ and R⁷ may together with the nitrogen atom towhich they are attached form a 4-, 5-, 6- or 7-membered saturatedheterocyclic ring optionally substituted by at least one substituent,e.g. one or two substituents, independently selected from halogen (e.g.fluorine, chlorine, bromine or iodine) and hydroxyl.

In one aspect, the saturated heterocyclic ring may contain a single ringheteroatom (being the nitrogen atom to which R⁶ and R⁷ are attached).

In an alternative aspect, the saturated heterocyclic ring may contain asecond ring heteroatom selected from a nitrogen or oxygen atom.

In one embodiment, R⁶ and R⁷ each independently represent a hydrogenatom or a C₁, C₂ or C₃ alkyl or C₃-C₆ or C₃—O₅ or C₅-C₆ cycloalkyl,particularly cyclopropyl, group, or R⁶ and R⁷ may together with thenitrogen atom to which they are attached form a 4- or 5-memberedsaturated heterocyclic ring optionally substituted by one or twosubstituents independently selected from fluorine, chlorine, bromine andhydroxyl.

In a second embodiment, R⁶ and R⁷ each represent a hydrogen atom.

In a third embodiment, R⁶ and R⁷ each represent a C₁-C₃ alkyl group.

In a fourth embodiment, one of R⁶ and R⁷ represents a hydrogen atom andthe other of R⁶ and R⁷ represents a C₁-C₃ alkyl group.

In a fifth embodiment, one of R⁶ and R⁷ represents a cyclopropyl groupand the other of R⁶ and R⁷ represents a C₁-C₃ alkyl group.

In a sixth embodiment, R⁶ and R⁷ together with the nitrogen atom towhich they are attached form an azetidinyl or pyrrolidinyl ringoptionally substituted by one or two substituents independently selectedfrom fluorine and hydroxyl.

R⁸ and R⁹ are defined as for R⁴ and R⁵ above.

R¹⁰ and R¹¹ are defined as for R⁶ and R⁷ above.

R¹² represents a hydrogen atom, methyl group or a C₂-C₃ alkylene chainthat links to R¹ to form a 5- or 6-membered ring. Thus, for example, thefollowing moiety may be formed when R¹² represents a C₃ alkylene chainand R¹ represents a pyridin-2-yl group:

In an embodiment of the invention, R¹² represents a hydrogen atom ormethyl group.

In another embodiment, R¹² represents a hydrogen atom.

In a preferred embodiment of the invention,

-   -   R¹ represents a 5- or 6-membered heteroaryl group optionally        substituted by at least one substituent independently selected        from halogen, cyclopropyl, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃        haloalkyl and C₁-C₃ haloalkoxy;    -   L represents CH₂, O or NR¹²;    -   R^(a) represents a hydrogen atom or a methyl group;    -   R^(b) represents a hydrogen atom;    -   X represents CH₂ or CF₂;    -   R² represents a hydrogen atom or cyclobutyl group;    -   R³ represents a phenyl or pyridinyl group optionally substituted        by at least one substituent independently selected from        fluorine, chlorine, bromine, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃        alkoxy, C₁-C₃ haloalkoxy, cyclopropyl, piperidinyl, or a 5- or        6-membered heteroaryl group, the heteroaryl group itself being        optionally substituted by at least one C₁-C₂ alkyl or C₁-C₂        alkoxy group.

In another preferred embodiment, the invention provides compounds offormula

wherein

-   -   R¹ as defined above;    -   R^(a1) represents a hydrogen atom or methyl group; and    -   R^(3a) represents 5- or 6-membered heteroaryl group.

In one aspect, R^(3a) in formula (Ia) represents a triazolyl (e.g.1,2,3-triazol-2-yl) or pyrimidinyl (e.g. pyrimidin-2-yl) group.

Examples of compounds of the invention include:

-   2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;-   5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-[(5-Ethylpyrimidin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-[(5-Chloropyridin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;-   5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;-   5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   is    2-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   5-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2R)-2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;-   2,6-Dimethoxy-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;-   5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;-   2,6-Dimethoxy-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   3-Bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   2-Ethoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-Ethoxy-6-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   2-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(1H-1,2,3-Triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Chloro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Fluoro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Methyl-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   2-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Fluoro-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Fluoro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Methyl-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Bromo-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Methoxy-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-(Piperidin-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Chloro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-(Trifluoromethoxy)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   5-Chloro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-Ethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(Trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-Cyclopropyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-(Difluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Cyclopropyl-6-fluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-3-yl]amino}cyclopentyl]benzamide;-   N-Cyclobutyl-2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;-   2-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   2,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   5-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   2-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;-   5-Fluoro-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;-   N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1R,2R)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   5-Fluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(1H-pyrazol-1-yl)pyridine-2-carboxamide;-   3-Ethoxy-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide,-   2-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;-   2,6-Difluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   3-Cyclopropyl-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(trifluoromethoxy)pyridine-2-carboxamide;-   N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;-   5-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-(2-Methyl-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   3-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   3-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;-   2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benz    amide;-   N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-[(5-Cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benz    amide;-   N-[(1S,2S)-2-{[5-(Propan-2-yl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benz    amide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;-   5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benz    amide;-   N-[(1S,2S)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benz    amide;-   2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-4,4-Difluoro-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   2-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;-   5-Fluoro-N-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;-   is    N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;-   2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;-   N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;-   N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   N-[(1S,2S)-2-{[5-(Difluoromethoxy)pyridin-2-yl]amino}-4,4-difluoro    cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-5-fluoro-2-(pyrimidin-2-yl)benzamide;-   N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;-   2-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;-   enantiomers thereof and pharmaceutically acceptable salts of any of    the foregoing.

It should be noted that each of the chemical compounds listed aboverepresents a particular and independent aspect of the invention.

The present invention further provides a process for the preparation ofa compound of formula (I) or a pharmaceutically acceptable salt thereofas defined above which comprises

(i) reacting a compound of formula

wherein L, X, R^(a), R^(b), R¹ and R² are as defined in formula (I),with a compound of formula

wherein R²⁰ represents a halogen atom (e.g. chlorine atom) or a hydroxylgroup and R³ is as defined in formula (I), or a salt (e.g. hydrochloridesalt) thereof; or(ii) when L represents NH or N(CH₃), reacting a compound of formula

wherein R²⁵ represents a hydrogen atom or methyl group and X, R^(a),R^(b), R² and R³ are as defined in formula (I), with a compound offormula (V), R¹-LG¹, wherein LG¹ represents a leaving group (e.g. ahalogen atom) and R¹ is as defined in formula (I);and optionally thereafter carrying out one or more of the followingprocedures:

-   -   converting a compound of formula (I) into another compound of        formula (I)    -   removing any protecting groups    -   forming a pharmaceutically acceptable salt.

Process (i) may conveniently be carried out by combining the amine offormula (II) with an acid chloride of formula (III) in the presence of abase such as triethyl amine or DIPEA (N,N-diisopropylethylamine) in asolvent such as dichloromethane. Alternatively the reaction can becarried out from the amine of formula (II) and a carboxylic acid offormula (III) using any of the known coupling reagents such as EDC(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and HOAt(7-aza-1-hydroxybenzotriazole), with or HATU(1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate) with a base such as DIPEA. Another methodis to activate the carboxylic acid to the corresponding acid chloride insitu for example with oxalyl chloride in the presence of a catalyticamount of DMF.

Process (ii) may conveniently be carried out by mixing the compound offormula (IV) with the compound of formula (V) in a solvent such as DMSO,acetonitrile or toluene and optionally in the presence of a base such asDIPEA, and heating conventionally or using microwave irradiation.

Compounds of formula (II) in which L represents CH₂, X represents CH₂and R^(a) and R^(b) are each hydrogen may be prepared according to thescheme below. The heterocyclic bromomethylene compound is likely to becommercially available or can be prepared by bromination of thecorresponding heterocyclic methyl compound using, for example, N-bromosuccinimide and benzoyl peroxide in carbon tetrachloride at elevatedtemperature. Reaction of the heterocyclic bromomethylene compound withtriphenylphosphine in toluene at raised temperature will afford thecorresponding phosphonium bromide which on treatment with a base such asn-butyl lithium in the presence of the Boc-protected cyclic ketone willafford the corresponding alkene. The alkene can be reduced byhydrogenation using hydrogen gas in the presence of a catalyst such aspalladium on carbon. Finally, the Boc protecting group can be removedusing methods known to those skilled in the art, e.g. acid hydrolysis.

Compounds of formula (II) in which L represents an oxygen atom may beprepared by reacting a compound of formula

wherein X, R^(a), R^(b) and R² is as defined in formula (II), with acompound of formula (V) as defined above, in the presence of a base suchas sodium hydride.

Compounds of formula (II) in which L represents NH or N(CH₃) may beprepared by reacting a compound of formula

in which LG² represents a protecting group such as atert-butyloxycarbonyl group, and X, R^(a), R^(b), R² and R²⁵ are asdefined in formula (IV) above, with a compound of formula (V) as definedabove.

Compounds of formula (IV) may be prepared by reacting a compound offormula (VII) with a compound of formula (III) followed by removal ofthe protecting group, LG², by acid treatment using, for example, an acidsuch as hydrochloric acid.

Compounds of formulae (III), (V), (VI) and (VII) are either commerciallyavailable, are well known in the literature or may be prepared usingknown techniques.

It will be appreciated by those skilled in the art that in the processesof the present invention certain functional groups such as phenol,hydroxyl or amino groups in the reagents may need to be protected byprotecting groups. Thus, the preparation of the compounds of formula (I)may involve, at an appropriate stage, the introduction and/or removal ofone or more protecting groups.

The protection and deprotection of functional groups is described in‘Protective Groups in Organic Chemistry’, edited by J. W. F. McOmie,Plenum Press (1973) and ‘Protective Groups in Organic Synthesis’, 3^(rd)edition, T. W. Greene and P. G. M. Wuts, Wiley-Interscience (1999).

The compounds of formula (I) above may be converted to apharmaceutically acceptable salt thereof, preferably an acid additionsalt such as a formate, hemi-formate, hydrochloride, hydrobromide,benzenesulphonate (besylate), saccharin (e.g. monosaccharin),trifluoroacetate, sulphate, nitrate, phosphate, acetate, fumarate,maleate, tartrate, lactate, citrate, pyruvate, succinate, valerate,propanoate, butanoate, malonate, oxalate, 1-hydroxy-2-napthoate(xinafoate), methanesulphonate or p-toluenesulphonate salt.

In one aspect of the invention, compounds of formula (I) may bear one ormore radiolabels. Such radiolabels may be introduced by usingradiolabel-containing reagents in the synthesis of the compounds offormula (I), or may be introduced by coupling the compounds of formula(I) to chelating moieties capable of binding to a radioactive metalatom. Such radiolabeled versions of the compounds may be used, forexample, in diagnostic imaging studies.

Unless stated otherwise, any atom specified herein may also be anisotope of said atom. For example, the term “hydrogen” encompasses ¹H,²H and ³H. Similarly carbon atoms are to be understood to include ¹²C,¹³C and ¹⁴C, nitrogen atoms are to be understood to include ¹⁴N and ¹⁵N,and oxygen atoms are to be understood to include ¹⁶O, ¹⁷O and ¹⁸O.

In a further aspect of the invention, compounds of formula (I) may beisotopically labelled. As used herein, an “isotopically labelled”compound is one in which the abundance of a particular nuclide at aparticular atomic position within the molecule is increased above thelevel at which it occurs in nature.

Compounds of formula (I) and their salts may be in the form of hydratesor solvates which form an aspect of the present invention. Such solvatesmay be formed with common organic solvents, including but not limitedto, alcoholic solvents e.g. methanol, ethanol or isopropanol.

Where compounds of formula (I) are capable of existing in stereoisomericforms, it will be understood that the invention encompasses the use ofall geometric and optical isomers (including atropisomers) of thecompounds of formula (I) and mixtures thereof including racemates. Theuse of tautomers and mixtures thereof also forms an aspect of thepresent invention. Enantiomerically pure forms are particularly desired.

Compounds of formula (I) and their salts may be amorphous or in apolymorphic form or a mixture of any of these, each of which forms anaspect of the present invention.

The compounds of formula (I) and their pharmaceutically acceptable saltshave activity as pharmaceuticals, in particular as orexin receptorantagonists, and may be used in the treatment of schizophrenia and otherpsychotic disorders (e.g., psychotic disorder, psychosis orschizoaffective disorder); dementia and other cognitive disorders;anxiety disorders (e.g., generalized anxiety disorder, post-traumaticstress disorder, panic disorders, acute stress disorder, social anxietydisorder, phobias including agoraphobia, obsessive compulsive disorder,trichlofillomania or body dismorphic disorder); mood disorders (e.g.,depressive disorders, major depressive disorders, bipolar disordersincluding bipolar I and II, bipolar mania, bipolar depression);addiction including substance dependence (e.g. cocaine, opiates,cannabis or prescription drug dependence), alcohol dependence, nicotinedependence or gambling disorder; eating disorders (e.g. binge eating,bulimia nervosa, anorexia nervosa or obesity); sleep disorders (e.g.rapid eye movement sleep disorder); disorders usually first diagnosed ininfancy, childhood, or adolescence (e.g., attention-deficit disorder,autistic spectrum disorders, Rett syndrome, Fragile X syndrome, Aspergersyndrome and disruptive behaviour disorders); restless leg syndrome;pain (e.g. neuropathic pain including chemotherapy induced pain ormigraine); and neurodegenerative disorders (e.g. Parkinson's orAlzheimer's disease).

Thus, the present invention provides a compound of formula (I) or apharmaceutically acceptable salt thereof as hereinbefore defined for usein therapy, in particular for the treatment of conditions whosedevelopment or symptoms are linked to orexin receptor activity.

The present invention also provides the use of a compound of formula (I)or a pharmaceutically acceptable salt thereof as hereinbefore definedfor the preparation of a medicament for the treatment of conditionswhose development or symptoms are linked to orexin receptor activity.

In the context of the present specification, the term “therapy” alsoincludes “prophylaxis” unless there are specific indications to thecontrary. The terms “therapeutic” and “therapeutically” should beconstrued accordingly.

Prophylaxis is expected to be particularly relevant to the treatment ofpersons who have suffered a previous episode of, or are otherwiseconsidered to be at increased risk of, the disorder or condition inquestion. Persons at risk of developing a particular disorder orcondition generally include those having a family history of thedisorder or condition, or those who have been identified by genetictesting or screening to be particularly susceptible to developing thedisorder or condition or those in the prodromal phase of a disorder.

In particular, the compounds of the invention (includingpharmaceutically acceptable salts) may be used in the treatment of thepositive symptoms of schizophrenia, schizophreniform disorder orschizoaffective disorder (e.g. voices or hallucinations), cognitivedisorders (such as dementia and impaired learning), anxiety disorders(such as post-traumatic stress disorder or panic disorders), oraddiction.

The invention also provides a method of treating at least one symptom orcondition associated with schizophrenia and other psychotic disorders(e.g., psychotic disorder, psychosis or schizoaffective disorder);dementia and other cognitive disorders; anxiety disorders (e.g.,generalized anxiety disorder, post-traumatic stress disorder, panicdisorders, acute stress disorder, social anxiety disorder, phobiasincluding agoraphobia, obsessive compulsive disorder, trichlofillomaniaor body dismorphic disorder); mood disorders (e.g., depressivedisorders, major depressive disorders, bipolar disorders includingbipolar I and II, bipolar mania, bipolar depression); addictionincluding substance dependence (e.g. cocaine, opiates, cannabis orprescription drug dependence), alcohol dependence, nicotine dependenceor gambling disorder; eating disorders (e.g. binge eating, bulimianervosa, anorexia nervosa or obesity); sleep disorders (e.g. rapid eyemovement sleep disorder); disorders usually first diagnosed in infancy,childhood, or adolescence (e.g., attention-deficit disorder, autisticspectrum disorders, Rett syndrome, Fragile X syndrome, Asperger syndromeand disruptive behaviour disorders); restless leg syndrome; pain (e.g.neuropathic pain including chemotherapy induced pain or migraine); andneurodegenerative disorders (e.g. Parkinson's or Alzheimer's disease)which comprises administering to a patient in need thereof atherapeutically effective amount of a compound of formula (I) or apharmaceutically acceptable salt thereof as hereinbefore defined.

Such symptoms and conditions include, but are not limited to, anxiety,agitation, hostility, panic, an eating disorder, an affective symptom, amood symptom, a negative and positive psychotic symptom commonlyassociated with psychosis and neurodegenerative disorder.

For the above-mentioned therapeutic uses the dosage administered will,of course, vary with the compound employed, the mode of administration,the treatment desired and the disorder indicated. For example, the dailydosage of the compound of the invention, if inhaled, may be in the rangefrom 0.05 micrograms per kilogram body weight (μg/kg) to 100 microgramsper kilogram body weight (μg/kg). Alternatively, if the compound isadministered orally, then the daily dosage of the compound of theinvention may be in the range from 0.01 micrograms per kilogram bodyweight (μg/kg) to 100 milligrams per kilogram body weight (mg/kg).

The compounds of formula (I) and pharmaceutically acceptable saltsthereof may be used on their own but will generally be administered inthe form of a pharmaceutical composition in which the formula (I)compound/salt (active ingredient) is in association with apharmaceutically acceptable adjuvant, diluent or carrier.

Therefore the present invention further provides a pharmaceuticalcomposition comprising a compound of formula (I) or a pharmaceuticallyacceptable salt thereof as hereinbefore defined, in association with apharmaceutically acceptable adjuvant, diluent or carrier.

The invention still further provides a process for the preparation of apharmaceutical composition of the invention which comprises mixing acompound of formula (I) or a pharmaceutically acceptable salt thereof ashereinbefore defined with a pharmaceutically acceptable adjuvant,diluent or carrier.

Conventional procedures for the selection and preparation of suitablepharmaceutical formulations are described in, for example,“Pharmaceutics—The Science of Dosage Form Design”, M. E. Aulton,Churchill Livingstone, 1988.

Pharmaceutically acceptable adjuvants, diluents or carriers that may beused in the pharmaceutical compositions of the invention are thoseconventionally employed in the field of pharmaceutical formulation, andinclude, but are not limited to, sugars, sugar alcohols, starches, ionexchangers, alumina, aluminium stearate, lecithin, serum proteins suchas human serum albumin, buffer substances such as phosphates, glycerine,sorbic acid, potassium sorbate, partial glyceride mixtures of saturatedvegetable fatty acids, water, salts or electrolytes such as protaminesulphate, disodium hydrogen phosphate, potassium hydrogen phosphate,sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol,sodium carboxymethylcellulose, polyacrylates, waxes,polyethylene-polyoxypropylene-block polymers, polyethylene glycol andwool fat.

The pharmaceutical compositions of the present invention may beadministered orally, parenterally, by inhalation spray, rectally,nasally, buccally, vaginally or via an implanted reservoir. Oraladministration is preferred. The pharmaceutical compositions of theinvention may contain any conventional non-toxic pharmaceuticallyacceptable adjuvants, diluents or carriers. The term parenteral as usedherein includes subcutaneous, intracutaneous, intravenous,intramuscular, intra-articular, intrasynovial, intrasternal,intrathecal, intralesional and intracranial injection or infusiontechniques.

The pharmaceutical compositions may be in the form of a sterileinjectable preparation, for example, as a sterile injectable aqueous oroleaginous suspension. The suspension may be formulated according totechniques known in the art using suitable dispersing or wetting agents(such as, for example, Tween 80) and suspending agents. The sterileinjectable preparation may also be a sterile injectable solution orsuspension in a non-toxic parenterally acceptable diluent or solvent,for example, as a solution in 1,3-butanediol. Among the acceptablediluents and solvents that may be employed are mannitol, water, Ringer'ssolution and isotonic sodium chloride solution. In addition, sterile,fixed oils are conventionally employed as a solvent or suspendingmedium. For this purpose, any bland fixed oil may be employed includingsynthetic mono- or diglycerides. Fatty acids, such as oleic acid and itsglyceride derivatives are useful in the preparation of injectables, asare natural pharmaceutically acceptable oils, such as olive oil orcastor oil, especially in their polyoxyethylated versions. These oilsolutions or suspensions may also contain a long-chain alcohol diluentor dispersant.

The pharmaceutical compositions of this invention may be orallyadministered in any orally acceptable dosage form including, but notlimited to, capsules, tablets, powders, granules, and aqueoussuspensions and solutions. These dosage forms are prepared according totechniques well-known in the art of pharmaceutical formulation. In thecase of tablets for oral use, carriers which are commonly used includelactose and corn starch. Lubricating agents, such as magnesium stearate,are also typically added. For oral administration in a capsule form,useful diluents include lactose and dried corn starch. When aqueoussuspensions are administered orally, the active ingredient is combinedwith emulsifying and suspending agents. If desired, certain sweeteningand/or flavouring and/or colouring agents may be added.

The pharmaceutical compositions of the invention may also beadministered in the form of suppositories for rectal administration.These compositions can be prepared by mixing the active ingredient witha suitable non-irritating excipient which is solid at room temperaturebut liquid at the rectal temperature and therefore will melt in therectum to release the active ingredient. Such materials include, but arenot limited to, cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may be administered bynasal aerosol or inhalation. Such compositions are prepared according totechniques well-known in the art of pharmaceutical formulation and maybe prepared as solutions in saline, employing benzyl alcohol or othersuitable preservatives, absorption promoters to enhance bioavailability,fluorocarbons, and/or other solubilising or dispersing agents known inthe art.

Depending on the mode of administration, the pharmaceutical compositionwill preferably comprise from 0.05 to 99% w (percent by weight), morepreferably from 0.05 to 80% w, still more preferably from 0.10 to 70% w,and even more preferably from 0.10 to 50% w, of active ingredient, allpercentages by weight being based on total composition.

The compounds of the invention (that is, compounds of formula (I) andpharmaceutically acceptable salts thereof) may also be administered inconjunction with other compounds used for the treatment of the aboveconditions.

The invention therefore further relates to combination therapies whereina compound of the invention or a pharmaceutical composition orformulation comprising a compound of the invention is administered withanother therapeutic agent or agents for the treatment of one or more ofthe conditions previously indicated. Such therapeutic agents may beselected from the following:

(i) antidepressants such as, for example, amitriptyline, amoxapine,bupropion, citalopram, clomipramine, desipramine, doxepin duloxetine,elzasonan, escitalopram, fluvoxamine, fluoxetine, gepirone, imipramine,ipsapirone, maprotiline, nortriptyline, nefazodone, paroxetine,phenelzine, protriptyline, reboxetine, robaizotan, sertraline,sibutramine, tianeptine, thionisoxetine, tranylcypromaine, trazodone,trimipramine, venlafaxine, vortioxetine and equivalents andpharmaceutically active isomer(s) and/or metabolite(s) thereof;

(ii) antipsychotics including, for example, amisulpride, aripiprazole,asenapine, benzisoxidil, bifeprunox, brexpiprazole, carbamazepine,cariprazine, clozapine, chlorpromazine, debenzapine, divalproex,duloxetine, eszopiclone, haloperidol, iloperidone, lamotrigine,loxapine, lurasidone, mesoridazine, olanzapine, paliperidone, perlapine,perphenazine, phenothiazine, phenylbutlypiperidine, pimozide,prochlorperazine, quetiapine, risperidone, sertindole, sulpiride,suproclone, suriclone, thioridazine, trifluoperazine, trimetozine,valproate, valproic acid, zopiclone, zotepine, zicronapine, ziprasidone,and equivalents and pharmaceutically active isomer(s) and/ormetabolite(s) thereof;

(iii) anxiolytics including, for example, alnespirone, azapirones,benzodiazepines, barbiturates, and equivalents and pharmaceuticallyactive isomer(s) and/or metabolite(s) thereof. Example anxiolyticsinclude adinazolam, alprazolam, balezepam, bentazepam, bromazepam,brotizolam, buspirone, clonazepam, clorazepate, chlordiazepoxide,cyprazepam, diazepam, diphenhydramine, estazolam, fenobam,flunitrazepam, flurazepam, fosazepam, lorazepam, lormetazepam,meprobamate, midazolam, nitrazepam, oxazepam, prazepam, quazepam,reclazepam, tracazolate, trepipam, temazepam, triazolam, uldazepam, andzolazepam; and equivalents and pharmaceutically active isomer(s) and/ormetabolite(s) thereof;

(iv) anticonvulsants including, for example, carbamazepine, valproate,lamotrigine, levetiracetam and gabapentin, and equivalents andpharmaceutically active isomer(s) and/or metabolite(s) thereof;

(v) Alzheimer's therapies including, for example, donepezil,galantamine, memantine, rivastigmine, tacrine, and equivalents andpharmaceutically active isomer(s) and/or metabolite(s) thereof;

(vi) Parkinson's therapies including, for example, L-dopa, ropinirole,pramipexole, monoamine oxidase type B (MAO-B) inhibitors such asdeprenyl, selegiline and rasagiline, catechol-O-methyl transferase(COMT) inhibitors such as entacapone or tolcapone, adenosine A-2inhibitors, dopamine re-uptake inhibitors, NMDA antagonists, Nicotineagonists, and Dopamine agonists and inhibitors of neuronal nitric oxidesynthase, and equivalents and pharmaceutically active isomer(s) and/ormetabolite(s) thereof;

(vii) migraine therapies including, for example, almotriptan,amantadine, botulinum toxin A, bromocriptine, butalbital, cabergoline,dichloralphenazone, dihydroergotamine, eletriptan, frovatriptan,lisuride, naratriptan, pergolide, pramipexole, rizatriptan, ropinirole,sumatriptan, topiramate, zolmitriptan, and zomitriptan, and equivalentsand pharmaceutically active isomer(s) and/or metabolite(s) thereof;

(viii) stroke therapies including, for example, abciximab, activase,citicoline, desmoteplase, and equivalents and pharmaceutically activeisomer(s) and/or metabolite(s) thereof;

(ix) urinary incontinence therapies including, for example, darafenacin,duloxetine, falvoxate, mirabegron, oxybutynin, propiverine, robalzotan,solifenacin, and tolterodine, and equivalents and pharmaceuticallyactive isomer(s) and/or metabolite(s) thereof;

(x) neuropathic pain therapies including, for example, capsaicin,gabapentin, lidoderm, and pregabalin, and equivalents andpharmaceutically active isomer(s) and/or metabolite(s) thereof;

(xi) nociceptive pain therapies such as, for example, celecoxib,etoricoxib, lumiracoxib, rofecoxib, valdecoxib, diclofenac, loxoprofen,naproxen, and paracetamol, and equivalents and pharmaceutically activeisomer(s) and/or metabolite(s) thereof;

(xii) insomnia therapies including, for example, allobarbital, alonimid,amobarbital, benzoctamine, butabarbital, capuride, chloral, cloperidone,clorethate, dexclamol, ethchlorvynol, eszopiclone, etomidate,glutethimide, halazepam, hydroxyzine, lorediplon, mecloqualone,melatonin, mephobarbital, methaqualone, midaflur, nisobamate,pentobarbital, phenobarbital, propofol, ralmeteon, roletamide,suvorexant, triclofos, secobarbital, zaleplon, and zolpidem, zopicloneand equivalents and pharmaceutically active isomer(s) and/ormetabolite(s) thereof;

(xiii) mood stabilizers including, for example, carbamazepine,divalproex, gabapentin, lamotrigine, lithium, olanzapine, quetiapine,valproate, valproic acid, and verapamil, and equivalents andpharmaceutically active isomer(s) and/or metabolite(s) thereof;

(xiv) 5HT1B ligands such as, for example, compounds disclosed in WO99/05134 and WO 02/08212;

(xv) mGluR2 agonists;

(xvi) alpha 7 nicotinic agonists such as, for example, compoundsdisclosed in WO 96/006098, WO 97/030998, WO 99/003859, WO 00/042044, WO01/029034, WO 01/60821, WO 01/36417, WO 02/096912, WO 03/087102, WO03/087103, WO 03/087104, WO 2004/016617, WO 2004/016616, and WO2004/019947;

(xvii) chemokine receptor CCR1 inhibitors; and

(xviii) delta opioid agonists such as, for example, compounds disclosedin WO 97/23466 and WO 02/094794.

Such combination products employ the compounds of this invention withinthe dosage range described herein and the other pharmaceutically activeagent within approved dosage ranges and/or the dosage such as describedin the publication reference.

In a further aspect the present invention provides a combination (forexample for the treatment of schizophrenia, cognitive disorders or pain)of a compound of formula (I) or a pharmaceutically acceptable saltthereof as hereinbefore defined and one or more agents selected fromcarbamazepine, olanzapine, quetiapine, verapamil, lamotrigine,oxcarbazepine, risperidone, aripiprazole, ziprasidone and lithium.

The invention also provides a pharmaceutical product comprising, incombination, a preparation of a first active ingredient which is acompound of formula (I) or a pharmaceutically acceptable salt thereof ashereinbefore defined, and a preparation of a second active ingredientwhich is carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine,oxcarbazepine, risperidone, aripiprazole, ziprasidone or lithium, forsimultaneous, sequential or separate use in therapy.

In another aspect, the invention provides a kit comprising a preparationof a first active ingredient which is a compound of formula (I) or apharmaceutically acceptable salt thereof as hereinbefore defined, and apreparation of a second active ingredient which is carbamazepine,olanzapine, quetiapine, verapamil, lamotrigine, oxcarbazepine,risperidone, aripiprazole, ziprasidone or lithium, and instructions forthe simultaneous, sequential or separate administration of thepreparations to a patient in need thereof.

The present invention will now be further explained by reference to thefollowing illustrative examples.

The methods used for synthesis of the compounds of the invention areillustrated by the general schemes below and the preparative examplesthat follow. The starting materials and reagents used in preparing thesecompounds are available from commercial suppliers. These general schemesare merely illustrative of methods by which the compounds of thisinvention can be synthesised, and various modifications to these schemescan be made and will be suggested to one skilled in the art havingreferred to this disclosure.

Nuclear magnetic resonance (NMR) spectra were recorded at 400 MHz; thechemical shifts (δ) are reported in parts per million. Spectra wererecorded using a Bruker 400 Avance instrument fitted with a 5 mm BBFOprobe or DUL probe. Instrument control was by Bruker TopSpin 2.1software, unless stated otherwise.

Purity was assessed using UPLC with UV (photodiode array) detection overa wide range of wavelengths, normally 220-450 nm, using a Waters AcquityUPLC system equipped with Acquity UPLC BEH or HSS C18 columns (2.1 mmid×50 mm long) operated at 50 or 60° C. Mobile phases typicallyconsisted of acetonitrile or methanol mixed with water containing either0.05% formic acid or 0.025% ammonia.

Mass spectra were recorded with a Waters SQD single quadrupole massspectrometer using atmospheric pressure ionisation, unless statedotherwise.

Compounds were purified using normal phase chromatography on silica oralumina, or by reverse phase chromatographic methods, using Biotage orIsolute KPNH Cartridge, SCX cartridge and SCX-2 solid phase extractioncartridges.

Preparative High Performance Liquid Chromatography (HPLC) was performedusing an Agilent Technologies 1100 Series system or Watersautopurification system typically using Waters 19 mm id×100 mm or 19 mmid×250 mm C18 columns such as)(Bridge or SunFire 5 μm materials at 20mL/min. Mobile phases typically consisted of acetonitrile or methanolmixed with water containing either 0.1% formic acid or 0.1% ammonia,unless stated otherwise.

In the following descriptions “room temperature” denotes a temperaturein the range from 20° C. to 25° C.

The abbreviations used in the specific examples have the followingmeanings:

-   Aza-HOBt (HOAt)=7-Aza-1-hydroxybenzotriazole-   BINAP=2,2′-bis(Diphenylphosphino)-1,1′-binaphthyl-   Boc=tert-Butyloxycarbonyl-   DCM=Dichloromethane-   DIAD=Diisopropyl azodicarboxylate-   DIPEA=N,N-Diisopropylethylamine-   DMF=N,N-Dimethylformamide-   DMSO=Dimethyl sulfoxide-   EDC=1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide-   HATU=1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium    3-oxid hexafluorophosphate-   IPA=propan-2-ol-   LiHMDS=Lithium bis(trimethylsilyl)amine-   MTBE=2-methoxy-2-methylpropane-   NMP=N-Methyl-2-pyrrolidone-   TBTU=O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    tetrafluoroborate-   TOTU=[Bis(dimethylamino)methylene][(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxonium    tetrafluoroborate

1. Intermediates Intermediate 1:(1S,2S)-1-N-[5-(Trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

A microwave vial was charged with tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 1.0 g,4.99 mmol), 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3;0.997 g, 5.49 mmol), DIPEA (2.62 ml, 14.98 mmol) and DMSO (16.6 ml). Thereaction was heated with microwave irradiation at 140° C. for 2 hoursand then partitioned between ethyl acetate and water. The organics werewashed with water and brine, dried over magnesium sulfate, filtered andconcentrated in vacuo. This was then purified by column chromatography(silica, 0-50% ethyl acetate/petrol) to afford a cream solid to whichwas then added methanol (10 ml) and HCl in 1,4-dioxane (4M, 6.24 ml,24.97 mmol) and the reaction was stirred at room temperature for 17hours. The reaction mixture was concentrated in vacuo and azeotropicallydistilled with toluene to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.56-1.83 (m, 4H), 2.02-2.22 (m, 2H), 3.25-3.35(m, 1H), 4.06-4.18 (m, 1H), 6.68-6.72 (m, 1H), 7.65-7.82 (m, 2H), 8.18(br. s., 2H), 8.37 (br. s., 1H).

MS ES⁺: 246

Intermediate 2:N-[(1S,2S)-2-Aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamidehydrochloride

A mixture of 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number475105-77-2; 0.84 g, 4.12 mmol), tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 0.75 g,3.74 mmol), HATU (2.14 g, 5.62 mmol) and triethylamine (1.57 ml, 11.23mmol) was stirred in dry DMF (12.5 ml) at room temperature for 17 hours.The reaction mixture was partitioned between ethyl acetate and water,washed with water and brine, dried over magnesium sulfate, filtered andconcentrated in vacuo. The crude material was then purified by columnchromatography (silica, 0-100% ethyl acetate/petrol). The resultingcream solid was recrystalised from ethyl acetate, to which was thenadded methanol (10 ml) and HCl in 1,4-dioxane (4M, 4.68 ml, 18.72 mmol)and the reaction was stirred at room temperature for 17 hours. Thereaction was concentrated in vacuo and azeotropically distilled withtoluene to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.56-1.82 (m, 4H), 1.94-2.04 (m, 2H), 2.42 (s,3H), 3.35-3.43 (m, 1H), 4.10-4.26 (m, 1H), 7.12-7.28 (m, 1H), 7.63-7.80(m, 2H), 7.94-8.00 (m, 1H), 8.08-8.25 (br. s., 2H) and 8.75-8.80 (m,1H).

MS ES⁺: 287

Intermediate 3: N-[(1S,2R)-2-Aminocyclopentyl]-2,6-dimethoxybenzamidehydrochloride

To a solution of tert-butyl N-[(1R,2S)-2-aminocyclopentyl]carbamate (CASnumber 721395-15-9; 0.50 g, 2.50 mmol) in dry DCM (8.3 ml) was addedDIPEA (1.3 ml, 7.49 mmol) and 2,6-dimethoxybenzoyl chloride (CAS number1989-53-3; 0.75 g, 3.74 mmol). The reaction was stirred at roomtemperature under an atmosphere of nitrogen for 17 hours and thenpartitioned between DCM and water, filtered through a hydrophobic fritand concentrated in vacuo. This was purified by column chromatography(silica, 50-100% ethyl acetate/petrol). To the resulting solid was thenadded 1,4-dioxane (2 ml) and HCl in 1,4-dioxane (4M, 2 ml) and thereaction was stirred at room temperature for 2 hours and thenconcentrated in vacuo, and azeotropically distilled with toluene toafford the title compound.

MS ES⁺: 265

Intermediate 4:N-[(1S,2S)-2-Aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

Prepared according to the procedure forN-[(1S,2S)-2-aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamidehydrochloride (Intermediate 2) from tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 1.58 g,7.94 mmol) and 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number1001401-62-2; 1.64 g, 8.68 mmol) to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.48-1.79 (m, 4H), 1.93-2.10 (m, 2H), 3.36-3.42(m, 1H), 4.06-4.14 (m, 1H), 7.49-7.61 (m, 1H), 7.62-7.69 (m, 2H),7.81-7.86 (m, 1H), 8.08 (br. s., 2H), 8.18 (br. s., 2H) and 8.62-8.68(m, 1H).

MS ES⁺: 272

Intermediate 5: N-[(1S,2S)-2-Aminocyclopentyl]-2,6-dimethoxybenzamidehydrochloride

Prepared according to the procedure forN-[(1S,2R)-2-aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride(Intermediate 3) from tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate(CAS number 586961-34-4; 1.0 g, 4.99 mmol) and 2,6-dimethoxybenzoylchloride (CAS number 1989-53-3; 1.50 g, 7.99 mmol) except that after thereaction was complete it was partitioned between DCM and a saturatedsolution of sodium bicarbonate, filtered through a hydrophobic frit andconcentrated in vacuo. The Boc protected intermediate was purified bycolumn chromatography (silica, 0-100% ethyl acetate/petrol) to give awhite solid. After deprotection with HCl in 1,4-dioxane, azeotropicdistillation from toluene afforded the title compound.

MS ES⁺: 265

Intermediate 6: 5-Methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid

To a solution of 2H-1,2,3-triazole (CAS number 288-36-8; 1.99 g, 28.93mmol) in DMF (7.0 ml) at 0-10° C. was added cesium carbonate (4.7 g,14.45 mmol), trans-1-N,2-N-dimethylcyclohexane-1,2-diamine (0.127 g,1.45 mmol), copper(I) iodide (0.068 g, 0.36 mmol) and2-iodo-5-methylbenzoic acid (CAS number 52548-14-8; 3.79 g, 14.46 mmol).The reaction was subjected to microwave irradiation at 125° C. for 15minutes, and then poured into water (20 ml) and extracted with ethylacetate. The combined organics were washed with brine, dried over sodiumsulfate and concentrated in vacuo. The crude product was purified bycolumn chromatography (0-3% methanol/DCM) to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 2.42 (s, 3H), 7.49-7.52 (m, 1H), 7.58-7.64 (m,2H), 8.05 (s, 2H), 13.01 (s, 1H).

MS ES⁺: 204

Intermediate 7:N-[(1S,2S)-2-Aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

To a solution of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid(Intermediate 6; 254 mg, 1.25 mmol) in dry DCM (4.16 ml) was added EDC(359 mg, 1.87 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (255 mg, 1.87mmol), triethylamine (6.9 ml, 4.99 mmol) and tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 250 mg,1.25 mmol). The solution was stirred at room temperature under anatmosphere of nitrogen for 72 hours and then partitioned between DCM andwater, filtered through a hydrophobic frit and concentrated in vacuo.This was then purified by column chromatography (silica, 0-100% ethylacetate/petrol) to afford a pale white solid. This Boc protectedintermediate was dissolved in HCl in 1,4-dioxane (4M, 3 ml) and stirredat room temperature for 17 hours. The reaction was concentrated in vacuoand azeotropically distilled with toluene to afford the title compound.

MS ES⁺: 285

Intermediates 8 and 9: 5-Fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid(Intermediate 8) and 5-Fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid(Intermediate 9)

To a solution of 2H-1,2,3-triazole (CAS number 288-36-8; 4.0 g, 57.97mmol) in DMF (14.0 ml) was added cesium carbonate (18.84 g, 57.97 mmol),trans-1-N,2-N-dimethylcyclohexane-1,2-diamine (0.510 g, 5.797 mmol),copper(I) iodide (0.276 g, 1.449 mmol) and 5-fluoro-2-iodobenzoic acid(CAS number 52548-63-7; 7.71 g, 28.98 mmol) at 0-10° C. The resultingreaction mixture was then heated with microwave irradiation at 125° C.for 15 hours with stirring. The reaction mass was poured into water andthe product was extracted into ethyl acetate. The combined organiclayers were washed with brine, dried over sodium sulfate andconcentrated in vacuo. This was then purified by column chromatography(silica, 0-3% methanol/DCM) to obtain5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 8) (alsocommercially available CAS number 1186050-64-5) and crude5-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 9).

The crude compound (Intermediate 9) obtained was further purified bycolumn chromatography (silica, 0-3% methanol/DCM) and then by reversephase preparative HPLC (eluted with acetonitrile/water with 0.1%ammonia) to afford the title compound.

Intermediate 9

¹H NMR (DMSO-d₆) δ ppm 7.41-7.45 (m, 1H), 7.50-7.52 (m, 1H), 7.57-7.60(m, 1H), 7.83-7.84 (m, 1H), 8.42 (s, 1H).

MS ES⁺: 208

Intermediates 10:N-[(1S,2R)-2-Hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Triethylamine (1.52 ml, 10.90 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (0.59 g, 4.36 mmol) and EDC (0.84g, 4.36 mmol) were added to a solution of(1R,2S)-2-aminocyclopentan-1-ol hydrochloride (CAS number 137254-03-6;0.50 g, 3.63 mmol) and 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number1001401-62-2; 0.76 g, 4.00 mmol) in DCM (10 ml). The reaction wasstirred at room temperature for 18 hours and then diluted with DCM (50ml) and washed with a saturated solution of sodium bicarbonate (2×20ml). The crude product was purified by column chromatography (silica,0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.36-1.59 (m, 3H), 1.62-1.88 (m, 3H),3.79-3.93 (m, 1H), 3.94-4.10 (m, 1H), 4.29-4.39 (m, 1H), 7.49-7.58 (m,1H), 7.58-7.67 (m, 2H), 7.71-7.82 (m, 2H), 8.05 (s, 2H)

MS ES⁺: 273

Intermediates 11:N-[(1S,2S)-2-Hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2R)-2-hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 10) from 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number1001401-62-2; 531 mg, 2.81 mmol), (1S,2S)-2-aminocyclopentan-1-olhydrochloride (CAS number 68327-04-8; 368 mg, 2.67 mmol) and DIPEA (1401μl, 8.02 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33-1.48 (m, 2H), 1.49-1.79 (m, 3H),1.83-1.97 (m, 1H), 3.80-3.88 (m, 1H), 3.89-3.98 (m, 1H), 4.57-4.67 (m,1H), 7.43-7.55 (m, 2H), 7.56-7.67 (m, 1H), 7.73-7.83 (m, 1H), 8.03 (s,2H), 8.09-8.23 (m, 1H)

MS ES⁺: 273

Intermediate 12:2-{[4-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine

Step (i):2-{[4-(Trifluoromethyl)pyridin-2-yl]methylidene}cyclopentan-1-one

A solution of 4-(trifluoromethyl)pyridine-2-carbaldehyde (CAS number132470-83-8; 1.00 g, 5.71 mmol) and 4-(cyclopent-1-en-1-yl)morpholine(CAS number 936-52-7; 0.90 ml, 5.60 mmol) in toluene (15 ml) was heatedat 90° C. for 18 hours. The reaction was then cooled to room temperatureand concentrated HCl (2 ml) and water (2 ml) was added drop wise. Thereaction was stirred at room temperature for 20 minutes and thenneutralised with a saturated solution of sodium bicarbonate and thenbasified with 2 M NaOH (aq). The organics were extracted with ethylacetate (2×40 ml) and the combined organics were washed with brine (10ml), dried over magnesium sulfate, filtered through a hydrophobic fritand concentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-20% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 2.01-2.10 (m, 2H), 2.34-2.48 (m, 2H),3.13-3.26 (m, 2H), 7.23-7.34 (m, 1H), 7.41-7.50 (m, 1H), 7.63-7.71 (m,1H), 8.83-8.94 (m, 1H)

MS ES⁺: 242

Step (ii): 2-{[4-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-one

A solution of2-{[4-(trifluoromethyl)pyridin-2-yl]methylidene}cyclopentan-1-one (0.513g, 2.13 mmol) in ethyl acetate (20 mL) was added palladium on carbon(10% wt, 50% wet, 0.226 g, 0.11 mmol) and the resulting mixture wasstirred under a balloon of hydrogen gas for 2 hours. The reaction wasfiltered through diatomaceous earth (commercially sold under the trademark “Celite”) and concentrated in vacuo. The crude product was purifiedby column chromatography (silica, 0-30% ethyl acetate/petrol) to affordthe title compound.

¹H NMR (300 MHz, DCM-d₂) δ ppm 1.44-1.67 (m, 1H), 1.68-1.89 (m, 1H),1.94-2.05 (m, 1H), 2.05-2.25 (m, 2H), 2.25-2.42 (m, 1H), 2.54-2.73 (m,1H), 2.74-2.95 (m, 1H), 3.21-3.41 (m, 1H), 7.27-7.47 (m, 2H), 8.59-8.80(m, 1H)

MS ES⁺: 244

Step (iii): 2-{[4-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol

Sodium borohydride (0.117 g, 3.08 mmol) was added to a solution of2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-one (0.375 g,1.54 mmol) in ethanol (10 ml). The reaction was stirred at roomtemperature for 3 hours and then quenched with water (5 mL) and 2M HCl(aq., 5 ml). The organics were extracted with ethyl acetate (2×30 ml)and the combined organics were washed with brine (10 ml), dried overmagnesium sulfate, filtered through a hydrophobic frit and concentratedin vacuo. The crude product was purified by column chromatography(silica, 0-35% ethyl acetate/petrol) to afford the title compound as twodiastereomers.

Diastereomer 1:2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.42-1.70 (m, 3H), 1.72-1.94 (m, 3H),1.97-2.13 (m, 1H), 2.87-3.00 (m, 1H), 3.02-3.17 (m, 1H), 3.82-4.00 (m,1H), 7.30-7.49 (m, 2H), 8.59-8.77 (m, 1H)

MS ES⁺: 246

Diastereomer 2:2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.27-1.43 (m, 1H), 1.51-1.80 (m, 3H),1.83-2.07 (m, 2H), 2.09-2.25 (m, 1H), 2.94-3.06 (m, 2H), 3.84-3.98 (m,1H), 7.31-7.47 (m, 2H), 8.63-8.73 (m, 1H)

MS ES⁺: 246

Step (iv):2-(2-{[4-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione

DIAD (0.26 ml, 1.36 mmol) was added to a solution of triphenylphosphine(0.350 g, 1.34 mmol), 2,3-dihydro-1H-isoindole-1,3-dione (CAS number136918-14-4; 0.197 g, 1.34 mmol) and2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol(Diastereomer 2) (0.252 g, 1.03 mmol) in THF (5 ml). The reaction wasstirred at room temperature for 24 hours and then furthertriphenylphosphine (0.175 g, 0.69 mmol) and DIAD (0.130 ml, 0.69 mmol)was added. The reaction was stirred for 72 hours at room temperature andthen concentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-100% ethyl acetate/petrol) and then by columnchromatography (basic silica, 0-100% ethyl acetate/petrol) to afford thetitle compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.46-1.65 (m, 2H), 1.78-1.93 (m, 2H),2.01-2.12 (m, 2H), 2.29-2.46 (m, 1H), 2.76-2.93 (m, 2H), 4.65-4.83 (m,1H), 7.11-7.26 (m, 2H), 7.63-7.81 (m, 4H), 8.50-8.58 (m, 1H)

MS ES⁺: 375

Step (v): 2-{[4-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine

Methanamine (40% aq, 1 ml, 11.55 mmol) was added to a solution of2-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione(0.100 g, 0.27 mmol) in ethanol (6 ml) in a microwave vial. The vial wassealed and stirred at room temperature for 18 hours and then heated to60° C. for 5 hours. The reaction was cooled to room temperature andconcentrated in vacuo. This was then purified by SCX chromatography (2Mammonia in methanol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.50-1.79 (m, 4H), 1.79-2.02 (m, 2H),2.18-2.35 (m, 1H), 2.86-3.02 (m, 1H), 3.05-3.21 (m, 1H), 3.26-3.38 (m,1H), 7.33-7.48 (m, 2H), 8.62-8.74 (m, 1H)

MS ES⁺: 245

Intermediate 13:2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine

Step (i): 5-(Trifluoromethyl)pyridine-2-carbaldehyde

Dess-Martin periodinane (CAS number 87413-09-0; 13.17 g, 31.10 mmol) wasadded to a solution of [5-(trifluoromethyl)pyridin-2-yl]methanol (CASnumber 31181-84-7; 5.00 g, 28.2 mmol) in DCM (60 ml). The reaction wasstirred at room temperature for 18 hours and then a saturated solutionof sodium thiosulfate (aq, 100 ml) was added. The reaction was stirredfor 45 min at room temperature and then phases separated. The aqueousphase was further extracted with DCM (60 ml) and the combined organicswere washed with a saturated solution of sodium bicarbonate (aq, 60 ml),filtered through a hydrophobic frit and concentrated in vacuo. The crudeproduct was purified by column chromatography (silica, 0-20% ethylacetate/petrol) to afford the title compound.

MS ES⁺: 176

Step (ii):2-{[5-(Trifluoromethyl)pyridin-2-yl]methylidene}cyclopentan-1-one

A solution of 5-(trifluoromethyl)pyridine-2-carbaldehyde (3.32 g, 18.96mmol) and 4-(cyclopent-1-en-1-yl)morpholine (CAS number 936-52-7; 2.97ml, 18.58 mmol) in toluene (50 ml) was heated to 90° C. for 18 hours.The reaction was then cooled to room temperature and concentrated HCl (2ml) and water (2 ml) was added drop wise. The reaction was stirred atroom temperature for 20 minutes and then neutralised with a saturatedsolution of sodium bicarbonate and then basified with 2M NaOH (aq). Theorganics were extracted with ethyl acetate (2×40 ml) and the combinedorganics were washed with brine (10 ml), dried over magnesium sulfate,filtered through a hydrophobic frit and concentrated in vacuo. The crudeproduct was purified by column chromatography (silica, 0-20% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.94-2.13 (m, 2H), 2.31-2.51 (m, 2H),3.11-3.36 (m, 2H), 7.22-7.43 (m, 1H), 7.51-7.72 (m, 1H), 7.87-8.09 (m,1H), 8.95 (s, 1H)

MS ES⁺: 242

Step (iii): 2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-one

A solution of2-{[5-(trifluoromethyl)pyridin-2-yl]methylidene}cyclopentan-1-one (0.513g, 2.13 mmol) in ethyl acetate (20 ml) was added palladium on carbon(10% wt, 50% wet, 0.226 g, 0.11 mmol) and the resulting mixture wasstirred under a balloon of hydrogen gas for 2 hours. The reaction wasfiltered through diatomaceous earth (commercially sold under the trademark “Celite”) and concentrated in vacuo. The crude product was purifiedby column chromatography (silica, 0-40% ethyl acetate/petrol) to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.50-1.67 (m, 1H), 1.71-1.88 (m, 1H),1.92-2.05 (m, 1H), 2.07-2.24 (m, 2H), 2.26-2.41 (m, 1H), 2.62-2.79 (m,1H), 2.82-3.02 (m, 1H), 3.16-3.41 (m, 1H), 7.18-7.50 (m, 1H), 7.80-8.00(m, 1H), 8.80 (br. s., 1H)

MS ES⁺: 244

Step (iv): 2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol

Sodium borohydride (0.036 g, 0.954 mmol) was added to a solution of2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-one (0.116 g,0.48 mmol) in ethanol (5 ml). The reaction was stirred at roomtemperature for 1 hour and then quenched with water (5 ml) and 2M HCl(aq, 5 ml), basified with 2M NaOH (aq) and extracted with ethyl acetate(2×30 ml). The combined organics were dried over dried over magnesiumsulfate, filtered through a hydrophobic frit and concentrated in vacuo.The crude product was purified by column chromatography (silica, 0-30%ethyl acetate/petrol) to afford the title compound as two diastereomers.

Diastereomer 1:2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.79-0.96 (m, 1H), 1.22-1.40 (m, 1H),1.44-1.59 (m, 2H), 1.60-1.71 (m, 1H), 1.73-1.91 (m, 2H), 1.98-2.13 (m,1H), 2.89-3.02 (m, 1 H), 3.03-3.14 (m, 1H), 3.84-3.98 (m, 1H), 7.26-7.41(m, 1H), 7.85-7.98 (m, 1H), 8.77 (s, 1H)

MS ES⁺: 246

Diastereomer 2:2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.80-0.95 (m, 1H), 1.26-1.40 (m, 1H),1.51-1.78 (m, 3H), 1.84-2.05 (m, 2H), 2.09-2.21 (m, 1H), 2.92-3.11 (m,2H), 3.84-3.98 (m, 1H), 7.29-7.45 (m, 1H), 7.79-7.94 (m, 1H), 8.78 (s,1H)

MS ES⁺: 246

Step (v):2-(2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione

DIAD (0.348 mL, 1.791 mmol) was added to a solution of2,3-dihydro-1H-isoindole-1,3-dione (CAS number 136918-14-4; 0.263 g,1.791 mmol), triphenylphosphine (0.470 g, 1.791 mmol) and2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-ol(Diastereomer 2) (0.366 g, 1.492 mmol) in THF (2 ml) under nitrogen. Thereaction was stirred at room temperature for 72 hours and thenconcentrated. The crude product was purified by column chromatography(silica, 0-20% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.48-1.66 (m, 1H), 1.74-1.92 (m, 2H),2.01-2.15 (m, 2H), 2.32-2.53 (m, 1H), 2.68-2.95 (m, 3H), 4.76 (m, 1H),7.06-7.19 (m, 1H), 7.64-7.81 (m, 5H), 8.59 (s, 1H)

MS ES⁺: 375

Step (vi):2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine

Methanamine (40% aq, 3 ml, 34.7 mmol) was added to a solution of2-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)-2,3-dihydro-1H-isoindole-1,3-dione(0.316 g, 0.84 mmol) in ethanol (5 ml). The reaction was stirred at roomtemperature for 24 hours and then further methanamine (40% aq, 3 ml,34.7 mmol) was added. The reaction was stirred for 24 hours at roomtemperature and then re-suspended in ethanol (5 ml) and methanamine (40%aq, 3 ml, 34.7 mmol). The reaction stirred for 72 hours at roomtemperature. The reaction mixture was concentrated in vacuo and was thenpurified by reverse phase preparative HPLC (eluted withacetonitrile/water with 0.1% ammonia) and then purified by columnchromatography (basic silica, 50-100% ethyl acetate/petrol) to affordthe title compound.

MS ES⁺: 245

Intermediate 14:(1S,2S)-1-N-[5-(Trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number799557-87-2; 5.01 g, 27.5 mmol), tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 5 g,24.97 mmol) and DIPEA (13.08 ml, 74.9 mmol) in DMSO (50 ml) was heatedin a sealed vial at 120° C. for 2 hours and then 140° C. for 2 hours.The reaction mixture was partitioned between ethyl acetate (400 ml) andwater (200 ml). The organics were washed with water (3×100 ml) and brine(100 ml), dried over sodium sulfate and concentrated in vacuo. Theresulting residue was purified by column chromatography (silica, 5-40%ethyl acetate/petrol). To the resulting solid was then added HCl in1,4-dioxane (4M, 30 ml, 120 mmol) and the reaction was stirred at roomtemperature overnight. The reaction was concentrated in vacuo,triturated with diethyl ether and filtered to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.49-1.88 (m, 4H), 2.02-2.22 (m, 2H),3.24-3.47 (m, 1H), 4.12-4.28 (m, 1H), 7.99-8.14 (m, 1H), 8.18-8.48 (m,5H)

MS ES⁺: 247

Intermediate 15: 2-Chloro-6-(2H-1,2,3-triazol-2-yl)benzoic acid

To the solution of 2H-1,2,3-triazole (CAS number 288-36-8; 4.0 g, 57.97mmol) in DMF (14 ml) was added cesium carbonate (18.84 g, 57.97 mmol),trans-1-N,2-N-dimethylcyclohexane-1,2-diamine (0.510 g, 5.80 mmol),copper(I) iodide (0.276 g, 1.45 mmol) and 2-bromo-6-chlorobenzoic acid(CAS number 93224-85-2; 6.78 g, 28.98 mmol) at 0-10° C. The reaction wassubjected to microwave irradiation at 125° C. for 15 minutes and wasthen partitioned between ethyl acetate (3×100 ml) and water (100 ml).The aqueous layer was acidified with 2M HCl (aq) to give pH 2 and thenextracted with ethyl acetate (3×100 ml). The combined organics werewashed with brine, dried over sodium sulfate and concentrated in vacuo.This was then purified by column chromatography (0-3% methanol/DCM) toafford the title compound.

¹H NMR (400 MHz DMSO-d₆) δ ppm 7.62-7.67 (m, 2H), 7.92-7.94 (m, 1H),8.17 (s, 2H), 13.73 (s, 1H)

MS ES⁺: 224, 226

Intermediate 16: 3-Cyclopropylpyridine-2-carboxylic acid

Step (i): Methyl 3-bromopyridine-2-carboxylate

To a solution of 3-bromopyridine-2-carboxylic acid (CAS number30683-23-9; 2.0 g, 9.90 mmol) in methanol (15 ml) was added concentratedH₂SO₄ (3 ml) and the reaction mixture was refluxed for 2 hours. Thereaction was diluted with a saturated solution of sodium bicarbonate andextracted with ethyl acetate (3×75 ml). The organics were washed withwater (50 ml), brine (20 ml), dried over sodium sulfate and concentratedin vacuo to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 3.91 (s, 3H), 7.53-7.56 (m, 1H),8.25-8.28 (m, 1H) 8.62-8.64 (m, 1H)

MS ES⁺: 218

Step (ii): Methyl 3-ethenylpyridine-2-carboxylate

Methyl 3-bromopyridine-2-carboxylate (1.0 g, 4.63 mmol) and potassiumvinyltrifluoroborate (CAS number 13682-77-4; 0.744 g, 5.56 mmol) weredissolved in IPA (15 ml). To this was then added triethylamine (0.467 g,4.63 mmol) and the mixture was degassed under nitrogen atmosphere for 15minutes. [1,1′-Bis(diphenyl phosphino)ferrocene]dichloropalladium(II)(0.075 g, 0.092 mmol) was added and the reaction was stirred at 100° C.for 4 hours. The reaction was diluted with water (75 ml) and filteredthrough diatomaceous earth (commercially sold under the trade mark“Celite”). The organics were extracted with ethyl acetate (3×50 ml),washed with water (25 ml), brine (20 ml), dried over sodium sulfate andconcentrated in vacuo. The resulting residue was purified by columnchromatography (silica, 0-18% ethyl acetate/n-hexane to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d) δ ppm 3.88 (s, 3H), 5.49-5.52 (m, 1H),5.93-5.98 (m, 1H), 7.03-7.10 (m, 1H), 7.58-7.62 (m, 1H), 8.19-8.21 (m,1H), 8.54-8.56 (m, 1H)

MS ES⁺: 164

Step (iii): Methyl 3-cyclopropylpyridine-2-carboxylate

To a stirred solution of diiodomethane (2.46 g, 9.20 mmol) in dry DCM (5ml) at −10° C. was added diethyl zinc in hexane (1 M, 9.2 ml, 9.20mmol). The reaction was stirred for 30 minutes under nitrogen. To thiswas then added methyl 3-ethenylpyridine-2-carboxylate (0.30 g, 1.84mmol) as a solution in DCM (5 ml) over a 15 minute period. The reactionwas then allowed to warm to room temperature and was stirred at roomtemperature for 15 hours. The reaction mixture was diluted with asaturated solution of ammonium chloride (25 ml) and the organics wereextracted with ethyl acetate (3×30 ml). The combined organics werewashed with water (25 ml), brine (25 ml), dried over sodium sulfate andconcentrated in vacuo. The resulting residue was purified by columnchromatography (silica, 0-15% ethyl acetate/n-hexane to afford the titlecompound.

MS ES⁺: 178

Step (iv): 3-cyclopropylpyridine-2-carboxylic acid

To a solution of methyl 3-cyclopropylpyridine-2-carboxylate (80 mg, 0.45mmol) in THF (2 ml) and water (2 ml) was added lithium hydroxide (55 mg,1.36 mmol) and the reaction mixture was refluxed for 2 hours. Thereaction was then acidified to pH 2 using 1M HCl (aq) and extracted withDCM (3×50 ml). The combined organics were washed with water (30 ml),brine (30 ml), dried over sodium sulfate and concentrated in vacuo toafford the title compound.

MS ES⁺: 164

Intermediate 17: 3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid

To the solution of 2H-1,2,3-triazole (CAS number 288-36-8; 0.23 g, 3.33mmol) in 1,4-dioxane (4.0 ml) was added cesium carbonate (1.0 g, 3.33mmol), trans-1-N,2-N-dimethylcyclohexane-1,2-diamine (0.047 g, 0.33mmol), copper(I) iodide (0.015 g, 0.08 mmol) and2-bromo-3,6-difluorobenzoic acid (CAS number 124244-65-1; 0.40 g, 1.68mmol). The reaction was stirred at 120° C. for 30 minutes and was thenpoured into water (10 ml) and extracted with ethyl acetate (2×30 ml).The organics were washed with brine, dried over sodium sulfate andconcentrated in vacuo. The resulting residue was purified by columnchromatography (silica, 0-5% methanol/DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) 7.63-7.69 (m, 1H), 7.73-7.79 (m, 1H), 8.19 (s,2H), 13.87 (br. s., 1H)

MS ES⁺: 225

Intermediate 18:N-[(1S,2S)-2-Aminocyclopentyl]-N-cyclobutyl-2,6-dimethoxybenzamidehydrochloride

Step (i): tert-Butyl N-[(1S,2S)-2-(cyclobutylamino)cyclopentyl]carbamate

To a solution of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate (CASnumber 586961-34-4; 600 mg, 3.00 mmol) in dry DCM (10 ml) was addedcyclobutanone (CAS number 1191-95-3; 248 μl, 3.30 mmol), acetic acid(257 μl, 4.49 mmol) and molecular sieves. The reaction was then stirredat room temperature for 1 hour. To this was then added sodiumtriacetoxyborohydride (952 mg, 4.49 mmol) and the reaction was allowedto stir at room temperature for 17 hours. The reaction was basified bythe addition of 2M NaOH (aq) and the organics were extracted DCM,filtered through a hydrophobic frit and concentrated in vacuo.

Step (ii): tert-ButylN-[(1S,2S)-2-(N-cyclobutyl-2,6-dimethoxybenzamido)cyclopentyl]carbamate

To a solution of tert-butylN-[(1S,2S)-2-(cyclobutylamino)cyclopentyl]carbamate (400 mg, 1.573 mmol)in dry DCM (5.3 ml) was added DIPEA (1.3 ml, 7.86 mmol) and2,6-dimethoxybenzoyl chloride (CAS number 1989-53-3; 473 mg, 2.359mmol). The reaction was stirred at room temperature for 1 hour and wasthen partitioned between DCM and water, filtered through a hydrophobicfrit and concentrated in vacuo. This was then purified by columnchromatography (basic silica, 0-100% ethyl acetate/petrol) to afford thetitle compound.

MS ES⁺: 419

Step (iii):N-[(1S,2S)-2-Aminocyclopentyl]-N-cyclobutyl-2,6-dimethoxybenzamidehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-(N-cyclobutyl2,6-dimethoxybenzamido)cyclopentyl]carbamate(1.34 g, 3.20 mmol) in methanol (11 ml) was added HCl in 1,4-dioxane (4M, 8.00 ml, 32.0 mmol). The reaction was stirred at room temperature for17 hours (overnight) and then was concentrated in vacuo, azeotropicallydistilled with toluene to afford the title compound.

MS ES⁺: 319

Intermediate 19: N-[(1S,2S)-2-Aminocyclopentyl]-2-chlorobenzamidehydrochloride

To a stirred solution of tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg,2.497 mmol) in dry DCM (8.3 ml) was added triethylamine (1.74 ml, 12.48mmol) and 2-chlorobenzoyl chloride (CAS number 609-65-4; 476 μl, 3.74mmol). The reaction was stirred at room temperature for 72 hours. Thereaction was partitioned between DCM and a saturated solution of sodiumbicarbonate, filtered through a hydrophobic frit and concentrated invacuo. The resulting residue was purified by column chromatography(silica, 0-100% ethyl acetate/petrol). The Boc protect intermediate wasdissolved in 1,4-dioxane (8 ml) and to this was added HCl in 1,4-dioxane(4 M, 6.0 ml, 23.91 mmol). The reaction was stirred at room temperaturefor 17 hours and then concentrated in vacuo, azeotropically distilledwith toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.50-1.83 (m, 4H), 1.98-2.16 (m, 2H),3.35-3.45 (m, 1H), 4.06-4.31 (m, 1H), 7.37-7.61 (m, 4H), 8.03-8.25 (m,2H), 8.62-8.74 (M, 1H)

MS ES⁺: 239

Intermediate 20:N-[(1S,2S)-2-Aminocyclopentyl]-2-fluoro-6-methoxybenzamide hydrochloride

Prepared according to the procedure forN-[(1S,2S)-2-aminocyclopentyl]-2-chlorobenzamide hydrochloride(Intermediate 19) from tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg,2.50 mmol), 2-fluoro-6-methoxybenzoic acid (CAS number 137654-21-8; 637mg, 3.74 mmol) and 1,3,5,2,4,6-trioxatriphosphorinane, 2,4,6-tripropyl-,2,4,6-trioxide (CAS number 68957-94-8; 50% in ethyl acetate, 2.2 ml,3.74 mmol). Subsequent deprotection with HCl afforded the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.51-1.79 (m, 4H), 1.95-2.14 (m, 2H),3.34-3.42 (m, 1H), 4.04-4.19 (m, 1H), 6.77-6.99 (m, 2H), 7.33-7.50 (m,1H), 7.94-8.11 (m, 2H), 8.64-8.78 (m, 1H)

MS ES⁺: 253

Intermediate 21: N-[(1S,2S)-2-Aminocyclopentyl]-2,6-dffluorobenzamidehydrochloride

Prepared according to the procedure forN-[(1S,2S)-2-aminocyclopentyl]-2-chlorobenzamide hydrochloride(Intermediate 19) from tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 500 mg,2.50 mmol), 2,6-difluorobenzoic acid (CAS number 385-00-2; 592 mg, 3.74mmol) and 1,3,5,2,4,6-trioxatriphosphorinane, 2,4,6-tripropyl-,2,4,6-trioxide (CAS number 68957-94-8; 50% in ethyl acetate, 2.2 ml,3.74 mmol). Subsequent deprotection with HCl afforded the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.49-1.79 (m, 4H), 1.94-2.13 (m, 2H),3.34-3.41 (m, 1H), 4.02-4.16 (m, 1H), 6.77-6.98 (m, 2H), 7.34-7.47 (m,1H), 7.93-8.11 (m, 2H), 8.66-8.78 (m, 1H)

MS ES⁺: 241

Intermediate 22:(1S,2S)-1-N-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

Step (i): tert-Butyl N-[(1S,2S)-2-(dibenzylamino)cyclopentyl]carbamate

To a suspension of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate(CAS number 586961-34-4; 500 mg, 2.50 mmol) and potassium carbonate (518mg, 3.74 mmol) in DMF (5 ml) was added (bromomethyl)benzene (CAS number100-39-0; 356 μl, 3.00 mmol). The reaction was stirred at roomtemperature for 24 hours. To this was then added further(bromomethyl)benzene (CAS number 100-39-0; 356 μl, 3.00 mmol) andstirring was continued for 24 hours. The reaction mixture was dilutedwith ethyl acetate (40 ml) and washed with water (3×30 ml) and brine (30ml). The organics were filtered through a hydrophobic frit andconcentrated in vacuo. This was then purified by column chromatography(silica, 0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.16-1.29 (m, 1H), 1.37-1.67 (m, 12H),1.68-1.82 (m, 1H), 1.92-2.06 (m, 1H), 2.70-2.87 (m, 1H), 3.46 (d,J=13.64 Hz, 2H), 3.77 (d, J=13.64 Hz, 2H), 4.28-4.49 (m, 1H), 7.15-7.47(m, 11H)

MS ES⁺: 381

Step (ii): (1S,2S)-1-N,1-N-Dibenzyl-2-N-methylcyclopentane-1,2-diamine

To a solution of tert-butylN-[(1S,2S)-2-(dibenzylamino)cyclopentyl]carbamate (320 mg, 0.841 mmol)in THF (2.8 ml) at room temperature was added drop wise lithiumaluminium hydride in THF (1 M, 1.3 ml, 1.261 mmol). The reaction wasstirred for 1 hour and then was heated to 60° C. for 3 hours. Thereaction was then cooled to room temperature and quenched by theaddition of sodium sulfate decahydrate, filtered and washed with THF andethyl acetate. The filtrate was concentrated in vacuo to afford thetitle compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.16-1.33 (m, 1H), 1.52-1.90 (m, 5H),2.24-2.33 (m, 3H), 2.72-2.94 (m, 2H), 3.37-3.50 (m, 2H), 3.56-3.66 (m,1H), 3.69-3.85 (m, 2H), 7.13-7.51 (m, 10H)

Step (iii):(1S,2S)-1-N,1-N-Dibenzyl-2-N-methyl-2-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number799557-87-2; 198 mg, 1.087 mmol),(1S,2S)-1-N,1-N-dibenzyl-2-N-methylcyclopentane-1,2-diamine (291 mg,0.988 mmol) and DIPEA (518 μl, 2.97 mmol) in DMSO (3.3 ml) was subjectedto microwave irradiation at 140° C. for 4 hours. The reaction wasdiluted with ethyl acetate (20 ml), washed with a saturated solution ofsodium bicarbonate (3×20 ml), brine (20 ml), filtered through ahydrophobic frit and concentrated in vacuo. This was then purified bycolumn chromatography (silica, 0-15% ethyl acetate/petrol) to afford thetitle compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.43-1.58 (m, 2H), 1.61-1.93 (m, 4H),2.58 (s, 3H), 3.17-3.33 (m, 1H), 3.41 (d, J=13.64 Hz, 2H), 3.76 (d,J=13.64 Hz, 2H), 5.12-5.29 (m, 1H), 7.03-7.29 (m, 10H), 7.96 (s, 1H),8.23 (s, 1H)

MS ES⁺: 441

Step (iv):(1S,2S)-1-N-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

To a solution of(1S,2S)-1-N,1-N-dibenzyl-2-N-methyl-2-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(285 mg, 0.647 mmol) in ethyl acetate (2 ml) and ethanol (1 ml) wasadded palladium on carbon (10% wt, 50% wet, 100 mg, 0.094 mmol). Theresulting mixture was stirred under a balloon of hydrogen gas for 18hours. The reaction was filtered through diatomaceous earth(commercially sold under the trade mark “Celite”) and concentrated invacuo to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.37-1.56 (m, 1H), 1.61-1.87 (m, 3H),1.88-2.08 (m, 2H), 3.01 (s, 3H), 3.24-3.42 (m, 1H), 4.52-4.71 (m, 1H),8.11 (s, 1H), 8.32 (s, 1H)

MS ES⁺: 261

Intermediate 23:(1S,2S)-1-N-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number799557-87-2; 2.0 g, 10.98 mmol), tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g,9.99 mmol) and DIPEA (5.23 ml, 30.0 mmol) in DMSO (20 ml) was sealed andheated at 140° C. for 3 hours. The reaction mixture was partitionedbetween ethyl acetate (200 ml) and water (100 ml). The organics werewashed with water (2×100 ml), brine (100 ml), dried over sodium sulfateand concentrated in vacuo. The residue was purified by columnchromatography (silica, 10-40% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.32-1.66 (m, 11H), 1.71-1.96 (m,2H), 2.07-2.24 (m, 1H), 2.30-2.51 (m, 1H), 3.76-4.04 (m, 2H), 4.69-4.92(m, 1H), 6.07-6.24 (m, 1H), 7.91 (s, 1H), 8.30 (s, 1H)

MS ES⁺: 347

Step (ii): tert-ButylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

To a solution of tert-butyl((1S,2S)-2-((5-(trifluoromethyl)pyrazin-2-yl)amino)cyclopentyl)carbamate(3.49 g, 10.08 mmol) in dry DCM (67 ml) at 0° C. was added1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 2.15 g, 12.09 mmol).The reaction was allowed to warm to room temperature overnight. Afurther portion of portion of 1-bromopyrrolidine-2,5-dione (CAS number128-08-5; 1.70 g, 9.56 mmol) was added and the reaction stirred for anadditional 24 hours. The reaction was concentrated in vacuo and thenpurified by column chromatography (silica, 0-30% ethyl acetate/petrol)to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.31-1.62 (m, 11H), 1.72-1.92 (m,2H), 2.08-2.24 (m, 1H), 2.36-2.56 (m, 1H), 3.75-4.14 (m, 2H), 4.63-4.87(m, 1H), 6.78-6.96 (m, 1H), 8.25 (s, 1H)

MS ES⁺: 425, 427

Step (iii): tert-ButylN-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A mixture of tert-butylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(800 mg, 1.88 mmol), methylboronic acid (CAS number 13061-96-6; 338 mg,5.64 mmol), tetrakis(triphenylphosphine)palladium (217 mg, 0.19 mmol)and, 2 M potassium carbonate (aq, 3.8 ml, 7.53 mmol) in 1,4-dioxane (6.3ml) was sealed, evacuated and purged with nitrogen and then subjected tomicrowave irradiation at 120° C. for 2 hours. The reaction mixture wasthen diluted with ethyl acetate (40 ml) and water (10 ml). The organicswere washed with water and brine, dried over sodium sulfate andconcentrated in vacuo. The residue was then purified by columnchromatography (silica, 0-50% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.34-1.53 (m, 11H), 1.73-1.93 (m,2H), 2.08-2.20 (m, 1H), 2.43 (s, 3H), 2.48-2.64 (m, 1H), 3.73-3.89 (m,1H), 3.95-4.09 (m, 1H), 4.75-4.85 (m, 1H), 6.45-6.57 (m, 1H), 8.20 (s,1H)

MS ES⁺: 361

Step (iv):(1S,2S)-1-N-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(480 mg, 1.332 mmol) in methanol (5 ml) was added HCl in 1,4-dioxane (4M, 3.33 ml, 13.32 mmol). The reaction was stirred at room temperatureovernight and then concentrated in vacuo, azeotropically distilled withtoluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.58-1.85 (m, 4H), 1.99-2.23 (m, 2H),2.43 (s, 3H), 3.46-3.65 (m, 1H), 4.28-4.46 (m, 1H), 7.24-7.41 (m, 1H),8.13-8.37 (m, 4H)

MS ES⁺: 261

Intermediate 24: tert-Butyl N-(2-amino-1-methylcyclopentyl)carbamate

Step (i): 1-Methyl-6-(4-methylbenzenesulfonyl)-6-azabicyclo[3.1.0]hexane

To a solution of 1-methylcyclopent-1-ene (CAS number 693-89-0; 50.0 g,609.75 mmol) iii and sodium chloro(4-methylbenzenesulfonyl)azanide (CASnumber 127-65-1; 192 g, 680.85 mmol) in THF (2500 ml) was addedtrimethylphenylammonium tribromide (13.3 g, 61.57 mmol). The reactionwas stirred vigorously at 25° C. for 12 hours. The reaction mixture waspoured into water (1500 ml) and the organics were extracted with ethylacetate (3×1000 ml). The combined organics were washed with water (500ml), brine (500 ml), dried over sodium sulfate and concentrated invacuo. This was then purified by column chromatography (silica, 0-2.5%ethyl acetate/n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.15-1.25 (m, 1H), 1.46-1.70 (m, 4H),1.75 (s, 3H), 1.88-1.93 (m, 1H), 2.50 (s, 3H), 3.34-3.35 (m, 1H),7.40-7.42 (m, 2H), 7.74-7.76 (m, 2H)

MS ES⁺: 251

Step (ii): N-(2-Azido-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide

To a solution of1-methyl-6-(4-methylbenzenesulfonyl)-6-azabicyclo[3.1.0]hexane (55 g,219.12 mmol) in IPA (1000 ml) and water (1000 ml) was added sodium azide(57.0 g, 876.92 mmol). The reaction mixture was stirred at roomtemperature for 17 hours. The reaction was cooled to room temperatureand water (1000 ml) was added. The aqueous layer was extracted withdiethyl ether (3×500 ml). The combined organics were washed with brine(250 ml), dried over sodium sulfate, concentrated in vacuo to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.20-1.30 (m, 4H), 1.45-1.63 (m, 5H),2.38 (s, 3H) 3.33-3.39 (m, 1H), 7.38-7.40 (m, 2H), 7.69-7.77 (m, 3H)

MS ES⁺: 294

Step (iii):N-(2-Amino-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide

To a solution ofN-(2-azido-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide (52.0 g,176.87 mmol) in methanol (1100 ml) was added palladium on carbon (10%wt, 10.0 g). The reaction mixture was stirred at room temperature undera balloon of hydrogen gas for 12 hours. The reaction was filteredthrough diatomaceous earth (commercially sold under the trade mark“Celite”) and concentrated in vacuo to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 0.93 (s, 3H), 1.20-1.22 (m, 1H),1.36-1.52 (m, 5H) 2.38 (s, 3H) 2.94-2.98 (m, 1H) 4.11 (br. s, 1H),7.37-7.39 (m, 2H), 7.69-7.71 (m, 2H)

MS ES⁺: 268

Step (iv): tert-ButylN-[1-methyl-2-(4-methylbenzenesulfonamido)-cyclopentyl]carbamate

To a solution ofN-(2-amino-2-methylcyclopentyl)-4-methylbenzene-1-sulfonamide (48.0 g,179.10 mmol) in DCM (1400 ml) was added triethylamine (27.13 g, 268.65mmol) and di-tert-butyl dicarbonate (CAS number 24424-99-5; 46.85 g,214.92 mmol). The reaction mixture was stirred at room temperature for15 hours. The reaction mixture was concentrated in vacuo and theresulting residue was partitioned between ethyl acetate (1000 ml) andwater (800 ml). The organics were dried over sodium sulfate andconcentrated in vacuo. The solid was then triturated with hexane (300ml) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.16 (s, 3H), 1.18-1.57 (m, 14H), 1.92(m, 1H) 2.67 (s, 3H) 3.53 (m, 1H) 6.24 (br. s, 1H), 7.27-7.39 (m, 2H),7.60-7.69 (m, 3H)

MS ES⁺: 368

Step (v): tert-Butyl N-(2-amino-1-methylcyclopentyl)carbamate

A mixture of lithium granules (7.17 g, 1195 mmol) and naphthalene (57.39g, 448.36 mmol) in dry dimethoxyethane (1900 ml) was stirred at roomtemperature for 2 hours. The deep blue solution was then cooled to 0° C.and a solution of tert-butylN-[1-methyl-2-(4-methylbenzenesulfonamido)cyclopentyl]carbamate (55.0 g,149.45 mmol) in dry dimethoxyethane (300 ml) was added drop wise over 30minutes. The mixture was stirred at 0° C. for 3 hours. The un-dissolvedlithium was removed by filtration and 1M HCl solution (aq, 720 ml) wasadded to the filtrate. The organic layer was washed with further 1M HCl(aq, 2×600 ml). The combined aqueous layers were washed with diethylether (2×600), and then basified with 2M NaOH (aq) to give pH 12-14. Theaqueous layer was then extracted with ethyl acetate (5×600 ml). Thecombined organics were dried over sodium sulfate and then concentratedin vacuo. This was then purified by column chromatography (silica, 0-4%methanol/DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.10 (s, 3H), 1.14-1.27 (m, 2H), 1.40(s, 9H) 1.44-1.55 (m, 2H) 1.76-1.86 (m, 2H) 2.72 (br. s, 2H), 3.09 (m,1H) 6.61 (br. s, 1H)

MS ES⁺: 214

Intermediate 25:(1S,2S)-1-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-{[(tert-butoxy)carbonyl]amino}-2-methylcyclopentyl)carbamate

To a solution of tert-butyl N-(2-amino-1-methylcyclopentyl)carbamate(Intermediate 24; 5.49 ml, 26.1 mmol) in DCM (87 ml) at 0° C. was addedDIPEA (4.56 ml, 26.1 mmol) followed by(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexyl chloroformate (CAS number14602-86-9; 17.15 g, 78 mmol) drop wise. The reaction mixture wasallowed to warm to room temperature and stirred overnight. The reactionwas diluted with DCM (150 ml) and a saturated solution of sodiumbicarbonate solution (200 ml). The aqueous layer was re-extracted withDCM (100 ml) and the combined organics were washed further with asaturated solution of sodium bicarbonate (100 ml), dried over magnesiumsulfate and concentrated in vacuo. The residue was purified by columnchromatography (silica, 0-50% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.72-1.79 (m, 30H), 1.81-2.34 (m, 6H),3.80-4.01 (m, 1H), 4.44-4.90 (m, 2H), 5.98-6.11 (m, 1H)

MS ES⁺: 397

Step (ii): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-{[(tert-butoxy)carbonyl]amino}-2-methylcyclopentyl)carbamate (6.12g, 15.43 mmol) in 1,4-dioxane (35 ml) was added HCl in 1,4-dioxane (4 M,38.6 ml, 154 mmol). The reaction mixture was stirred at room temperatureovernight, concentrated in vacuo and azeotropically distilled withtoluene to afford the title compound.

¹H NMR (300 MHz, DMSO-d6) δ ppm 0.62-2.09 (m, 27H), 3.75-4.00 (m, 1H),4.30-4.55 (m, 1H), 7.31-7.46 (m, 1H), 7.96 (br. s., 3H)

MS ES⁺: 297

Step (iii): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (5.14 g, 15.44mmol), 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2;2.097 ml, 16.98 mmol) and DIPEA (8.10 ml, 46.32 mmol) in DMSO (51.5 ml)was heated to 140° C. for 17 hours. The reaction mixture was dilutedwith water (200 ml) and extracted with ethyl acetate (2×200 ml). Thecombined organics were washed with brine (3×200 ml), dried overmagnesium sulfate and concentrated in vacuo. The residue was purified bycolumn chromatography (silica, 0-15% ethyl acetate/petrol) to afford thetitle compound as a single diastereomer.

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.68-2.04 (m, 27H), 2.06-2.20 (m, 1H),2.41-2.64 (m, 1H), 4.56-4.70 (m, 1H), 4.85-5.03 (m, 1H), 7.64-8.08 (m,1H), 8.21 (br. s., 1H)

MS ES⁺: 443

Step (iv):(1S,2S)-1-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(1.03 g, 2.328 mmol) in acetic acid (8 ml) was added HBr (6 M, 1.940 ml,11.64 mmol). The reaction was heated to 90° C. for 20 hours in a sealedvial and then cooled. To this was then added further HBr (6 M, 1.00 ml,6 mmol) and the reaction was heated at 90° C. for 36 hours. The reactionwas cooled to room temperature and concentrated in vacuo. The crudeproduct was purified by reverse phase chromatography (C18 silica, 5-100%water (with 0.05% ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.32 (s, 3H), 1.37-1.51 (m, 1H),1.63-1.76 (m, 2H), 1.85-2.22 (m, 3H), 3.17-3.35 (m, 1H), 5.44 (br. s.,1H), 7.89 (s, 1H), 8.29 (s, 1H)

MS ES⁺: 261

Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number799557-87-2; 0.816 ml, 6.61 mmol),(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (Intermediate 27;2.00 g, 6.01 mmol) and DIPEA (3.15 ml, 18.02 mmol) in DMSO (10 mL) wassubjected to microwave irradiation at 140° C. for 5 hours. The reactionwas diluted with ethyl acetate (100 ml) and a saturated solution ofsodium bicarbonate (50 m). The organics were washed with water (40 ml),brine (40 ml), dried over magnesium sulfate, filtered through ahydrophobic frit and concentrated in vacuo. The crude product waspurified by column chromatography (silica, 0-20% ethyl acetate/petrol)to afford the title compound

MS ES⁺: 443

Step (ii):(1S,2S)-1-Methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(1.03 g, 2.33 mmol) in acetic acid (8 ml) was added HBr (6M, 1.94 ml,11.64 mmol). The reaction was sealed and heated to 90° C. for 20 hours.To this was added further HBr (6M, 1.00 ml, 6.00 mmol) and the reactionwas heated at 90° C. for 36 hours and was then concentrated in vacuo.The crude product was purified by reverse phase chromatography (C18silica, 0-100% water (with 0.05% ammonia)/acetonitrile) to afford thetitle compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.32 (s, 3H), 1.33-2.19 (m, 6H),3.21-3.35 (m, 1H), 5.44 (br. s., 1H), 7.89 (s, 1H), 8.29 (s, 1H)

MS ES⁺: 261

Intermediate 26:N-(2-Amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

To a solution of 2-(2H-1,2,3-triazol-2-yl)benzoyl chloride (213 mg, 1.03mmol) (which was prepared from 2-(2H-1,2,3-triazol-2-yl)benzoic acid(CAS number 1001401-62-2; 0.194 g, 1.03 mmol) and thionyl chloride(0.112 ml, 1.541 mmol)) in dry DCM (3.1 ml) was added tert-butylN-(2-amino-1-methylcyclopentyl)carbamate (Intermediate 24; 200 mg, 0.93mmol) and DIPEA (489 μl, 2.80 mmol). The reaction was stirred at roomtemperature for 17 hours and was then partitioned between a saturatedsolution of sodium bicarbonate and DCM, filtered through a hydrophobicfrit and concentrated in vacuo. This was then purified by columnchromatography (silica, 0-100% ethyl acetate/petrol). The resultingproduct was then dissolved in 1,4-dioxane (5 ml) and to this was thenadded HCl in 1,4-dioxane (4 M, 2.3 ml, 9.33 mmol). The reaction wasstirred at room temperature for 1 hour and then concentrated in vacuo,azeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.23 (s, 3H), 1.55-1.80 (m, 4H),1.84-2.01 (m, 2H), 4.10-4.28 (m, 1H), 7.54-7.60 (m, 1H), 7.62-7.70 (m,2H), 7.81-7.86 (m, 1H), 7.98 (br. s., 3H), 8.07 (s, 2H), 8.60-8.76 (m,1H)

MS ES⁺: 286

Intermediate 27: (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride

Step (i): 5-Methyl-6-azabicyclo[3.2.0]heptan-7-one

To a solution of 1-methylcyclopent-1-ene (CAS number 693-89-0; 38.5 mL,365 mmol) in diethyl ether (220 ml) at 0° C. was added drop wise[(chlorosulfonyl)imino]methanone (CAS number 1189-71-5; 33.3 ml, 383mmol). The reaction was then allowed to warm to room temperature andthen heated to 36° C. for 72 hours. The reaction was then cooled to roomtemperature and a solution of sodium sulfite (73.5 g) in water (400 ml)was added drop wise, followed by the addition of 15% w/v potassiumhydroxide (500 ml) to obtain pH 7-8. The phases were separated andaqueous phase was extracted with diethyl ether (2×200 ml). The combinedorganics were dried over magnesium sulfate and concentrated in vacuo toafford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.23-1.36 (m, 1H), 1.37-1.81 (m, 8H),2.82-2.95 (m, 1H), 7.60 (br. s., 1H)

Step (ii): tert-Butyl5-methyl-7-oxo-6-azabicyclo[3.2.0]heptane-6-carboxylate

To a solution of 5-methyl-6-azabicyclo[3.2.0]heptan-7-one (41.39 g, 331mmol) in THF (500 ml) was added N,N-dimethylpyridin-4-amine (0.404 g,3.31 mmol), triethylamine (115 ml, 827 mmol) and di-tert-butyldicarbonate (81 ml, 347 mmol). The reaction was stirred at roomtemperature for 20 hours and then concentrated in vacuo. The residue waspurified by column chromatography (silica, petrol then 10% ethylacetate/petrol then 20% ethyl acetate/petrol (step gradient)) to affordthe title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.30-1.69 (m, 15H), 1.75-1.88 (m, 2H),2.07-2.20 (m, 1H), 3.08-3.17 (m, 1H)

Step (iii): Methyl2-{[(tert-butoxy)carbonyl]amino}-2-methylcyclopentane-1-carboxylate

Sodium methoxide (30%, 85 ml, 457 mmol) was added drop wise to asolution of tert-butyl5-methyl-7-oxo-6-azabicyclo[3.2.0]heptane-6-carboxylate (51.52 g, 229mmol) in methanol (400 ml) at 0° C. The reaction was stirred at roomtemperature for 68 hours. The reaction was then concentrated in vacuo,partitioned between ethyl acetate (200 ml) and water (100 ml) and theaqueous phase re-extracted with ethyl acetate (200 ml). The combinedorganics were dried over magnesium sulfate and concentrated in vacuo toafford the title compound which was used without further purification.

Step (iv):2-{[(tert-Butoxy)carbonyl]amino}-2-methylcyclopentane-1-carboxylic acid

Lithium hydroxide (23.50 g, 981 mmol) was added to a solution of methyl2-{ [(tert-butoxy)carbonyl]amino}-2-methylcyclopentane-1-carboxylate(50.51 g, 196 mmol) in THF (300 ml) and water (150 ml). The reaction washeated at 50° C. for 18 hours and then to 60° C. for 18 hours. Thereaction was concentrated in vacuo and then acidified to pH 7 withconcentrated HCl and then to pH 3 with 2 M HCl (aq). The organics wereextracted with ethyl acetate (3×300 ml) and the combined organics werewashed with brine (50 ml), dried over magnesium sulfate and concentratedin vacuo to afford the title compound which was used without furtherpurification.

Step (v): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-{[(tert-butoxy)carbonyl]amino}-2-methylcyclopentyl)carbamate

To a solution of2-{[(tert-butoxy)carbonyl]amino}-2-methylcyclopentane-1-carboxylic acid(42.68 g, 175 mmol) and triethylamine (25.7 ml, 184 mmol) in toluene(250 ml) at room temperature was added{[azido(phenoxy)phosphoryl]oxy}benzene (CAS number 26386-88-9; 37.8 ml,175 mmol) as a solution in toluene (100 ml). The reaction was heated to60° C. for 2 hours, then(1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexan-1-ol (CAS number2216-51-5; 14.25 g, 91 mmol) was added. The reaction was heated at 90°C. for 20 hours and then cooled to room temperature, quenched by theaddition of water (50 ml) and diluted with ethyl acetate (200 ml). Theorganics were washed with a saturated solution of sodium bicarbonate(2×100 ml), brine (100 ml), dried over magnesium sulfate, filteredthrough a hydrophobic frit and concentrated in vacuo. The residue waspurified by column chromatography (silica, petrol—10% ethylacetate/petrol—20% ethyl acetate/petrol (step gradient)) to afford thetitle compound (a mixture of trans-amino compounds) which was taken onto next stage without further purification.

Step (vi): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-{[(tert-butoxy)carbonyl]amino}-2-methylcyclopentyl)carbamate (25.2g, 63.5 mmol) in DCM (100 ml) was added HCl in 1,4-dioxane (4 M, 60 ml,240 mmol). The reaction mixture was stirred at room temperature for 18hours and then further HCl in 1,4-dioxane (4 M, 20 ml, 80 mmol) wasadded and the stirred for an additional 24 hours at room temperature.The reaction was concentrated in vacuo and purified by SCXchromatography (2M ammonia in methanol). The resulting residue wassuspended in DCM/methanol and to this was added HCl in 1,4-dioxane (4 M,10 ml, 40 mmol) and stirred for 2 hours. The reaction was concentratedin vacuo and further evaporated from diethyl ether and then methanol toafford the title compound as a mixture of trans-amino compounds.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.68-1.76 (m, 22H), 1.77-2.09 (m, 5H),3.81-4.00 (m, 1H), 4.35-4.54 (m, 1H), 7.29-7.46 (m, 1H), 7.88-8.10 (m,3H)

Intermediate 28:1-N-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine

Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)carbamate

A solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (Intermediate 27;1.00 g, 3.00 mmol), 2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number89402-42-6; 0.412 ml, 3.30 mmol) and DIPEA (1.57 ml, 9.01 mmol) in DMSO(10 ml) was subjected to microwave irradiation at 140° C. for 3 hours.The reaction was then partitioned between ethyl acetate (10 ml) andwater (10 ml), filtered through a hydrophobic frit and concentrated invacuo. The residue was purified by column chromatography (silica, 0-12%diethyl ether/petrol) to afford the title compound as a singletrans-enantiomer.

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.68-2.17 (m, 26H), 2.51-2.72 (m, 1H),4.02-4.23 (m, 1H), 4.53-4.69 (m, 1H), 4.92 (br. s., 1H), 7.15-7.32 (m,2H), 8.03-8.19 (m, 1H)

MS ES⁺: 460

Step (ii):1-N-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine

To a solution (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)carbamate(0.533 g, 1.16 mmol) in acetic acid (4 ml) was added HBr (6 M, 0.98 ml,5.80 mmol). The reaction was sealed and heated at 90° C. for 24 hours.To this was then added further HBr (6 M, 0.50 ml, 3.00 mmol) and thereaction was heated at 90° C. for a further 6 hours. The reaction wascooled to room temperature and concentrated in vacuo. The residue waspurified by SCX chromatography (2M ammonia in methanol) and thenconcentrated in vacuo. The crude product was further purified by reversephase chromatography (C18 silica, 0-100% water (with 0.05%ammonia)/acetonitrile) to afford the title compound as a singletrans-enantiomer.

¹H NMR (300 MHz, DCM-d₂) δ ppm 1.28-1.50 (m, 4H), 1.59-1.79 (m, 4H),1.88-2.25 (m, 3H), 3.25-3.45 (m, 1H), 5.25 (br. s., 1H), 7.21-7.36 (m,1H), 8.08-8.19 (m, 1H)

MS ES⁺: 278

Intermediate 29:N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Step (i): tert-ButylN-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate (CASnumber 586961-34-4; 1 g, 4.99 mmol),2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 1.09 g,5.99 mmol) and DIPEA (2.62 ml, 14.98 mmol) in DMSO (17 ml) was subjectedto microwave irradiation at 140° C. for 1 hour. The reaction waspartitioned between ethyl acetate and water, washed with water, brine,dried over magnesium sulfate and concentrated in vacuo. The resultingresidue was purified by column chromatography (silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.35 (s, 9H), 1.48-1.64 (m, 2H),1.71-1.85 (m, 2H), 2.03-2.23 (m, 2H), 3.72-3.86 (m, 1H), 4.14-4.25 (m,1H), 7.84-7.98 (m, 1H), 8.18-8.29 (m, 1H)

MS ES⁺: 347

Step (ii):(1S,2S)-1-N-[3-Chloro-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(1.04 g, 3.00 mmol) in dry DCM (10 ml) at 0° C. under an atmosphere ofnitrogen was added 1-bromopyrrolidine-2,5-dione (CAS number 128-08-5;0.80 g, 4.50 mmol). The reaction was allowed to warm to room temperatureand stirred for 17 hours and then was concentrated in vacuo. Theresulting residue was purified by column chromatography (basic silica,0-50% ethyl acetate/petrol). To this was then added HCl in 1,4-dioxane(4 M, 7.51 ml, 30.0 mmol) and stirred at room temperature for 72 hours.The reaction mixture was concentrated in vacuo and azeotropicallydistilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.58-1.83 (m, 4H), 2.00-2.16 (m, 2H),3.54-3.66 (m, 1H), 4.39-4.57 (m, 1H), 7.80-8.04 (m, 4H), 8.42-8.53 (m,1H)

MS ES⁺: 281

Step (iii):N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution of(1S,2S)-1-N-[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (530 mg, 1.67 mmol) in dry DMF (5.6 ml) was added2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 348 mg,1.84 mmol), HATU (953 mg, 2.51 mmol) and triethylamine (699 μl, 5.01mmol) and then stirred at room temperature for 17 hours. The reactionwas partitioned between ethyl acetate and a saturated solution of sodiumbicarbonate. The organics were washed with water, brine, dried overmagnesium sulfate and concentrated in vacuo. The resulting residue waspurified by column chromatography (basic silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.49-1.77 (m, 4H), 1.93-2.05 (m, 1H),2.06-2.17 (m, 1H), 4.18-4.29 (m, 1H), 4.33-4.44 (m, 1H), 7.40-7.46 (m,1H), 7.46-7.53 (m, 1H), 7.56-7.64 (m, 1H), 7.72-7.78 (m, 1H), 7.79-7.87(m, 3H), 8.41-8.57 (m, 2H)

MS ES⁺: 452

Intermediate 30a and 30b:N-[(1S,2S)-2-[(5-Bromopyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 30a) andN-[(1S,2S)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 30b)

A solution ofN-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 4; 1.00 g, 3.25 mmol),2-bromo-5-chloropyrazine (CAS number 912773-21-8; 0.691 g, 3.57 mmol)and DIPEA (1.7 ml, 9.75 mmol) in DMSO (11 ml) was subjected to microwaveirradiation at 140° C. for 3 hours. The reaction was partitioned betweenethyl acetate and water, washed with water, brine, dried over magnesiumsulfate and concentrated in vacuo. This was then purified by columnchromatography (silica, 0-100% ethyl acetate/petrol then 0-20%methanol/ethyl acetate) to afford title compound as a mixture of bothproducts.

Intermediate 31:N-[(1S,2S)-2-Aminocyclopentyl]-5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-[5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl]carbamate

A solution of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate (CASnumber 586961-34-4; 120 mg, 0.60 mmol),5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 38a; CASnumber 1293284-54-4; 134 mg, 0.60 mmol), TBTU (231 mg, 0.72 mmol) andDIPEA (0.116 g, 0.9 mmol) in DMF (3 ml) was stirred at room temperaturefor 2 hours. The reaction was diluted with water (30 ml) and extractedwith ethyl acetate (3×30 ml). The combined organics were washed withwater (20 ml), brine (20 ml), dried over sodium sulfate and concentratedin vacuo. The residue was purified by column chromatography (silica,0-30% ethyl acetate/n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.20-1.42 (m, 11H), 1.55-1.60 (m, 2H),1.83-1.86 (m, 2H), 3.73-3.77 (m, 1H), 3.92-3.96 (m, 1H), 6.85-6.87 (m,1H), 7.58 (s, 1H), 7.67-7.70 (m, 1H), 7.81-7.83 (m, 1H), 8.05 (s, 2H),8.45-8.47 (m, 1H)

MS ES⁺: 406

Step (ii):N-[(1S,2S)-2-Aminocyclopentyl]-5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-[5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl]carbamate(170 mg, 0.418 mmol) in DCM (5 ml) was added HCl in 1,4-dioxane (4 M, 3ml). The reaction was stirred at room temperature overnight and thenconcentrated in vacuo. The solid was triturated with diethyl ether (3×1ml) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.55-1.73 (m, 4H), 1.92-2.10 (m, 2H),3.40-3.42 (m, 1H), 4.06-4.13 (m, 1H), 7.72-7.75 (m, 1H), 7.79-7.80 (m,1H), 7.87-7.90 (m, 1H), 8.10-8.14 (m, 4H), 8.76-8.78 (m, 2H)

MS ES⁺: 306

Intermediate 33:(1S,2S)-1-N-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate

A solution of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate (CASnumber 586961-34-4; 2 g, 9.99 mmol),3-chloro-2-fluoro-5-(trifluoromethyl)pyridine (CAS number 72537-17-8;1.44 ml, 10.98 mmol), DIPEA (1.744 ml, 9.99 mmol) in DMSO (35 ml) washeated at 140° C. for 5 hours. The reaction was partitioned betweenethyl acetate and water. The phases were separated and the aqueous layerwas re-extracted with ethyl acetate (2×50 ml). The combined organicswere washed with brine (50 ml), filtered through a hydrophobic frit andconcentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-15% ethyl acetate/petrol) and then by columnchromatography (silica, 0-10% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.31 (s, 9H), 1.39-1.77 (m, 4H),1.81-1.95 (m, 1H), 2.03-2.21 (m, 1H), 3.86-3.98 (m, 1H), 4.09-4.20 (m,1H), 6.78-7.10 (m, 2H), 7.95 (s, 1H), 8.31 (s, 1H)

MS ES⁺: 380

Step (ii):(1S,2S)-1-N-[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate(2.23 g, 5.87 mmol) in 1,4-dioxane (20 ml) was added HCl in 1,4-dioxane(4 M, 15 ml, 60.0 mmol). The reaction was stirred at room temperaturefor 18 hours. The reaction mixture was concentrated in vacuo to affordthe title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.57-1.83 (m, 4H), 1.98-2.19 (m, 2H),4.35-4.53 (m, 1H), 7.17-7.36 (m, 1H), 7.95-8.05 (m, 1H), 8.15 (br. s.,3H), 8.31-8.44 (m, 1H)

MS ES⁺: 280

Intermediate 34:(1S,2S)-1-N-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate

A solution of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate (CASnumber 586961-34-4; 2 g, 9.99 mmol),2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 2.011g, 10.98 mmol) and DIPEA (1.744 ml, 9.99 mmol) in DMSO (35 ml) washeated at 140° C. for 5 hours. The reaction was partitioned betweenethyl acetate and water. The phases were separated and the aqueous layerwas re-extracted with ethyl acetate (2×50 ml). The combined organicswere washed with brine (50 ml), filtered through a hydrophobic frit andconcentrated in vacuo. The crude product was purified by columnchromatography (0-15% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.41 (s, 9H), 1.47-1.65 (m, 2H),1.73-1.92 (m, 2H), 2.08-2.24 (m, 1H), 2.29-2.48 (m, 1H), 3.78-4.17 (m,2H), 4.93-5.15 (m, 1H), 5.86-6.03 (m, 1H), 7.26-7.39 (m, 1H), 8.08-8.21(m, 1H)

MS ES⁺: 364

Step (ii):(1S,2S)-1-N-[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate(2.57 g, 7.08 mmol) in 1,4-dioxane (25 ml) was added HCl in 1,4-dioxane(4 M, 20 ml, 80 mmol). The reaction was stirred at room temperature for20 hours. The reaction mixture was concentrated in vacuo andazeotropically distilled with toluene to afford the title compound.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.51-1.83 (m, 4H), 1.99-2.20 (m, 2H),3.39-3.53 (m, 1H), 4.29-4.47 (m, 1H), 7.54-7.69 (m, 1H), 7.73-7.89 (m,1H), 8.11-8.33 (m, 4H)

MS ES⁺: 264

Intermediate 35:(1S,2S)-1-N-[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate

A solution of tert-butyl N-[(1S,2S)-2-aminocyclopentyl]carbamate (CASnumber 586961-34-4; 2 g, 9.99 mmol),3-bromo-2-chloro-5-(trifluoromethyl)pyridine (CAS number 71701-92-3;2.86 g, 10.98 mmol), DIPEA (1.74 ml, 9.99 mmol) in DMSO (35 ml) washeated at 140° C. for 5 hours. The reaction was partitioned betweenethyl acetate and water. The phases were separated and the aqueous layerwas re-extracted with ethyl acetate (2×50 ml). The combined organicswere washed with brine (50 ml), filtered through a hydrophobic frit andconcentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-50% ethyl acetate/petrol), then by columnchromatography (silica, 0-15% ethyl acetate/petrol) and then by columnchromatography (silica, 0-10% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.42 (s, 9H), 1.45-1.56 (m, 2H),1.75-1.92 (m, 2H), 2.09-2.53 (m, 2H), 3.77-4.19 (m, 2H), 4.80-5.09 (m,1H), 6.20-6.37 (m, 1H), 7.72-7.89 (m, 1H), 8.21-8.38 (m, 1H)

MS ES⁺: 425

Step (ii): tert-ButylN-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate

A mixture of tert-butylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate(1.26 g, 2.96 mmol), methylboronic acid (CAS number 13061-96-6; 0.532 g,8.88 mmol), tetrakis(triphenylphosphine)palladium (0.342 g, 0.296 mmol)and potassium carbonate (1.303 g, 9.43 mmol) in 1,4-dioxane (10 ml) andwater (1.5 ml) was sealed, evacuated and purged with nitrogen andsubjected to microwave irradiation at 140° C. for 1 hour. The mixturewas partitioned between ethyl acetate (10 ml) and water (10 ml). Theorganics were extracted with ethyl acetate (2×20 ml). The combinedorganics were washed with brine (20 ml), filtered through a hydrophobicfrit and concentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-60% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.31 (s, 9H), 1.37-1.57 (m, 2H),1.58-1.71 (m, 2H), 1.82-1.95 (m, 1H), 2.08-2.19 (m, 4H), 3.81-3.97 (m,1H), 4.07-4.19 (m, 1H), 6.31-6.47 (m, 1H), 6.86-7.00 (m, 1H), 7.43-7.54(m, 1H), 8.11-8.21 (m, 1H)

MS ES⁺: 360

Step (iii):(1S,2S)-1-N-[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]carbamate(580 mg, 1.614 mmol) in 1,4-dioxane (5 ml) was added HCl in 1,4-dioxane(4M, 4 ml, 16.00 mmol). The reaction was stirred at room temperature for18 hours. The reaction mixture was concentrated in vacuo andazeotropically distilled with toluene to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.74-1.96 (m, 4H), 2.17-2.32 (m, 1H),2.37-2.57 (m, 1H), 3.63 (s, 3H), 4.30-4.50 (m, 1H), 4.77-4.94 (m, 1H),7.63 (s, 1H), 8.10 (s, 1H), 8.53-8.86 (m, 4H)

MS ES⁺: 260

Intermediate 36:2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-aminehydrochloride

Step (i): [5-(Trifluoromethyl)pyridin-2-yl]methanol

To the solution of 2-iodo-5-(trifluoromethyl)pyridine (CAS number100366-75-4; 10 g, 69.4 mmol) in toluene (250 ml) at −78° C. was addedn-BuLi in hexane (2.5 M, 15.0 mL, 37.5 mmol). The reaction was stirredat −78° C. for 15 minutes. To this was then added drop wise DMF (3.5 ml)and then stirred at −78° C. for 1 hour. Sodium borohydride (2.74 g, 72.0mmol) and methanol (50 ml) were added and the resulting reaction mixturewas stirred for 30 minutes and then allowed to warm to room temperature.The reaction was cooled to −10° C. and to this was then added asaturated solution of ammonium chloride. The organics were extractedwith ethyl acetate (2×200 ml) and the combined organics were washed withbrine, dried over sodium sulfate and concentrated in vacuo to afford thetitle compound which was used without further purification.

¹H NMR (400 MHz, DMSO) δ ppm 4.66-4.65 (m, 2H), 5.69-5.66 (m, 1H),7.71-7.69 (m, 1H), 8.23-8.21 (m, 1H), 8.87 (s, 1H)

MS ES⁺: 178

Step (ii): 2-(Bromomethyl)-5-(trifluoromethyl)pyridine

To a solution of [5-(trifluoromethyl)pyridin-2-yl]methanol (5.0 g, 28.24mmol) in DCM (50 ml) was added tribromophosphane (0.58 g, 3.50 mmol) at0° C. The reaction was allowed to warm to room temperature and stirredfor 3 hours. The reaction was then poured into water (50 ml) and theorganics were extracted with DCM (2×50 ml), washed with brine, driedover sodium sulfate and concentrated in vacuo to afford the titlecompound which was used without further purification.

MS ES⁺: 240, 242

Step (iii): Diethyl {[5-(trifluoromethyl)pyridin-2-yl]methyl}phosphonate

To a solution of 2-(bromomethyl)-5-(trifluoromethyl)pyridine (3.0 g,12.5 mmol) in toluene (100 ml) was added triethyl phosphite (6.2 g, 37.0mmol). The reaction was refluxed for 17 hours and was then concentratedin vacuo. The resulting residue was purified by column chromatography(silica, 0-50% ethyl acetate/n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO) δ ppm 1.06-1.27 (m, 6H), 3.57-3.65 (m, 2H),3.95-4.08 (m, 4H), 7.61-7.59 (m, 1H), 8.20-8.18 (m, 1H), 8.90-8.89 (m,1H)

MS ES⁺: 298

Step (iv): tert-ButylN-[(2E)-2-{[5-(trifluoromethyl)pyridin-2-yl]methylidene}cyclopentyl]carbamate

To the suspension of diethyl((5-(trifluoromethyl)pyridin-2-yl)methyl)phosphonate (2.0 g, 6.71 mmol)in THF (50 ml) at 0° C. was added potassium tert-butoxide (1.5 g, 13.42mmol) and then stirred at room temperature for 30 minutes. To this wasthen added a solution of tert-butyl N-(2-oxocyclopentyl)carbamate (CASnumber 477585-30-1; 1.62 g, 8.05 mmol) in THF (20 ml) and the resultingreaction was stirred at room temperature for 1 hour and then heated atreflux overnight. The reaction was quenched with water (50 ml) andextracted with ethyl acetate (3×100 ml). The combined organics werewashed with brine, dried over sodium sulfate and concentrated in vacuo.The resulting residue was purified by column chromatography (silica,0-15% ethyl acetate/n-hexane) to afford the title compound.

MS ES⁺: 343

Step (v): tert-ButylN-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)carbamate

To a solution of tert-butylN-[(2E)-2-{[5-(trifluoromethyl)pyridin-2-yl]methylidene}cyclopentyl]carbamate(1.5 g, 4.38 mmol) in methanol (5 ml) was added palladium on carbon (10%wt, 50% wet, 300 mg) and 2M NaOH (5 ml). The resulting reaction wasstirred under a balloon of hydrogen gas for 2 hours. The reaction wasfiltered through diatomaceous earth (commercially sold under the trademark “Celite”) and concentrated in vacuo to afford the title compound.The resulting residue was purified by column chromatography (silica,0-70% ethyl acetate/n-hexane) to afford the title compound.

MS ES⁺: 345

Step (vi):2-{[5-(Trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-aminehydrochloride

To a solution of tert-butylN-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)carbamate (1.0g, 2.9 mmol) in 1,4-dioxane (5 ml) at 0° C. was added drop wise HCl in1,4-dioxane (12%, 15.0 ml). The reaction was stirred at room temperaturefor 1 hour, then concentrated in vacuo. To this was then added DCM (50ml) and a solution of sodium bicarbonate (aq, 7.5%, 15 ml). The organicswere dried over sodium sulfate and concentrated in vacuo. The resultingresidue was purified by column chromatography (0-2% methanol/DCM) andthen treated with HCl in 1,4-dioxane (12%, 5 ml), stirred for 2 hours,concentrated in vacuo, triturated with diethyl ether to afford the titlecompound as a single diastereomer.

¹H NMR (400 MHz, DMSO) δ ppm 1.40-1.76 (m, 5H), 1.95-1.99 (m, 1H),2.79-2.85 (m, 1H), 3.05-3.15 (m, 1H), 3.55-3.59 (m, 1H), 7.54-7.56 (m,1H), 7.75 (bs, 3H), 8.15-8.17 (m, 1H), 8.90 (s, 1H)

MS ES⁺: 245

Intermediate 37a and 37b:2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37a) and 2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)benzoic acid(Intermediate 37b)

To a solution of 2H-1,2,3-triazole (CAS number 288-36-8; 1.0 g, 10.86mmol) in DMF (4 ml) at 0-10° C. was added cesium carbonate (4.71 g,14.49 mmol), copper (I) iodide (68 mg, 0.36 mmol),trans-1-N,2-N-dimethylcyclohexane-1,2-diamine (200 mg, 1.44 mmol) and2-iodo-5-(trifluoromethyl)benzoic acid (CAS number 702641-04-1; 2.28 g,7.24 mmol). The reaction was subjected to microwave irradiation at 120°C. for 15 minutes and was then partitioned between ethyl acetate (2×100ml) and water (50 ml). The aqueous layer was acidified with HCl (aq, 2M)to give pH 2 and the organics were extracted with ethyl acetate (3×100ml). The combined organics were washed with brine, dried over sodiumsulfate and concentrated in vacuo. The resulting residue was purified bycolumn chromatography (silica, 0-3% methanol/DCM) to afford2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37a; also commercially available CAS number 1384066-81-2). The mixedfractions were further purified by column chromatography (silica, 0-3%methanol/DCM) followed by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% formic acid) to afford2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37b).

Intermediate 37a

¹H NMR (400 MHz, DMSO) δ ppm 8.07-8.08 (m, 3H), 8.20 (s, 2H), 13.57 (bs,1H)

MS ES⁺: 258

Intermediate 37b

¹H NMR (400 MHz, DMSO) δ ppm 7.90-7.97 (m, 2H), 8.16-8.21 (m, 2H), 8.65(s, 1H), 13.65 (bs, 1H)

MS ES⁺: 258

Intermediate 38a and 38b: 5-Chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid(Intermediate 38a) and 5-Chloro-2-(1H-1,2,3-triazol-1-yl)benzoic acid(Intermediate 38b)

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37a) and 2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid(Intermediate 37b) from 2H-1,2,3-triazole (CAS number 288-36-8; 1.0 g,10.86 mmol) and 5-chloro-2-iodobenzoic acid (CAS number 13421-00-6; 2.00g, 7.24 mmol). The crude solid was purified by column chromatography(silica, 0-3% methanol/DCM) to afford5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 38a; alsocommercially available CAS number 1293284-54-4). The mixed fractionswere further purified by column chromatography (silica, 0-3%methanol/DCM) to afford 5-chloro-2-(1H-1,2,3-triazol-1-yl)benzoic acid(Intermediate 38b).

Intermediate 38a

¹H NMR (400 MHz, DMSO) δ ppm 7.76-7.83 (m, 3H), 8.12 (s, 2H), 13.42 (bs,1H)

MS ES⁺: 224

Intermediate 38b

¹H NMR (400 MHz, DMSO) δ ppm 7.66-7.68 (m, 1H), 7.84-7.93 (m, 3H), 8.54(s, 1H), 13.50 (bs, 1H)

MS ES⁺: 224

Intermediate 39a and 39b: 2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)benzoicacid (Intermediate 39a) and2,3-Difluoro-6-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 39b)

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37a) and 2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid(Intermediate 37b) from 2H-1,2,3-triazole (CAS number 288-36-8; 0.75 g,10.86 mmol) and 2,3-difluoro-6-iodobenzoic acid (CAS number 333780-75-9;1.54 g, 5.43 mmol) in 1,4-dioxane (10 ml) and water (0.2 ml). The crudesolid was purified by column chromatography (silica, 0-3% methanol/DCM)to afford 2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid(Intermediate 39a). The mixed fractions were further purified by columnchromatography (silica, 0-3% methanol/DCM) followed by reverse phasepreparative HPLC (eluted with acetonitrile/water containing 0.1% formicacid) to afford 2,3-difluoro-6-(1H-1,2,3-triazol-1-yl)benzoic acid(Intermediate 39b).

Intermediate 39a

¹H NMR (400 MHz, DMSO) δ ppm 7.73-7.79 (m, 2H), 8.16 (s, 2H), 14.05 (bs,1H)

MS ES⁺: 226

Intermediate 39b

¹H NMR (400 MHz, DMSO) δ ppm 7.60-7.63 (m, 1H), 7.79-7.86 (m, 1H), 7.96(s, 1H), 8.61 (s, 1H), 14.17 (bs, 1H)

MS ES⁺: 226

Intermediate 40a and 40b: 3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)benzoicacid (Intermediate 40a) and3,5-Difluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 40b)

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37a) and 2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid(Intermediate 37b) from 2H-1,2,3-triazole (CAS number 288-36-8; 1.0 g,10.86 mmol) and 2-bromo-3,5-difluorobenzoic acid (CAS number651027-01-9; 1.27 g, 5.43 mmol) in 1,4-dioxane (5 ml) and water (1 ml).The crude solid was purified by using column chromatography (silica,0-3% methanol/DCM) to afford3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 40a).The mixed fractions were further purified by column chromatography(silica, 0-3% methanol/DCM) followed by reverse phase preparative HPLC(eluted with acetonitrile/water containing 0.1% formic acid) to afford3,5-difluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 40b).

Intermediate 40a

¹H NMR (400 MHz, DMSO) δ ppm 7.63-7.66 (m, 1H), 7.86-7.92 (m, 1H), 8.12(s, 2H), 13.63 (bs, 1H)

MS ES⁺: 226

Intermediate 40b

¹H NMR (400 MHz, DMSO) δ ppm 7.68-7.71 (m, 1H), 7.90-7.95 (m, 2H), 8.54(s, 1H), 13.70 (bs, 1H)

MS ES⁺: 226

Intermediate 41:(1S,2S)-1-N-[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number799557-87-2; 2.0 g, 10.98 mmol), tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 2 g,9.99 mmol) and DIPEA (5.23 ml, 30.0 mmol) in DMSO (20 ml) was sealed andheated at 140° C. for 3 hours. The reaction mixture was partitionedbetween ethyl acetate (200 ml) and water (100 ml). The organics werewashed with water (2×100 ml), brine (100 ml), dried over sodium sulfateand concentrated in vacuo. The residue was purified by columnchromatography (silica, 10-40% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.32-1.66 (m, 11H), 1.71-1.96 (m,2H), 2.07-2.24 (m, 1H), 2.30-2.51 (m, 1H), 3.76-4.04 (m, 2H), 4.69-4.92(m, 1H), 6.07-6.24 (m, 1H), 7.91 (s, 1H), 8.30 (s, 1H)

MS ES⁺: 347

Step (ii): tert-ButylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

To a solution of tert-butyl((1S,2S)-2-((5-(trifluoromethyl)pyrazin-2-yl)amino)cyclopentyl)carbamate(3.49 g, 10.08 mmol) in dry DCM (67 ml) at 0° C. was added1-bromopyrrolidine-2,5-dione (CAS number 128-08-5; 2.15 g, 12.09 mmol).The reaction was allowed to warm to room temperature overnight. Afurther portion of portion of 1-bromopyrrolidine-2,5-dione (CAS number128-08-5; 1.70 g, 9.56 mmol) was added and the reaction stirred for anadditional 24 hours. The reaction was concentrated in vacuo and thenpurified by column chromatography (silica, 0-30% ethyl acetate/petrol)to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 1.31-1.62 (m, 11H), 1.72-1.92 (m,2H), 2.08-2.24 (m, 1H), 2.36-2.56 (m, 1H), 3.75-4.14 (m, 2H), 4.63-4.87(m, 1H), 6.78-6.96 (m, 1H), 8.25 (s, 1H)

MS ES⁺: 425, 427

Step (iii): tert-ButylN-[(1S,2S)-2-{[3-ethenyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A suspension of tert-butylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(650 mg, 1.53 mmol), 2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS number 75927-49-0; 942 mg, 6.11 mmol),tetrakis(triphenylphosphine)palladium (177 mg, 0.15 mmol) and potassiumcarbonate (845 mg, 6.11 mmol) in 1,4-dioxane (5 ml) and water (0.8 ml)was subjected to microwave irradiation at 120° C. for 1 hour. Thereaction was partitioned between ethyl acetate (10 ml) and water (10ml). The aqueous layer was further extracted with ethyl acetate (3×20ml). The combined organics were washed with brine (20 ml), filteredthrough a hydrophobic frit and concentrated in vacuo. The resultingresidue was purified by column chromatography (silica, 0-50% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DICHLOROMETHANE-d₂) δ ppm 1.30-1.62 (m, 11H), 1.74-1.87(m, 2H), 2.02-2.17 (m, 1H), 2.41-2.61 (m, 1H), 3.73-3.85 (m, 1H),3.91-4.04 (m, 1H), 4.81-4.95 (m, 1H), 5.62-5.74 (m, 1H), 6.30-6.42 (m,1H), 6.71-6.90 (m, 2H), 8.21 (s, 1H)

MS ES⁺: 373

Step (iv): tert-ButylN-[(1S,2S)-2-{[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

To a solution of tert-butylN-[(1S,2S)-2-{[3-ethenyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(460 mg, 1.24 mmol) in methanol (12 ml) was added palladium on carbon(10% wt, 50% wet) (131 mg, 0.124 mmol) and the resulting mixture wasstirred under a balloon of hydrogen gas for 2 hours. The reaction wasfiltered through diatomaceous earth (commercially sold under the trademark “Celite”). To this was then added further palladium on carbon (10%wt, 50% wet) (131 mg, 0.124 mmol) and the resulting mixture was stirredunder a balloon of hydrogen gas for 72 hours. The reaction was filteredthrough diatomaceous earth (commercially sold under the trade mark“Celite”) and concentrated in vacuo to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.24-1.64 (m, 14H), 1.71-1.89 (m, 2H),2.01-2.19 (m, 1H), 2.37-2.57 (m, 1H), 2.61-2.80 (m, 2H), 3.77-3.90 (m,1H), 3.91-4.09 (m, 1H), 4.82-4.97 (m, 1H), 6.36-6.55 (m, 1H), 8.16 (s,1H)

MS ES⁺: 375

Step (v):(1S,2S)-1-N-[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(366 mg, 0.98 mmol) in 1,4-dioxane (3 ml) was added HCl in 1,4-dioxane(4M, 3 ml, 12.0 mmol). The reaction was stirred at room temperature for18 hours and was then concentrated in vacuo and azeotropically distilledwith toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.16-1.29 (m, 3H), 1.53-1.84 (m, 4H),1.95-2.20 (m, 2H), 2.66-2.82 (m, 2H), 3.43-3.71 (m, 1H), 4.28-4.47 (m,1H), 8.16 (br. s., 3H), 8.30 (s, 1H)

MS ES⁺: 275

Intermediate 42:N-(2-Amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

Step (i): 1-[(Cyclopent-3-en-1-yloxy)methyl]-4-methoxybenzene

To a solution of cyclopent-3-en-1-ol (CAS number 14320-38-8; 15 g, 178mmol) in dry THF (357 ml) at 0° C. under nitrogen was added sodiumhydride (60%, 9.27 g, 232 mmol). After fizzing had ceased, to this wasthen added drop wise 1-(chloromethyl)-4-methoxybenzene (CAS number824-94-2; 31.4 ml, 232 mmol). The reaction was allowed to warm to roomtemperature and stirred for 17 hours then quenched by the addition ofmethanol and concentrated in vacuo. The residue was partitioned betweenethyl acetate and water. The organics were dried over magnesium sulfate,filtered and concentrated in vacuo. The crude material was purified bycolumn chromatography (silica, 0-50% DCM/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 2.33-2.47 (m, 2H), 2.49-2.66 (m, 2H),3.79 (s, 3H), 4.20-4.32 (m, 1H), 4.40 (s, 2H), 5.62-5.75 (m, 2H), 6.86(d, J=8.59 Hz, 2H), 7.24 (d, J=8.59 Hz, 2H)

Step (ii): 3-[(4-Methoxyphenyl)methoxy]-6-oxabicyclo[3.1.0]hexane

To a solution of 1-[(cyclopent-3-en-1-yloxy)methyl]-4-methoxybenzene(9.64 g, 47.2 mmol) in dry DCM (52 ml) at 0° C. under an atmosphere ofnitrogen was added 3-chlorobenzene-1-carboperoxoic acid (CAS number937-14-4; 16.29 g, 94 mmol). The reaction mixture was warmed to roomtemperature for 17 hours then filtered. The filtrate was washed with asaturated solution of sodium thiosulfate and then with a saturatedsolution of sodium bicarbonate. The organics were dried over magnesiumsulfate, filtered and concentrated in vacuo. The crude material waspurified by column chromatography (silica, 0-50% ethyl acetate/petrol)to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.86-2.17 (m, 4H), 3.39-3.50 (m, 2H),3.78 (s, 3H), 3.99-4.14 (m, 1H), 4.32 (s, 2H), 6.85 (d, J=8.60 Hz, 2H),7.22 (d, J=8.59 Hz, 2H)

Step (iii):2-[Bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentan-1-ol

To a solution of 3[(4-methoxyphenyl)methoxy]-6-oxabicyclo[3.1.0]hexane(10.21 g, 46.4 mmol) in ethanol (66 ml) was addedbis(prop-2-en-1-yl)amine (CAS number 124-02-7; 13.51 g, 139 mmol). Thereaction was heated in a sealed vial at 105° C. for 72 hours. Thereaction mixture was concentrated in vacuo then purified by columnchromatography (silica, 0-50% ethyl acetate/petrol then 0-30% (0.1%ammonia/methanol)/ethyl acetate) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33-1.54 (m, 1H), 1.56-1.73 (m, 1H),1.73-1.88 (m, 1H), 2.06-2.25 (m, 1H), 2.78-2.95 (m, 1H), 2.99-3.23 (m,4H), 3.74 (s, 3H), 3.78-3.94 (m, 1H), 3.95-4.09 (m, 1H), 4.27-4.36 (m,2H), 4.57-4.67 (m, 1H), 5.02-5.25 (m, 4H), 5.71-5.90 (m, 2H), 6.89 (d,J=8.59 Hz, 2H), 7.22 (d, J=8.60 Hz, 2H)

MS ES⁺: 318

Step (iv):4-[(4-Methoxyphenyl)methoxy]-1-N,1-N-bis(prop-2-en-1-yl)cyclopentane-1,2-diamine

To a solution of2-[bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentan-1-ol(8.75 g, 27.6 mmol) in dry MTBE (92 ml) at 0° C. under nitrogen wasadded triethylamine (7.68 ml, 55.1 mmol) and methanesulfonyl chloride(2.58 ml, 33.1 mmol). The reaction mixture was stirred at 0° C. for 30minutes. To this was then added further triethylamine (7.68 ml, 55.1mmol) and the reaction was stirred at 0° C. for 30 minutes followed bythe addition of ammonium hydroxide (25% aq, 82 ml, 590 mmol). Thereaction was warmed to room temperature for 17 hours then partitionedbetween MTBE and water. The aqueous layer was re-extracted with MTBE.The combined organics were dried over magnesium sulphate, filtered andconcentrated in vacuo to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28-2.21 (m, 4H), 2.72-3.29 (m, 6H),3.66-3.78 (m, 3H), 3.81-3.99 (m, 1H), 4.25-4.43 (m, 2H), 5.00-5.32 (m,4H), 5.65-5.93 (m, 2H), 6.82-6.98 (m, 2H), 7.14-7.29 (m, 2H)

MS ES⁺: 317

Step (v): tert-ButylN-{2-[bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentyl}carbamate

To a solution of4-[(4-methoxyphenyl)methoxy]-1-N,1-N-bis(prop-2-en-1-yl)cyclopentane-1,2-diamine(9.79 g, 30.9 mmol) in THF (56 ml) at 0° C. under nitrogen was added asaturated solution of sodium carbonate (46.4 ml, 46.4 mmol) anddi-tert-butyl dicarbonate (CAS number 24424-99-5; 10.77 ml, 46.4 mmol).The reaction was warmed to room temperature for 72 hours thenpartitioned between ethyl acetate and water. The organics were washedwith water and brine, dried over magnesium sulfate, filtered andconcentrated in vacuo. The crude material was purified by reverse phasecolumn chromatography (C18 silica, 5-95% water (0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.38 (s, 9H), 1.47-1.59 (m, 1H),1.61-1.79 (m, 1H), 1.79-1.93 (m, 1H), 1.93-2.21 (m, 1H), 2.91-3.07 (m,3H), 3.07-3.24 (m, 2H), 3.74 (s, 3H), 3.79-3.98 (m, 2H), 4.24-4.41 (m,2H), 4.93-5.26 (m, 4H), 5.66-5.89 (m, 2H), 6.89 (d, J=8.34 Hz, 2H), 7.22(d, J=8.34 Hz, 2H)

MS ES⁺: 417

Step (vi): tert-ButylN-{2-amino-4-[(4-methoxyphenyl)methoxy]cyclopentyl}-carbamate

To a solution of tert-butylN-{2-[bis(prop-2-en-1-yl)amino]-4-[(4-methoxyphenyl)methoxy]cyclopentyl}carbamate(1.77 g, 4.25 mmol) in dry DCM (21 ml) was added1,3-dimethyl-1,3-diazinane-2,4,6-trione (CAS number 769-42-6; 1.161 g,7.44 mmol) and tetrakis(triphenylphosphane) palladium (0.113 g, 0.098mmol). The reaction was stirred at 45° C. under an atmosphere ofnitrogen for 3 hours. The reaction mixture was concentrated in vacuo andpurified by SCX chromatography (2M ammonia in methanol) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28-1.42 (m, 10H), 1.44-1.61 (m, 1H),1.81-2.07 (m, 1H), 2.12-2.37 (m, 1H), 2.72-3.09 (m, 1H), 3.18-3.52 (m,1H), 3.73 (s, 3H), 3.81-3.95 (m, 1H), 4.22-4.38 (m, 2H), 6.89 (d, J=8.34Hz, 2H), 7.22 (d, J=8.30 Hz, 2H)

MS ES⁺: 337

Step (vii): tert-ButylN-{4-[(4-methoxyphenyl)methoxy]-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of tert-butylN-{2-amino-4-[(4-methoxyphenyl)methoxy]cyclopentyl}-carbamate (1.71 g,5.08 mmol) in dry DMF (17 ml) was added 2-(2H-1,2,3-triazol-2-yl)benzoicacid (CAS number 1001401-62-2; 1.06 g, 5.59 mmol), HATU (2.90 g, 7.62mmol) and triethylamine (2.13 ml, 15.25 mmol). The reaction was stirredat room temperature for 72 hours then partitioned between ethyl acetateand water. The organics were washed with brine, dried over magnesiumsulfate, filtered and concentrated in vacuo. The crude material waspurified by column chromatography (silica, 0-100% ethyl acetate/petrol)to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37 (s, 9H), 1.46-1.59 (m, 1H),1.58-1.77 (m, 1H), 1.86-1.97 (m, 1H), 2.18-2.37 (m, 1H), 3.67-3.79 (m,4H), 3.83-4.01 (m, 2H), 4.32 (s, 2H), 6.85-6.95 (m, 2H), 7.17-7.31 (m,2H), 7.44-7.54 (m, 2H), 7.55-7.66 (m, 1H), 7.76 (s, 1H), 7.96-8.05 (m,2H)

MS ES⁺: 508

Step (viii): tert-ButylN-{4-hydroxy-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of tert-butylN-{4-[(4-methoxyphenyl)methoxy]-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate(1.85 g, 3.64 mmol) in DCM (36 ml) and water (0.364 ml) at 0° C. underan atmosphere of nitrogen was added4,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile (CAS number84-58-2; 1.655 g, 7.29 mmol). The reaction was stirred at 0° C. for 1hour, then was partitioned between a saturated solution of sodiumbicarbonate and DCM. The organics were filtered through a hydrophobicfrit and concentrated in vacuo. The crude material was purified bycolumn chromatography (silica, 0-100% ethyl acetate/petrol then 0-30%methanol/ethyl acetate) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.25-1.48 (m, 10H), 1.55-1.86 (m, 2H),2.11-2.27 (m, 1H), 3.90-3.94 (m, 1H), 3.99-4.11 (m, 1H), 4.57-4.71 (m,1H), 6.64-6.86 (m, 1H), 7.41-7.56 (m, 2H), 7.57-7.66 (m, 1H), 7.71-7.83(m, 1H), 7.95-8.06 (m, 2H), 8.19-8.36 (m, 1H)

MS ES⁺: 388

Step (ix): tert-ButylN-{4-oxo-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of tert-butylN-{4-hydroxy-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate(910 mg, 2.35 mmol) in dry DCM (12 ml) at 0° C. under an atmosphere ofnitrogen was added Dess-Martin periodinane (3.4 g, 7.99 mmol). Thereaction was warmed to room temperature for 2 hours then concentrated invacuo. The crude material was purified by column chromatography (silica,0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.28-1.47 (m, 10H), 1.56-1.87 (m, 2H),2.07-2.27 (m, 1H), 3.82-4.00 (m, 1H), 4.00-4.12 (m, 1H), 6.58-6.79 (m,1H), 7.41-7.54 (m, 2H), 7.55-7.71 (m, 1H), 7.73-7.85 (m, 1H), 7.93-8.06(m, 2H), 8.17-8.40 (m, 1H)

MS ES⁺: 386

Step (x): tert-ButylN-{4,4-difluoro-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate

To a solution of tert-butylN-{4-oxo-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate(950 mg, 2.47 mmol) in dry DCM (12.3 ml) at 0° C. under an atmosphere ofnitrogen was added drop wise diethylaminosulfur trifluoride (CAS number38078-09-0; 1.63 ml, 12.32 mmol) as a solution in dry DCM (12.3 ml). Thereaction mixture was warmed to room temperature for 2 hours then cooledto 0° C. To this was added further diethylaminosulfur trifluoride (CASnumber 38078-09-0; 1.63 ml, 12.32 mmol). The reaction was then allowedto warm to room temperature for 17 hours. The reaction was then cooledto 0° C. and basified by the cautious addition of sodium carbonate (2M,aq). The reaction mixture was extracted with DCM, filtered through ahydrophobic frit and concentrated in vacuo. The crude material waspurified by column chromatography (silica, 0-100% ethyl acetate inpetrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37 (s, 9H), 1.88-2.17 (m, 2H),2.36-2.48 (m, 2H), 3.93-4.09 (m, 1H), 4.14-4.30 (m, 1H), 6.97-7.15 (m,1H), 7.45-7.56 (m, 2H), 7.57-7.70 (m, 1H), 7.75-7.86 (m, 1H), 8.03 (s,2H), 8.46-8.60 (m, 1H)

MS ES⁺: 408

Step (xi):N-(2-Amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride

To a solution of tert-butylN-{4,4-difluoro-2-[2-(2H-1,2,3-triazol-2-yl)benzamido]cyclopentyl}carbamate(640 mg, 1.57 mmol) in dry 1,4-dioxane (5 ml) was added HCl in1,4-dioxane (4M, 3.9 ml, 15.71 mmol). The reaction was stirred at roomtemperature for 6 hours then concentrated in vacuo and azeotropicallydistilled with toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.01-2.42 (m, 2H), 2.55-2.78 (m, 2H),3.30-3.54 (m, 1H), 3.60-3.75 (m, 1H), 7.50-7.61 (m, 1H), 7.62-7.77 (m,2H), 7.80-7.91 (m, 1H), 8.08 (s, 2H), 8.51 (br. s, 3H), 8.72-8.88 (m,1H)

MS ES⁺: 308

Intermediate 43: N-Chloro-2-methyl-N-sodiopropane-2-sulfonamide

To a rapidly stirred sodium hypochlorite solution (25 ml, 12.76 mmol),with the temperature maintained below 10° C. and in the dark was added asolution of acetic acid (1.85 ml, 12.76 mmol) and 2-methylpropan-2-ol(1.22 ml, 12.76 mmol) in a single portion and the reaction mixturestirred for 3 minutes. The reaction mixture was partitioned and theorganics washed with 10% aqueous sodium carbonate and water, dried overcalcium chloride and filtered to afford tert-butyl hypochlorite (845 mg,7.78 mmol). This was slowly added to a stirred solution of2-methylpropane-2-sulfonamide (2 g, 14.58 mmol) in sodium hydroxidesolution (1M, 20.60 ml, 20.6 mmol) at room temperature. The resultingmixture was stirred at room temperature for 1 hour then concentrated invacuo. The resultant solid was triturated with diethyl ether, filteredand dried in vacuo to afford the title compound.

Prepared as detailed in Organic Letters 1999, 1, 783-786

Intermediate 44: BenzylN-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-N-[(1R)-1-phenylethyl]carbamate

Step (i): 1,4-Dioxaspiro[4.4]non-7-ene

To a solution of trimethylsilyl trifluoromethanesulfonate (CAS number27607-77-8; 0.22 ml, 1.22 mmol) in DCM (12 ml) at −78° C. wassuccessively added 2,2,7,7-tetramethyl-3,6-dioxa-2,7-disilaoctane (CASnumber 7381-30-8; 2.51 g, 12.18 mmol) and cyclopent-3-en-1-one (CASnumber 14320-37-7; 1 g, 12.18 mmol). The reaction mixture was stirred at−78° C. for 3 hours, quenched with triethylamine (2 ml, 14.35 mmol),poured into a saturated solution of sodium bicarbonate and extractedwith diethyl ether. The organics were dried over sodium sulfate,filtered and concentrated in vacuo to afford the title compound.

¹H NMR (300 MHz, CHLOROFORM-d) δ ppm 2.59 (s, 4H), 3.96 (s, 4H), 5.71(s, 2H)

Step (ii):6-(2-Methylpropane-2-sulfonyl)-6-azaspiro[bicyclo[3.1.0]hexane-3,2′-[1,3]dioxolane]

To a solution of 1,4-dioxaspiro[4.4]non-7-ene (370 mg, 2.93 mmol) andN-chloro-2-methyl-N-sodiopropane-2-sulfonamide (Intermediate 43; 965 mg,4.99 mmol) in acetonitrile (16 ml) was added trimethylphenylammoniumtribromide (CAS number 4207-56-1; 110 mg, 0.29 mmol) under an atmosphereof nitrogen. The reaction mixture was stirred at room temperature for 2hours then heated to 40° C. for 18 hours. The reaction mixture wasfiltered through a plug of silica, washed with diethyl ether and thefiltrate concentrated in vacuo. The crude material was purified columnchromatography (silica, 0-50% diethyl ether/petroleum) to afford thetitle compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45-1.53 (m, 9H), 2.16-2.23 (m,4H), 3.34 (s, 2H), 3.77-3.86 (m, 2H), 3.88-3.93 (m, 2H)

Step (iii):2-Methyl-N-(8-{[(M)-1-phenylethyl]amino}-1,4-dioxaspiro[4.4]nonan-7-yl)propane-2-sulfonamide

To a solution of6-(2-methylpropane-2-sulfonyl)-6-azaspiro[bicyclo[3.1.0]hexane-3,2′-[1,3]dioxolane](477 mg, 1.83 mmol) in acetonitrile (10 ml) was added lithiumperchlorate (20 mg, 0.19 mmol) and (R)-1-phenylethanamine (CAS number3886-69-9; 0.29 ml, 2.28 mmol). The reaction was heated to reflux for 24hours. Further portions of lithium perchlorate (12 mg, 0.11 mmol) and(R)-1-phenylethanamine (0.20 ml, 1.57 mmol) were added and the reactionmixture heated to 100° C. overnight. The reaction mixture wastransferred to a microwave vial and was then subjected to microwaveirradiation at 120° C. for 3 hours. To this was then added water (1 ml)and the volume reduced to a third by concentrating in vacuo. Theresultant mixture was partitioned between ethyl acetate and water. Theorganics were washed with water and brine, dried over sodium sulfate,filtered and concentrated in vacuo. The crude material was purified bycolumn chromatography (silica, 0-70% ethyl acetate/petrol) to afford thetitle compound.

MS ES⁺: 383

Step (iv): BenzylN-[8-(2-methylpropane-2-sulfonamido)-1,4-dioxaspiro[4.4]nonan-7-yl]-N-[(1R)-1-phenylethyl]carbamate

To a solution of2-methyl-N-(8-{[(1R)-1-phenylethyl]amino}-1,4-dioxaspiro[4.4]nonan-7-yl)propane-2-sulfonamide(274 mg, 0.72 mmol) and sodium carbonate (114 mg, 1.074 mmol) in1,4-dioxane (2 ml) and water (0.4 ml) at 0° C. was added drop wisebenzyl chloroformate (CAS number 501-53-1; 0.13 ml, 0.90 mmol). Thereaction mixture was allowed to warm to room temperature for 2 hoursthen concentrated in vacuo. The residue was diluted with ethyl acetateand washed with water and brine, dried over sodium sulfate, filtered andconcentrated in vacuo. The crude material was purified by columnchromatography (silica, 0-70% ethyl acetate/petrol) to afford the titlecompound.

MS ES⁻: 515

Step (v): BenzylN-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-N-[(1R)-1-phenylethyl]carbamate

To a solution of benzylN-[8-(2-methylpropane-2-sulfonamido)-1,4-dioxaspiro[4.4]nonan-7-yl]-N-[(1R)-1-phenylethyl]carbamate(331 mg, 0.64 mmol) in THF (1.1 ml) was added HCl (aq, 2M, 1.65 ml, 3.30mmol) was stirred at room temperature for 18 hours. The reaction mixturewas concentrated in vacuo and azeotropically distilled with toluene toafford the title compound.

MS ES⁺: 473

Intermediate 45:4,4-Difluoro-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

Step (i): BenzylN-[4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-N-[(1R)-1-phenylethyl]carbamate

To a solution of benzylN-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-N-[(JR)-1-phenylethyl]carbamate(Intermediate 44; 330 mg, 0.70 mmol) in DCM (3.5 ml) at 0° C. was addeddiethylaminosulfur trifluoride (CAS number 38078-09-0; 0.92 ml, 6.98mmol). The mixture was stirred at 0° C. for 20 minutes and then at roomtemperature for 5 hours. The reaction mixture was quenched at 0° C. witha saturated solution of sodium u) bicarbonate and extracted with DCM.The organics were dried over sodium sulfate, filtered and concentratedin vacuo. The crude material was purified by column chromatography(silica, 0-50% ethyl acetate/petrol) to afford the title compound.

MS ES⁻: 493

Step (ii):N-(2-Amino-4,4-difluorocyclopentyl)-2-methylpropane-2-sulfonamide

A solution of benzylN-[4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-N-[(1R)-1-phenylethyl]carbamate(130 mg, 0.26 mmol) and palladium hydroxide on carbon (20%, 100 mg, 0.14mmol) in methanol (3.5 ml) was stirred under a balloon of hydrogen gasfor 2 hours. The reaction was filtered through diatomaceous earth(commercially sold under the trade mark “Celite”) and concentrated invacuo to afford the title compound.

MS ES⁺: 257

Step (iii):N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-methylpropane-2-sulfonamide

To a solution ofN-(2-amino-4,4-difluorocyclopentyl)-2-methylpropane-2-sulfonamide (66mg, 0.26 mmol) in DMSO (650 μl) was added DIPEA (135 μl, 0.77 mmol) and2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 47 mg,0.26 mmol). The reaction mixture was sealed and heated at 120° C. for 18hours then partitioned between ethyl acetate and water. The organicswere washed with water and brine, dried over sodium sulfate, filteredand concentrated in vacuo. The crude material was purified by columnchromatography (silica, 10-60% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.42 (s, 9H), 1.92-2.04 (m, 1H),2.12-2.30 (m, 1H), 2.68-2.85 (m, 1H), 2.96-3.12 (m, 1H), 3.86-4.03 (m,1H), 4.18-4.27 (m, 1H), 4.43-4.54 (m, 1H), 5.90-6.04 (m, 1H), 8.02 (s,1H), 8.34 (s, 1H)

MS ES⁺: 403

Step (iv):4,4-Difluoro-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine

To a solution ofN-(4,4-difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-methylpropane-2-sulfonamide(45 mg, 0.11 mmol) in DCM (3 ml) at 0° C. was added anisole (CAS number100-66-3; 0.22 ml, 2.01 mmol) followed by the drop wise addition oftrifluoromethanesulfonic acid in DCM (0.2M, 2.5 ml, 0.500 mmol). Thereaction mixture was stirred at 0° C. for 1 hour then at roomtemperature for 2 hours. A further portion of trifluoromethanesulfonicacid in DCM (0.2M, 0.5 ml, 0.100 mmol) was added, the reaction mixturestirred for another hour at room temperature then quenched with sodiumhydroxide (0.1M) until pH 11 was obtained. The reaction mixture was thenextracted with DCM. The organics were filtered through a hydrophobicfrit and concentrated in vacuo. The crude material was purified by SCXchromatography (2M ammonia in methanol) to afford the title compound.

MS ES⁺: 283

Intermediate 46:N-[(1S,2S)-2-Amino-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Step (i): BenzylN-[(1S,2S)-4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-N-[(1R)-1-phenylethyl]carbamate

To a solution of benzylN-[2-(2-methylpropane-2-sulfonamido)-4-oxocyclopentyl]-N-[(1R)-1-phenylethyl]carbamate(Intermediate 44; 6.39 g, 13.52 mmol) in DCM (67.6 ml) at 0° C. wasadded diethylaminosulfur trifluoride (CAS number 38078-09-0; 8.93 ml,67.6 mmol). The mixture was stirred at 0° C. for 15 minutes then at roomtemperature for 3.5 hours. A further portion of diethylaminosulfurtrifluoride (3 ml, 22.71 mmol) was added and the mixture stirred at roomtemperature for a further 2 hours. The reaction mixture was thenquenched at 0° C. by the addition of a saturated solution of sodiumbicarbonate until pH7 was achieved. The reaction mixture was thenextracted with DCM. The combined organics were washed with brine, driedover sodium sulfate, filtered and concentrated in vacuo. The crudematerial was purified by column chromatography (silica, 35-60% diethylether/petrol) to afford the title compound.

MS ES⁻: 493

Step (ii):N-[(1S,2S)-2-Amino-4,4-difluorocyclopentyl]-2-methylpropane-2-sulfonamide

A solution of benzylN-[(1S,2S)-4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-N-[(1R)-1-phenylethyl]carbamate(2.24 g, 4.53 mmol) and palladium hydroxide on carbon (20%, 1.59 g, 2.26mmol) in methanol (65 ml) was stirred under a balloon of hydrogen gasfor 17 hours. The reaction was filtered through diatomaceous earth(commercially sold under the trade mark “Celite”) and concentrated invacuo to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.44 (s, 9H), 1.84-2.17 (m, 2H),2.52-2.67 (m, 1H), 2.68-2.85 (m, 1H), 3.26-3.38 (m, 1H), 3.57-3.68 (m,1H)

MS ES⁺: 257

Step (iii):N-[(1S,2S)-4,4-Difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-[(1S,2S)-2-amino-4,4-difluorocyclopentyl]-2-methylpropane-2-sulfonamide(1.03 g, 4.02 mmol) in dry DCM (13.4 ml) was added2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 0.91 g,4.82 mmol), EDC (2.31 g, 12.06 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (1.64 g, 12.06 mmol) and DIPEA(2.11 ml, 12.06 mmol). The reaction was stirred at room temperatureovernight then partitioned between ethyl acetate and water. The organicswere washed with water and brine, dried over sodium sulfate, filteredand concentrated in vacuo. The crude material was purified by columnchromatography (silica, 30-80% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.36-1.44 (m, 9H), 1.93-2.08 (m, 1H),2.10-2.28 (m, 1H), 2.65-2.84 (m, 2H), 3.75-3.96 (m, 1H), 4.24-4.41 (m,1H), 4.89-5.06 (m, 1H), 6.35-6.52 (m, 1H), 7.51-7.57 (m, 1H), 7.61-7.70(m, 2H), 7.83-7.88 (m, 1H), 7.90 (s, 2H)

MS ES⁺: 428

Step (iv):N-[(1S,2S)-2-Amino-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-[(1S,2S)-4,4-difluoro-2-(2-methylpropane-2-sulfonamido)cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(1.7 g, 3.98 mmol) in DCM (100 ml) at 0° C. was added anisole (CASnumber 100-66-3; 7.82 ml, 71.6 mmol) followed by the drop wise additionof trifluoromethanesulfonic acid in DCM (0.2M, 1.55 ml, 17.5 mmol). Thereaction mixture was stirred at 0° C. for 1 hour and then at roomtemperature for 18 hours. The reaction mixture was quenched with sodiumhydroxide (0.2M) until pH 11 obtained then extracted with DCM. Theorganics were filtered through a hydrophobic frit and concentrated invacuo. The crude material was purified by SCX chromatography (2M ammoniain methanol) to afford the title compound.

MS ES⁺: 308

Intermediate 47: 2-(5-Ethoxypyrimidin-2-yl)benzoic acid

Step (i): 2-(5-Fluoropyrimidin-2-yl)benzonitrile

A suspension of 2-bromo-5-fluoropyrimidine (CAS number 947533-45-1; 301mg, 1.70 mmol), potassium carbonate (705 mg, 5.10 mmol) and[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (62 mg,0.085 mmol) in DMF (5 ml) was purged and evacuated with nitrogen. Tothis was then added (2-cyanophenyl)boronic acid (CAS number 138642-62-3;300 mg, 2.04 mmol) and the reaction was subjected to microwaveirradiation at 140° C. for 10 minutes and then at 130° C. for 35minutes. The reaction was partitioned between ethyl acetate (50 ml) andwater (50 ml) and filtered through diatomaceous earth (commercially soldunder the trade mark “Celite”). The organics were washed with brine,dried over magnesium sulfate and concentrated in vacuo. The resultingresidue was purified column chromatography (silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (300 MHz, DCM-d₂) δ ppm 7.54-7.65 (m, 1H), 7.67-7.79 (m, 1H),7.81-7.92 (m, 1H), 8.27-8.40 (m, 1H), 8.78 (s, 2H)

MS ES⁺: 200

Step (ii): 2-(5-Ethoxypyrimidin-2-yl)benzoic acid

To a solution of 2-(5-fluoropyrimidin-2-yl)benzonitrile (40 mg, 0.20mmol) in ethanol (1 ml) was added sodium hydroxide (3M, 3 ml, 9.0 mmol).The reaction was heated to reflux for 20 hours and then was concentratedin vacuo. The reaction was diluted with water and concentrated HCl wasadded drop wise until pH2 was reached. The aqueous layer wasconcentrated in vacuo and the resulting residue was dissolved inmethanol, filtered through a hydrophobic frit and concentrated in vacuoto afford the title compound.

MS ES⁻: 243

Intermediate 48:(1S,2S)-1-N-[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

Step (i): tert-ButylN-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A solution of 2-chloro-5-(trifluoromethyl)pyrazine (CAS number799557-87-2; 6.78 ml, 54.9 mmol), tert-butylN-[(1S,2S)-2-aminocyclopentyl]carbamate (CAS number 586961-34-4; 10 g,49.9 mmol) and DIPEA (26.2 ml, 150 mmol) in DMSO (160 ml) was heated at140° C. for 18 hours. The reaction mixture was partitioned between ethylacetate (200 ml) and water (200 ml). The aqueous layer was extractedwith ethyl acetate (2×100 ml). The combined organics were washed withbrine (3×100 ml), filtered through a hydrophobic frit, further driedover magnesium sulphate and then concentrated in vacuo. The resultingresidue was purified by column chromatography (silica, 0-40% ethylacetate/petrol). Impure fractions were further purified by columnchromatography (silica, 10-40% ethyl acetate/petrol) and combined toafford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.29 (s, 9H), 1.40-1.54 (m, 2H),1.58-1.73 (m, 2H), 1.86-2.10 (m, 2H), 3.68-3.83 (m, 1H), 4.07-4.17 (m,1H), 6.83-6.96 (m, 1H), 7.84-7.95 (m, 1H), 7.99 (br. s., 1H), 8.28-8.37(m, 1H)

MS ES⁺: 347

Step (ii): tert-ButylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

To a solution of tert-butylN-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(11.61 g, 33.5 mmol) in DCM (70 ml) and acetonitrile (35 ml) at 0° C.under was added 1-bromopyrrolidine-2,5-dione (12.53 g, 70.4 mmol). Thereaction was allowed to warm to room temperature and stirred for 20hours. The mixture was concentrated in vacuo and then purified by columnchromatography (silica, 0-50% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.29 (s, 9H), 1.42-1.73 (m, 4H),1.82-1.96 (m, 1H), 1.98-2.13 (m, 1H), 3.92-4.17 (m, 2H), 6.90-7.01 (m,1H), 7.39-7.48 (m, 1H), 8.43 (s, 1H)

MS ES⁺: 425, 427

Step (iii): tert-ButylN-[(1S,2S)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate

A suspension of tert-butylN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(2.44 g, 5.73 mmol), cyclopropylboronic acid (2.46 g, 28.6 mmol),potassium carbonate (3.17 g, 22.9 mmol) andtetrakis(triphenylphosphine)palladium (0.662 g, 0.57 mmol) in1,4-dioxane (15 ml) and water (4 ml) was subjected to microwaveirradiation at 140° C. for 2 hours. The reaction was partitioned betweenethyl acetate (20 ml) and water (20 ml). The aqueous layer was extractedwith ethyl acetate (2×50 ml) and combined organics were washed withbrine (50 ml), filtered through a hydrophobic frit and concentrated invacuo. The crude product was purified by column chromatography (silica,0-50% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.83-0.91 (m, 2H), 0.96-1.03 (m, 2H),1.29 (s, 9H), 1.44-1.58 (m, 2H), 1.59-1.73 (m, 2H), 1.85-1.96 (m, 1H),2.03-2.13 (m, 1H), 2.15-2.24 (m, 1H), 3.89-4.00 (m, 1H), 4.11-4.27 (m,1H), 6.88-7.00 (m, 1H), 7.23-7.38 (m, 1H), 8.14 (s, 1H)

MS ES⁺: 387

Step (iv):(1S,2S)-1-N-[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride

To a solution of tert-butylN-[(1S,2S)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]carbamate(1.54 g, 3.99 mmol) in 1,4-dioxane (14 ml) was added HCl in 1,4-dioxane(4M, 10 ml, 40 mmol). The reaction was stirred at room temperature for20 hours and was then concentrated in vacuo and azeotropically distilledwith toluene to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.80-0.92 (m, 1H), 0.94-1.12 (m, 3H),1.57-1.89 (m, 4H), 2.03-2.26 (m, 2H), 2.36-2.48 (m, 1H), 3.52-3.69 (m,1H), 4.30-4.48 (m, 1H), 7.67-7.80 (m, 1H), 8.15-8.40 (m, 4H)

MS ES⁺: 287

Intermediate 50:1-Methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine

Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)carbamate

A solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (Intermediate 27;2.0 g, 6.01 mmol), 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number69034-12-4; 1.21 g, 6.61 mmol) and DIPEA (3.15 ml, 18.02 mmol) in dryDMSO (15 ml) was subjected to microwave irradiation at 140° C. for 4hours. The reaction was partitioned between ethyl acetate and brine. Theaqueous layer was extracted further with ethyl acetate (2×100 ml). Thecombined organics were washed with brine (3×125 ml), dried overmagnesium sulfate and concentrated in vacuo. The resulting residue waspurified by column chromatography (silica, 0-30% diethyl ether/petrol)to afford the title compound as a single trans-enantiomer.

MS ES⁺: 443

Step (ii):1-Methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)carbamate(1.04 g, 2.35 mmol) in acetic acid (8 ml) was added HBr (1.28 ml, 23.48mmol). The reaction was heated sealed and heated at 90° C. overnight. Tothis was then added further HBr (1.28 ml, 23.48 mmol) and the reactionmixture heated at 90° C. for 24 hours. Further acetic acid (5 ml) andHBr (5 ml) was added and the reaction mixture heated to 90° C. for 5hours. The reaction mixture was concentrated in vacuo and azeotropicallydistilled with toluene. The resulting residue was purified by SCXchromatography (2M ammonia in methanol) to afford the title compound asa single trans-enantiomer.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.25-1.43 (m, 4H), 1.60-1.73 (m, 2H),1.86-2.00 (m, 1H), 2.00-2.16 (m, 2H), 3.30-3.37 (m, 1H), 5.84 (br. s.,1H), 8.32-8.56 (m, 2H)

MS ES⁺: 261

Intermediate 51:1-Methyl-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine

Step (i): (1R,2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexylN-(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)carbamate

A solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-amino-2-methylcyclopentyl)carbamate hydrochloride (Intermediate 27;1.50 g, 4.51 mmol), 2-fluoro-5-(trifluoromethyl)pyridine (CAS number69045-82-5; 0.652 mL, 5.41 mmol) and DIPEA (2.36 ml, 13.5 mmol) in DMSO(10 ml) was subjected to microwave irradiation at 140° C. for 4 hours.The reaction was diluted with ethyl acetate (200 ml) and a saturatedsolution of sodium bicarbonate (100 ml). The aqueous layer was furtherextracted with ethyl acetate (100 ml). The combined organics were washedwith water (50 ml), brine (50 ml), dried over magnesium sulfate,filtered through a hydrophobic frit and concentrated in vacuo. The crudeproduct was purified by column chromatography (silica, 10-20% diethylether/petrol) to afford the title compound as a single trans-enantiomer.

MS ES⁺: 442

Step (ii):1-Methyl-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine

To a solution of (1R,2S,5R)-5-methyl-2-(propan-2-yl)cyclohexylN-(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)carbamatein acetic acid (3 ml) was added HBr (6 M, 1.68 ml, 10.10 mmol). Thereaction was sealed and heated at 90° C. for 24 hours. To this was thenadded further HBr (6 M, 1.68 ml, 10.10 mmol) and the reaction was heatedat 90° C. for 24 hours. The reaction was concentrated in vacuo and theresulting residue was purified by SCX chromatography (2M ammonia inmethanol). The product was purified by reverse phase chromatography (C18silica, 5-100% water (with 0.05% ammonia)/acetonitrile) to afford thetitle compound as a single trans-enantiomer.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.33 (s, 3H), 1.43-1.58 (m, 1H),1.66-1.78 (m, 2H), 1.84-1.97 (m, 1H), 2.04-2.16 (m, 2H), 3.21-3.36 (m,1H), 5.14-5.21 (m, 1H), 6.43-6.55 (m, 1H), 7.47-7.60 (m, 1H), 8.25-8.33(m, 1H)

MS ES⁺: 260

2. Examples Example 12,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

A mixture of 2-chloro-5-(trifluoromethyl)pyridine (CAS number52334-81-3; 266 mg, 1.46 mmol),N-[(1S,2S)-2-aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride(Intermediate 5; 400 mg, 1.33 mmol), DIPEA (0.70 ml, 3.99 mmol) and DMSO(4.8 ml) was subjected to microwave irradiation at 140° C. for 2 hours.Upon cooling, the resulting mixture was partitioned between ethylacetate (10 ml) and water (10 ml) and the combined organics were washedwith brine (10 ml), dried over magnesium sulfate, filtered andconcentrated in vacuo. The crude product was further purified bytrituration with di-isopropylether to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.39-1.60 (m, 2H), 1.70 (m, 2H), 1.95-2.11 (m,2H), 3.32 (s, 6H), 4.03-4.20 (m, 2H), 6.59-6.78 (m, 3H), 7.21-7.34 (m,2H), 7.63-7.70 (m, 1H), 7.65 7.69 (m, 1H) and 8.08 (m, 1H)

MS ES⁺: 410

Example 22,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide

A microwave vial was charged with N-[(1S,2S)-2-aminocyclopentyl]-2,6-mdimethoxybenzamide hydrochloride (Intermediate 5; 80 mg, 0.27 mmol),DIPEA (0.139 ml, 0.80 mmol), 2-chloro-5-(trifluoromethyl)pyrimidine (CASnumber 69034-12-4; 0.058 mg, 0.32 mmol) and dry NMP (0.9 ml). Theresulting mixture was subjected to microwave irradiation at 250° C. for20 minutes. The crude material was purified by reverse phase preparativeHPLC (eluted with acetonitrile/water with 0.1% ammonia) to afford thetitle compound.

¹H NMR (DMSO-d₆) δ ppm 1.45-1.75 (m, 4H), 1.96-2.14 (m, 2H), 3.61 (s,6H), 4.18-4.33 (m, 2H), 6.51-6.69 (m, 2H), 7.16-7.38 (m, 1H), 8.03 (m,2H) and 8.60 (s, 2H).

MS ES⁺: 411

Example 35-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide

To a mixture ofN-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 100 mg, 0.31 mmol) and NMP (1 ml) wasadded DIPEA (0.200 mg, 1.56 mmol) and2-bromo-5-(trifluoromethyl)pyrimidine (70 mg, 0.31 mmol). The mixturewas subjected to microwave irradiation at 150° C. for 1 hour. Uponcooling, the reaction mass was poured into water (5 ml) and extractedwith ethyl acetate (2×10 ml). The combined organics were dried oversodium sulfate and concentrated in vacuo. The crude product was purifiedby reverse phase preparative HPLC (eluted with acetonitrile/watercontaining 0.1% ammonia) to afford the title compound.

¹H NMR (CD₃CN) δ ppm 1.52-1.59 (m, 2H), 1.74-1.80 (m, 2H), 2.09-2.19 (m,2H), 2.42 (s, 3H), 4.06-4.18 (m, 2H), 6.65-6.67 (m, 1H), 6.90-6.92 (m,1H), 7.30-7.30 (m, 1H), 7.40-7.42 (m, 1H), 7.63-7.65 (m, 1H), 7.73 (s,2H), 8.52 (s, 2H).

MS ES⁺: 432

Example 4N-[(1S,2S)-2-[(5-Ethylpyrimidin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide

A mixture ofN-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 100 mg, 0.31 mmol), toluene (1 ml), BINAP(19 mg, 0.03 mmol), cesium carbonate (404 mg, 0.12 mmol) and2-chloro-5-ethylpyrimidine (CAS number 111196-81-7; 48 mg, 0.34 mmol)was purged with nitrogen gas for 5 minutes beforetris(dibenzylideneacetone)dipalladium(0) (14 mg, 0.02 mmol) was added.The reaction mixture was stirred at 100° C. for 15 hours and uponcooling poured into water (3 ml) and extracted with ethyl acetate (3×10ml). The combined organics were dried over sodium sulfate andconcentrated in vacuo. The crude product was purified by reverse phasepreparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.02-1.15 (m, 3H), 1.45-1.49 (m, 2H), 1.50-1.58(m, 2H), 1.60-1.65 (m, 2H), 2.32 (s, 3H), 2.33-2.39 (m, 2H), 4.03-4.10(m, 2H), 6.84-6.86 (m, 1H), 7.22-7.22 (m, 1H), 7.38-740 (m, 1H),7.61-7.63 (m, 1H), 7.90 (s, 2H), 8.15 (m, 1H), 8.30 (m, 1H), 8.33-8.35(m, 1H)

MS ES⁺: 392

Example 5N-[(1S,2S)-2-[(5-Chloropyridin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 100 mg, 0.31 mmol) in toluene (1.0 ml)was added BINAP (19 mg, 0.03 mmol), cesium carbonate (405 mg, 1.25 mmol)and 2-bromo-5-chloropyridine (CAS number 40473-01-6; 72 mg, 0.38 mmol).The mixture was purged with nitrogen for 5 minutes and thentris(dibenzylideneacetone)dipalladium(0) (14 mg, 0.02 mmol) was addedand the resulting mixture was stirred at 100° C. for 15 hours. Theresulting mass was poured into water (3 ml) and extracted into ethylacetate (3×10 ml). The combined organics were dried over sodium sulfateand concentrated in vacuo. The crude product was purified by reversephase preparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.40-1.52 (m, 2H), 1.63-1.64 (m, 2H), 1.93-2.01(m, 2H), 2.37 (s, 3H), 3.97-4.06 (m, 2H), 6.56-6.58 (m, 1H), 6.73-6.75(m, 1H), 7.19 (m, 1H), 7.38-7.44 (m, 2H), 7.62-7.64 (m, 2H), 7.93 (m,1H), 7.94 (m, 1H), 8.34-8.36 (m, 1H).

MS ES⁺: 396

Example 65-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

A microwave vial was chargedN-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 650 mg, 2.02 mmol),2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 403 mg,2.22 mmol) and DIPEA (1058 μl, 6.06 mmol) in dry DMSO (6.7 ml). Thereaction was subjected to microwave irradiation at 120° C. for 2 hoursand then at 140° C. for 5 hours. Upon cooling the mixture waspartitioned between ethyl acetate and water, washing with water andbrine, dried over magnesium sulfate, filtered through a hydrophobic fritand concentrated in vacuo. This was then purified by columnchromatography (silica, 0-100% ethyl acetate/petrol) and then furtherpurified by column chromatography (basic silica 0-100% DCM/petrol) toafford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.43-1.59 (m, 2H), 1.62-1.73 (m, 2H), 1.92-2.08(m, 2H), 2.39 (s, 3H), 4.00-4.45 (m, 2H), 6.62-6.69 (m, 1H), 7.19-7.21(m, 1H), 7.28-7.32 (m, 1H), 7.38-7.44 (m, 1H), 7.61-7.67 (m, 2H), 7.93(s, 2H), 7.28-7.32 (m, 1H), 8.33-8.39 (m, 1H).

MS ES⁺: 431

Example 75-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A microwave vial was charged withN-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 450 mg, 1.40 mmol),2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 306 mg,1.68 mmol) and DIPEA (733 μl, 4.20 mmol) in dry DMSO (4.7 ml). Thereaction was subjected to microwave irradiation at 140° C. for 2 hoursand then partitioned between ethyl acetate and water, washed with water,brine and concentrated in vacuo. The crude product was then purified bycolumn chromatography (basic silica, 0-100% ethyl acetate/petrol) togive a cream solid which was then recrystallised from a mixture of ethylacetate and pentane to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.45-1.60 (m, 2H), 1.62-1.72 (m, 2H), 1.93-2.10(m, 2H), 2.38 (s, 3H), 4.08-4.25 (m, 2H), 7.19 (m, 1H), 7.39-7.42 (m,1H), 7.63-7.68 (m, 1H), 7.89 (s, 2H), 7.94-7.89 (m, 1H), 8.03-8.08 (br.s., 1H), 8.36 (s, 2H).

MS ES⁺: 432

Example 82-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

A solution of 2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number475105-77-2; 57.4 mg, 0.28 mmol),(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 72 mg, 0.26 mmol), HATU (146 mg, 0.38mmol) and triethylamine (107 μl, 0.77 mmol) in dry DMF (852 μl) wasstirred at room temperature for 72 hours. The reaction was diluted withDMSO and filtered through cotton wool before being purified by reversephase preparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (DMSO-d₆) δ ppm 1.42-1.78 (m, 4H), 1.98-2.15 (m, 2H), 2.39 (s,3H), 4.10-4.29 (m, 2H), 6.64-6.69 (m, 1H), 7.36-7.42 (m, 1H), 7.46-7.52(m, 1H), 7.62-7.72 (m, 3H), 7.91-7.97 (m, 1H), 8.26 (br. s., 1H),7.56-7.63 (m, 1H).

MS ES⁺: 432

Example 9N-[(1S,2S)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 100 mg, 0.31 mmol) in NMP (1.0 ml) wasadded DIPEA (160 mg, 1.24 mmol) and 2,5-dichloropyrazine (CAS number19745-07-4; 92 mg, 0.62 mmol). The resulting reaction mixture wasstirred and heated under microwave irradiation at 180° C. for 15minutes. Upon completion, the reaction mixture was poured into water (3ml) and extracted with ethyl acetate (3×10 ml). The combined organicswere dried over sodium sulfate and concentrated in vacuo. The crudeproduct was purified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.44-1.56 (m, 2H), 1.62-1.68 (m, 2H), 1.92-2.04(m, 2H), 2.38 (s, 3H), 4.01-4.10 (m, 2H), 7.19 (s, 1H), 7.28-7.30 (m,1H), 7.39-7.41 (m, 1H), 7.62-7.64 (m, 1H), 7.80-7.81 (s, 1H), 7.93 (s,2H), 8.03 (s, 1H), 8.35-8.37 (m, 1H)

MS ES⁺: 398

Example 105-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 8) from 5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid(Intermediate 8; 72 mg, 0.26 mmol) and(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 61 mg, 0.28 mmol) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.42-1.59 (m, 2H), 1.60-1.75 (m, 2H), 1.92-2.10(m, 2H), 4.02-4.23 (m, 2H), 6.64-6.70 (m, 1H), 7.21-7.26 (m, 1H),7.27-7.30 (m, 1H), 7.42-7.51 (m, 1H), 7.62-7.66 (m, 1H), 7.78-7.84 (m,1H), 7.96 (s, 2H), 8.26-8.29 (br. s., 1H), 8.46-8.51 (m, 1H)

MS ES⁺: 435

Example 112-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 8) from 2-(1H-pyrazol-1-yl)benzoic acid (CAS number 55317-53-8;53 mg, 0.28 mmol) and(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 72 mg, 0.26 mmol) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.38-1.53 (m, 2H), 1.60-1.74 (m, 2H), 1.91-2.09(m, 2H), 3.95-4.18 (m, 2H), 6.28-6.32 (m, 1H), 6.62-6.67 (m, 1H),7.28-7.36 (m, 1H), 7.46-7.48 (m, 1H), 7.52-7.59 (m, 1H), 7.60-7.68 (m,3H), 8.09 (s, 1H), 8.29 (br. s., 1H), 8.44-8.50 (m, 1H), 8.74 (s, 1H).

MS ES⁺: 416

Example 122-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 8) from 2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number1001401-62-2; 57 mg, 0.28 mmol) and(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 72 mg, 0.26 mmol) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.37-1.60 (m, 2H), 1.61-1.86 (m, 2H), 1.92-2.10(m, 2H), 4.02-4.20 (m, 2H), 6.70-6.80 (m, 1H), 7.26-7.35 (m, 1H),7.37-7.53 (m, 2H), 7.45-7.54 (m, 2H), 7.73-7.79 (m, 1H), 7.98 (s, 2H),8.27 (br. s., 1H), 8.37-8.45 (m, 1H).

MS ES⁺: 417

Example 132-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 8) from 2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8;56 mg, 0.28 mmol) and(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 72 mg, 0.26 mmol) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.37-1.73 (m, 4H), 1.94-2.10 (m, 2H), 4.04-4.21(m, 2H), 6.64-6.69 (m, 1H), 7.33-7.41 (m, 3H), 7.43-7.57 (m, 2H),7.59-7.64 (m, 1H), 7.95-7.99 (m, 1H), 8.27 (br. s., 2H), 8.83-8.85 (m,2H).

MS ES⁺: 428

Example 145-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(3-methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 8) from 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number1293284-57-7; 61 mg, 0.28 mmol) and(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 72 mg, 0.26 mmol) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.42-1.75 (m, 4H), 1.95-2.13 (m, 2H), 4.04-4.23(m, 2H), 6.63-6.69 (m, 1H), 7.12-7.18 (m, 1H), 7.31-7.45 (m, 3H),7.60-7.67 (m, 1H), 8.03-8.09 (m, 1H), 8.26 (br. s., 1H), 8.32-8.38 (m,1H), 8.76-8.92 (m, 2H).

MS ES⁺: 446

Example 152-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 1) fromN-[(1S,2S)-2-aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamidehydrochloride (Intermediate 2; 100 mg, 0.31 mmol) and2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 68 mg,0.37 mmol). The crude reaction was filtered through cotton wool beforebeing purified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.45-1.76 (m, 4H), 2.00-2.18 (m, 2H), 2.34 (s,3H), 4.16-4.32 (m, 2H), 7.47-7.52 (m, 1H), 7.59-7.74 (m, 2H), 7.92-7.96(m, 1H), 7.99-8.09 (m, 2H), 8.35 (br. s., 1H), 8.56-8.63 (m, 1H).

MS ES⁺: 433

Example 162-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 1) fromN-[(1S,2S)-2-aminocyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamidehydrochloride (Intermediate 2; 100 mg, 0.31 mmol) and2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 68 mg,0.37 mmol). The crude reaction was filtered through cotton wool beforebeing purified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.45-1.73 (m, 4H), 1.95-2.13 (m, 2H), 2.37 (s,3H), 4.21-4.37 (m, 2H), 7.45-7.49 (m, 1H), 7.59-7.71 (m, 2H), 7.91-7.95(m, 1H), 8.09-8.16 (m, 1H), 8.51-8.64 (m, 3H).

MS ES⁺: 433

Example 172-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 1) from N-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride(Intermediate 4; 100 mg, 0.33 mmol) and2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 59 mg,0.33 mmol). The crude reaction was filtered through cotton wool beforebeing purified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.43-1.59 (m, 2H), 1.62-1.74 (m, 2H), 1.95-2.10(m, 2H), 4.08-4.25 (m, 2H), 7.41-7.44 (m, 1H), 7.46-7.51 (m, 1H),7.57-7.62 (m, 1H), 7.76-7.79 (m, 1H), 7.92-7.99 (m, 3H), 8.06 (br. s.,1H), 8.36 (s, 1H), 8.39-8.44 (m, 1H).

MS ES⁺: 418

Example 182-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 1) from N-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride(Intermediate 4; 100 mg, 0.325 mmol) and2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 59.3 mg,0.325 mmol). The crude reaction was filtered through cotton wool beforebeing purified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (DMSO-d₆) δ ppm 1.45-1.59 (m, 2H), 1.60-1.73 (m, 2H), 1.94-2.08(m, 2H), 4.13-4.21 (m, 2H), 7.41-7.44 (m, 1H), 7.46-7.51 (m, 1H),7.55-7.63 (m, 1H), 7.74-7.79 (m, 1H), 7.92 (s, 2H), 8.03-8.08 (m, 1H),8.35-8.39 (m, 1H), 8.62 (m, 2H).

MS ES⁺: 418

Example 192-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2R)-2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}cyclopentyl]benzamide

LiHMDS in THF (1.0 M, 0.477 ml, 0.477 mmol) was added to a solution ofN-[(1S,2R)-2-hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 10; 0.100 g, 0.37 mmol) in THF (3 ml) at 0° C. undernitrogen. The reaction was stirred at this temperature for 1 hour andthen 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 0.059ml, 0.48 mmol) was added. The mixture was allowed to warm to roomtemperature and stirred for 5 hours. The reaction was then quenched withwater (2 ml) and extracted with ethyl acetate (30 ml). The organics werewashed with brine (10 ml), dried over magnesium sulfate and concentratedin vacuo. The crude product was purified by column chromatography(silica, 0-50% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.31-1.43 (m, 1H), 1.57-1.80 (m, 2H),1.82-1.92 (m, 1H), 2.04-2.14 (m, 2H), 4.36-4.45 (m, 1H), 5.39-5.44 (m,1H), 5.46-5.52 (m, 1H), 7.50-7.56 (m, 1H), 7.63-7.73 (m, 2H), 7.77-7.86(m, 4H) and 8.30 (s, 1H).

MS ES⁺: 419

Example 202-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide

To a solution ofN-[(1S,2S)-2-hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 11; 200 mg, 0.73 mmol) in dry DMF (1.2 ml) was addedsodium hydride (60% dispersion in mineral oil, 29.4 mg, 0.73 mmol). Tothis was then added 2-chloro-4-(trifluoromethyl)pyridine (CAS number81565-18-6; 133 mg, 0.73 mmol) as a solution in dry DMF (1.2 ml). Thereaction was stirred at room temperature for 17 hours and was thenpartitioned between ethyl acetate and water. The organics were washedwith water and brine, dried over magnesium sulfate and concentrated invacuo. The crude oil was purified by reverse phase preparative HPLC(eluted with acetonitrile/water containing 0.1% ammonia) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.52-1.78 (m, 4H), 2.00-2.13 (m, 2H),4.18-4.30 (m, 1H), 5.30-5.38 (m, 1H), 7.22 (s, 1H), 7.30-7.34 (m, 1H),7.47-7.56 (m, 2H), 7.59-7.65 (m, 1H), 7.77-7.81 (m, 1H), 7.98 (s, 2H),8.40-8.48 (m, 2H)

MS ES⁺: 418

Example 212,6-Dimethoxy-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide(Example 20) fromN-[(1S,2S)-2-hydroxycyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 11; 100 mg, 0.37 mmol) and2-bromo-4-(trifluoromethyl)pyridine (CAS number 175205-81-9; 100 mg,0.45 mmol) except that the reaction was stirred at room temperature for2 hours. After work-up, the resulting residue was purified by reversephase preparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.64-1.79 (m, 4H), 2.04-2.14 (m, 2H),3.68 (s, 6H), 4.25-4.31 (m, 1H), 5.29-5.32 (m, 1H), 6.64-6.66 (m, 2H),7.24-7.32 (m, 3H), 8.17-8.19 (m, 1H), 8.43-8.44 (m, 1H)

MS ES⁺: 411

Example 222-(2H-1,2,3-Triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide

Triethylamine (0.099 ml, 0.71 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (0.039 g, 0.29 mmol) and EDC(0.055 g, 0.29 mmol) were added to a solution2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine(Intermediate 12; 0.058 g, 0.24 mmol) and2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 0.054 g,0.29 mmol) in DCM (3 ml). The reaction was stirred at room temperaturefor 24 hours and then diluted with DCM (40 ml) and washed with asaturated solution of sodium bicarbonate (10 ml). The organics weredried over magnesium sulfate, filtered through a hydrophobic frit andconcentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-80% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.19-1.31 (m, 1H), 1.39-1.49 (m, 1H),1.50-1.64 (m, 2H), 1.65-1.75 (m, 1H), 1.91-2.02 (m, 1H), 2.48-2.59 (m,1H), 2.68-2.76 (m, 1H), 3.00-3.08 (m, 1H), 4.36-4.45 (m, 1H), 6.45-6.53(m, 1H), 7.30-7.34 (m, 1H), 7.37 (s, 1H), 7.48-7.54 (m, 1H), 7.55-7.61(m, 1H), 7.62-7.66 (m, 1H), 7.71-7.75 (m, 1H), 7.82 (s, 2H) and8.59-8.62 (m, 1H).

MS ES⁺: 416

Example 232-(2H-1,2,3-Triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide(Example 22) except this was then was chirally separated using SFC(Waters prep30/MS system using 20% Ethanol, Daicel IA 10 mm id×250 mmlong columns at 30 ml/min, 40° C. and 100 bar) to afford the titlecompound as a single enantiomer.

¹H NMR (300 MHz, DCM-d₂) δ ppm 1.15-1.35 (m, 1H), 1.35-1.79 (m, 4H),1.85-2.06 (m, 1H), 2.42-2.63 (m, 1H), 2.64-2.79 (m, 1H), 2.95-3.16 (m,1H), 4.28-4.53 (m, 1H), 6.44-6.59 (m, 1H), 7.26-7.43 (m, 2H), 7.43-7.68(m, 3H), 7.69-7.77 (m, 1H), 7.82 (s, 2H), 8.54-8.68 (m, 1H).

MS ES⁺: 416

Example 242-(2H-1,2,3-Triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide(Example 22) from2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-amine(Intermediate 13; 33 mg, 0.14 mmol) and 2-(2H-1,2,3-triazol-2-yl)benzoicacid (CAS number 1001401-62-2; 31 mg, 0.16 mmol) and then was purifiedby column chromatography (silica, 0-100% ethyl acetate/petrol) to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.22-1.32 (m, 1H), 1.38-1.48 (m, 1H),1.50-1.65 (m, 2H), 1.66-1.77 (m, 1H), 1.90-2.01 (m, 1H), 2.47-2.58 (m,1H), 2.69-2.77 (m, 1H), 3.00-3.08 (m, 1H), 4.36-4.45 (m, 1H), 6.37-6.44(m, 1H), 7.29-7.34 (m, 1H), 7.49-7.54 (m, 1H), 7.56-7.65 (m, 2H),7.72-7.76 (m, 1H), 7.83 (s, 2H), 7.84-7.86 (m, 1H) and 8.67-8.71 (m, 1H)

MS ES⁺: 416

Example 252-(2H-1,2,3-Triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide

Prepared according to the procedure for2-(2H-1,2,3-triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide(Example 24) except this was then was chirally separated using SFC(Waters prep30/MS system using 20% Ethanol, Daicel IA 10 mm id×250 mmlong columns at 30 ml/min, 40° C. and 100 bar) to afford the titlecompound as a single enantiomer.

¹H NMR (300 MHz, DCM-d₂) δ ppm 1.14-1.35 (m, 1H), 1.35-1.81 (m, 4H),1.86-2.08 (m, 1H), 2.41-2.60 (m, 1H), 2.62-2.81 (m, 1H), 2.95-3.13 (m,1H), 4.29-4.50 (m, 1H), 6.35-6.49 (m, 1H), 7.23-7.35 (m, 1H), 7.44-7.67(m, 3H), 7.68-7.77 (m, 1H), 7.77-7.88 (m, 3H), 8.69 (s, 1H)

MS ES⁺: 416

Example 265-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide

To a solution of2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentan-1-aminehydrochloride (Intermediate 36; 0.60 g, 2.44 mmol) in DMF (5 ml) wasadded DIPEA (0.63 g, 4.80 mmol), TBTU (0.94 g, 2.93 mmol) and added5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 6; 0.49 g,2.44 mmol). The reaction was stirred at room temperature for 1 hour andthen partitioned between ethyl acetate (50 ml) and water (10.0 ml). Theaqueous layer was further extracted with ethyl acetate (50 ml) and thecombined organics were concentrated in vacuo. The resulting residue waspurified by column chromatography (silica, 0-2% methanol/DCM) to affordthe title compound.

¹H NMR (400 MHz, DMSO) δ ppm 1.61-1.38 (m, 6H), 2.33 (s, 3H), 2.68-2.74(m, 1H), 3.04-3.09 (m, 1H), 4.24-4.26 (m, 1H), 7.30 (s, 1H), 7.41-7.43(m, 1H), 7.47-7.49 (m, 1H), 7.64-7.66 (m, 1H), 7.98 (m, 2H), 8.09-8.11(m, 1H), 8.28-8.30 (m, 1H), 8.87 (s, 1H)

MS ES⁺: 430

Example 272,6-Dimethoxy-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

To a microwave vial were chargedN-[(1S,2S)-2-Aminocyclopentyl]-2,6-dimethoxybenzamide hydrochloride(Intermediate 5; 80 mg, 0.266 mmol) in dry NMP (1 ml). To this was thenadded DIPEA (138 μl, 0.798 mmol) and2-fluoro-6-(trifluoromethyl)pyridine (CAS number 94239-04-0; 53 mg,0.319 mmol). The reaction was subjected to microwave irradiation at 200°C. for 30 minutes and then at 250° C. for 20 minutes. The reactionmixture was directly purified by reverse phase preparative HPLC (elutedwith acetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.44-1.58 (m, 2H), 1.65-1.76 (m, 2H),1.97-2.10 (m, 2H), 3.63 (s, 6H), 3.95-4.04 (m, 1H), 4.04-4.13 (m, 1H),6.55-6.67 (m, 2H), 6.84-6.92 (m, 2H), 7.05-7.11 (m, 1H), 7.21-7.29 (m,1H), 7.55-7.62 (m, 1H), 8.02-8.09 (m, 1H)

MS ES⁺: 410

Example 283-Bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

EDC (509 mg, 2.65 mmol) was added to a solution of3-bromopyridine-2-carboxylic acid (429 mg, 2.12 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (361 mg, 2.65 mmol),(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 500 mg, 1.77 mmol) and triethylamine(0.74 ml, 5.31 mmol) in DCM (5.9 ml). The reaction was stirred at roomtemperature overnight. The reaction was diluted with DCM, washed withwater, brine, filtered through a hydrophobic frit and concentrated invacuo. The crude product was purified by column chromatography (silica0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.57-1.82 (m, 2H), 1.82-2.04 (m, 2H),2.19-2.35 (m, 1H), 2.35-2.47 (m, 1H), 4.06-4.23 (m, 1H), 4.24-4.39 (m,1H), 6.99 (br. s., 1H), 7.27-7.32 (m, 1H), 8.02-8.06 (m, 1H), 8.11-8.21(m, 1H), 8.22 (s, 1H), 8.46-8.52 (m, 1H)

MS ES⁺: 432

Example 292-Ethoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for3-bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide(Example 28) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 75 mg, 0.27 mmol) and2-ethoxy-5-methylbenzoic acid (CAS number 854645-34-4; 57 mg, 0.32 mmol)and was then purified by column chromatography (silica, 40-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.47 (t, J=6.95 Hz, 3H), 1.57-1.71 (m,2H), 1.82-1.97 (m, 2H), 2.14-2.28 (m, 1H), 2.31 (s, 3H), 2.41-2.54 (m,1H), 3.84-3.94 (m, 1H), 4.15 (q, J=6.95 Hz, 2H), 4.35-4.49 (m, 1H),6.85-6.90 (m, 1H), 7.22-7.28 (m, 1H), 7.92-7.96 (m, 1H), 8.08 (br. s.,1H), 8.23 (s, 1H), 8.38-8.47 (m, 1H)

MS ES⁺: 409

Example 303-Ethoxy-6-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

Prepared according to the procedure for3-bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide(Example 28) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 75 mg, 0.27 mmol) and3-ethoxy-6-methylpyridine-2-carboxylic acid (CAS number 1228188-14-4; 58mg, 0.32 mmol) and was then purified by column chromatography (silica,40-100% ethyl acetate/petrol) followed by partitioning between ethylacetate and a saturated solution of sodium bicarbonate. The organicswere filtered through a hydrophobic frit and concentrated in vacuo toafford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.39-1.47 (m, 3H), 1.51-1.63 (m, 1H),1.63-1.76 (m, 1H), 1.82-1.95 (m, 2H), 2.17-2.30 (m, 1H), 2.39-2.49 (m,1H), 2.50 (s, 3H), 3.95-4.06 (m, 1H), 4.07-4.14 (m, 2H), 4.32-4.47 (m,1H), 6.64-7.05 (m, 1H), 7.20-7.36 (m, 2H), 7.97-8.10 (m, 2H), 8.23-8.25(m, 1H)

MS ES⁺: 410

Example 312-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 213 mg, 0.75 mmol), HATU (430 mg, 1.13mmol), triethylamine (0.315 ml, 2.26 mmol) and2-(1H-pyrazol-1-yl)benzoic acid (CAS number 55317-53-8; 156 mg, 0.83mmol) was stirred at room temperature overnight. This was thenpartitioned between DCM and a saturated solution of sodium bicarbonate,filtered through a hydrophobic frit and concentrated in vacuo. Theresulting residue was purified by reverse phase preparative HPLC (elutedwith acetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39-1.53 (m, 2H), 1.60-1.72 (m, 2H),1.92-2.07 (m, 2H), 4.09-4.20 (m, 2H), 6.27-6.31 (m, 1H), 7.35-7.44 (m,2H), 7.51-7.60 (m, 3H), 7.88-7.92 (m, 1H), 7.94-8.00 (m, 1H), 8.03 (s,1H), 8.34 (s, 1H), 8.36-8.41 (m, 1H)

MS ES⁺: 417

Example 322-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 31) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 213 mg, 0.75 mmol) and2-fluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1186050-58-7;172 mg, 0.83 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.59 (m, 2H), 1.60-1.75 (m, 2H),1.96-2.08 (m, 2H), 4.12-4.24 (m, 2H), 7.32-7.38 (m, 1H), 7.58-7.65 (m,1H), 7.70-7.74 (m, 1H), 7.94-8.00 (m, 3H), 8.06 (br. s., 1H), 8.35 (s,1H) and 8.60-8.65 (m, 1H)

MS ES⁺: 436

Example 332,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 31) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 213 mg, 0.75 mmol) and2,6-difluorobenzoic acid (CAS number 385-00-2; 131 mg, 0.83 mmol) toafford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.44-1.60 (m, 2H), 1.68-1.77 (m, 2H),2.01-2.14 (m, 2H), 4.18-4.29 (m, 2H), 7.07-7.15 (m, 2H), 7.43-7.52 (m,1H), 7.99-8.09 (m, 2H), 8.33 (s, 1H), 8.79-8.87 (m, 1H)

MS ES⁺: 387

Example 342,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 31) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 213 mg, 0.75 mmol) and2,6-dimethoxybenzoic acid (CAS number 1466-76-8; 151 mg, 0.83 mmol)except this was then purified by column chromatography (silica, 0-100%ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.60 (m, 2H), 1.64-1.75 (m, 2H),1.95-2.09 (m, 2H), 3.61 (s, 6H), 4.13-4.24 (m, 2H), 6.60-6.64 (m, 2H),7.21-7.28 (m, 1H), 7.93-8.01 (m, 1H), 8.03-8.12 (m, 2H) and 8.34 (s,1H).

MS ES⁺: 411

Example 352-(1H-1,2,3-Triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 31) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 213 mg, 0.75 mmol) and2-(1H-1,2,3-triazol-1-yl)benzoic acid (CAS number 1085458-53-2; 157 mg,0.83 mmol) except this was then purified by column chromatography(silica, 0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.35-1.49 (m, 2H), 1.58-1.72 (m, 2H),1.87-2.09 (m, 2H), 4.01-4.19 (m, 2H), 7.47-7.54 (m, 1H), 7.55-7.69 (m,3H), 7.76 (s, 1H), 7.89-7.98 (m, 1H), 7.98-8.07 (m, 1H), 8.27 (s, 1H),8.35 (s, 1H), 8.43-8.53 (m, 1H)

MS ES⁺: 418

Example 365-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 31) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 213 mg, 0.75 mmol) and5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 8; 172 mg,0.83 mmol) except this was then purified by column chromatography(silica, 0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.60 (m, 2H), 1.61-1.77 (m, 2H),1.93-2.10 (m, 2H), 4.02-4.26 (m, 2H), 7.22-7.33 (m, 1H), 7.42-7.53 (m,1H), 7.75-7.85 (m, 1H), 7.90-8.00 (m, 3H), 8.00-8.08 (m, 1H), 8.36 (s,1H), 8.45-8.54 (m, 1H)

MS ES⁺: 436

Example 372-Methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 75 mg, 0.27 mmol),2-methoxy-5-methylbenzoic acid (CAS number 25045-36-7; 53 mg, 0.32mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (61 mg, 0.40 mmol), EDC (76mg, 0.40 mmol) and triethylamine (111 μl, 0.80 mmol) in dry DCM (1 ml)was stirred at room temperature for 24 hours. The reaction mixture waspartitioned between DCM (3 ml) and water (2 ml), filtered through ahydrophobic frit and concentrated in vacuo. The resulting residue waspurified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.49-1.74 (m, 2H), 1.83-1.94 (m, 2H),2.16-2.27 (m, 1H), 2.31 (s, 3H), 2.41-2.54 (m, 1H), 3.86-4.01 (m, 4H),4.40-4.53 (m, 1H), 6.82-7.04 (m, 2H), 7.24-7.30 (m, 1H), 7.86-8.00 (m,2H), 8.08-8.21 (m, 1H), 8.24 (s, 1H)

MS ES⁺: 395

Example 382-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 75 mg, 0.27 mmol) and2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 64 mg, 0.32mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.44-1.59 (m, 2H), 1.75-1.89 (m, 2H),2.11-2.24 (m, 1H), 2.32-2.45 (m, 1H), 3.86-3.98 (m, 1H), 4.20-4.34 (m,1H), 6.40-6.44 (m, 1H), 6.53-6.71 (m, 1H), 7.03-7.10 (m, 1H), 7.44-7.59(m, 3H), 7.85 (s, 1H), 7.97-8.08 (m, 1H), 8.21 (s, 1H), 8.51-8.60 (m,2H)

MS ES⁺: 429

Example 395-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14, 75 mg, 0.27 mmol) and5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 69 mg,0.32 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.48-1.70 (m, 2H), 1.74-1.98 (m, 2H),2.17-2.43 (m, 2H), 3.94-4.09 (m, 1H), 4.17-4.28 (m, 1H), 6.47-6.61 (m,1H), 6.83-7.05 (m, 1H), 7.07-7.13 (m, 1H), 7.17-7.28 (m, 2H), 7.96-8.08(m, 1H), 8.09-8.19 (m, 2H), 8.53-8.62 (m, 2H)

MS ES⁺: 447

Example 402-Chloro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.265 mmol) and2-chloro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 15; 71 mg,0.318 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.52-1.67 (m, 2H), 1.81-1.95 (m, 2H),2.21-2.41 (m, 2H), 4.04-4.15 (m, 1H), 4.24-4.38 (m, 1H), 6.14-6.29 (m,1H), 6.47-6.62 (m, 1H), 7.46-7.55 (m, 2H), 7.61 (s, 2H), 7.88-7.96 (m,2H), 8.17 (s, 1H)

MS ES⁺: 452

Example 415-Fluoro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and5-fluoro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 9; 66 mg,0.32 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.39-1.64 (m, 2H), 1.77-1.92 (m, 2H),2.08-2.22 (m, 1H), 2.25-2.41 (m, 1H), 3.92-4.04 (m, 1H), 4.08-4.23 (m,1H), 6.28-6.47 (m, 1H), 6.69-6.80 (m, 1H), 7.28-7.44 (m, 2H), 7.47-7.56(m, 1H), 7.72 (d, J=1.01 Hz, 1H), 7.87 (d, J=1.01 Hz, 1H), 8.09 (s, 1H),8.24 (s, 1H)

MS ES⁺: 436

Example 425-Methyl-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and5-methyl-2-(1H-1,2,3-triazol-1-yl)benzoic acid (CAS number 1149352-55-5;65 mg, 0.32 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.42-1.65 (m, 2H), 1.76-1.91 (m, 2H),2.07-2.19 (m, 1H), 2.27-2.40 (m, 1H), 3.89-4.05 (m, 1H), 4.09-4.28 (m,1H), 6.55-6.78 (m, 2H), 7.34-7.41 (m, 1H), 7.43-7.49 (m, 2H), 7.70 (d,J=1.01 Hz, 1H), 7.86 (d, J=1.01 Hz, 1H), 8.13 (s, 1H), 8.23 (s, 1H)

MS ES⁺: 432

Example 433-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

A solution of3-bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide(Example 28; 100 mg, 0.23 mmol), 1H-pyrazole (CAS number 288-13-1; 32mg, 0.47 mmol), cesium carbonate (151 mg, 0.47 mmol), copper (I) iodide(2.2 mg, 0.012 mmol) and trans-1-N,2-N-dimethylcyclohexane-1,2-diamine(1.7 mg, 0.012 mmol) in dry DMF (0.8 ml) was subjected to microwaveirradiation at 120° C. for 1 hour. The reaction mixture was diluted withethyl acetate and washed with water (×3) and brine, filtered through ahydrophobic frit and concentrated in vacuo. The resulting residue waspurified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DCME-d₂) δ ppm 1.42-1.59 (m, 1H), 1.59-1.77 (m, 1H),1.77-1.93 (m, 2H), 2.10-2.31 (m, 1H), 2.31-2.48 (m, 1H), 3.94-4.18 (m,1H), 4.19-4.35 (m, 1H), 6.21-6.36 (m, 1H), 6.37-6.43 (m, 1H), 7.51-7.58(m, 1H), 7.61-7.67 (m, 1H), 7.71-7.75 (m, 1H), 7.84-7.88 (m, 1H),7.90-7.96 (m, 1H), 7.97-8.07 (m, 1H), 8.25 (s, 1H), 8.49-8.59 (m, 1H)

MS ES⁺: 418

Example 442-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid (CAS number 898289-64-0;75 mg, 0.37 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.53-1.69 (m, 2H), 1.80-1.94 (m, 2H),2.23-2.34 (m, 1H), 2.37-2.47 (m, 1H), 2.50 (s, 3H), 3.98-4.14 (m, 1H),4.26-4.40 (m, 1H), 6.53-6.74 (m, 1H), 6.78-6.90 (m, 1H), 7.48-7.55 (m,1H), 7.55-7.61 (m, 2H), 7.80-7.90 (m, 1H), 8.12 (s, 1H), 8.15 (s, 1H)

MS ES⁺: 433

Example 452-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and2-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37a; CAS number 1384066-81-2; 94 mg, 0.37 mmol) except this was purifiedby column chromatography (silica, 40-100% ethyl acetate/petrol) toafford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.49-1.73 (m, 2H), 1.75-2.00 (m, 2H),2.21-2.40 (m, 2H), 4.03-4.16 (m, 1H), 4.15-4.30 (m, 1H), 6.58-6.67 (m,1H), 6.67-6.89 (m, 1H), 7.64-7.71 (m, 2H), 7.76-7.80 (m, 1H), 7.81-7.86(m, 1H), 8.01-8.06 (m, 1H), 8.09 (s, 1H), 8.14 (s, 1H)

MS ES⁺: 486

Example 462-Fluoro-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and2-fluoro-6-(1H-pyrazol-1-yl)benzoic acid (CAS number 1521055-55-9; 75mg, 0.37 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.41-1.59 (m, 2H), 1.73-1.93 (m, 2H),2.12-2.38 (m, 2H), 3.93-4.04 (m, 1H), 4.16-4.27 (m, 1H), 6.24 (s, 1H),6.52-6.60 (m, 1H), 7.10-7.18 (m, 1H), 7.29-7.35 (m, 1H), 7.42-7.53 (m,2H), 7.72-7.76 (m, 1H), 8.01 (s, 1H), 8.16 (s, 1H)

MS ES⁺: 435

Example 475-Fluoro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and5-fluoro-2-(1H-pyrazol-1-yl)benzoic acid (CAS number 1152964-04-9; 75mg, 0.37 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.30-1.58 (m, 2H), 1.68-1.90 (m, 2H),1.97-2.11 (m, 1H), 2.22-2.36 (m, 1H), 3.70-3.81 (m, 1H), 4.08-4.21 (m,1H), 6.31-6.39 (m, 2H), 6.73-6.81 (m, 1H), 7.21-7.30 (m, 1H), 7.36-7.42(m, 1H), 7.42-7.49 (m, 1H), 7.61 (s, 2H), 7.99 (s, 1H), 8.23 (s, 1H)

MS ES⁺: 435

Example 485-Methyl-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and5-methyl-2-(1H-pyrazol-1-yl)benzoic acid (CAS number 1214622-46-4; 74mg, 0.37 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.37-1.51 (m, 1H), 1.53-1.70 (m, 1H),1.71-1.95 (m, 2H), 2.01-2.13 (m, 1H), 2.26-2.38 (m, 1H), 2.47 (s, 3H),3.75-3.86 (m, 1H), 4.13-4.25 (m, 1H), 6.36-6.41 (m, 1H), 6.75-6.81 (m,1H), 7.27-7.34 (m, 1H), 7.37-7.42 (m, 1H), 7.55-7.60 (m, 1H), 7.62-7.68(m, 2H), 8.16-8.20 (m, 1H), 8.24 (s, 1H)

MS ES⁺: 431

Example 492-Bromo-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 250 mg, 0.88 mmol) and2-bromo-6-methoxybenzoic acid (CAS number 31786-45-5; 245 mg, 1.06 mmol)except this was purified by column chromatography (silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.55-1.74 (m, 2H), 1.80-2.00 (m, 2H),2.19-2.43 (m, 2H), 3.69 (s, 3H), 4.14-4.27 (m, 1H), 4.30-4.41 (m, 1H),6.33-6.39 (m, 1H), 6.84-6.91 (m, 1H), 7.11-7.17 (m, 1H), 7.18-7.26 (m,1H), 8.16 (s, 1H), 8.23-8.27 (m, 1H)

MS ES⁺: 559

Example 502-Methoxy-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for3-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide(Example 43) from2-bromo-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 49; 100 mg, 0.218 mmol) and 1H-pyrazole (30 mg, 0.435 mmol) toafford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.34-1.59 (m, 2H), 1.69-1.90 (m, 2H),2.04-2.18 (m, 1H), 2.24-2.39 (m, 1H), 3.75 (s, 3H), 3.81-3.93 (m, 1H),4.14-4.28 (m, 1H), 6.12-6.18 (m, 1H), 6.28-6.37 (m, 2H), 6.89-6.99 (m,1H), 7.06-7.13 (m, 1H), 7.37-7.48 (m, 2H), 7.68-7.73 (m, 1H), 7.89 (s,1H), 8.21 (s, 1H)

MS ES⁺: 447

Example 513-(Piperidin-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol),3-(piperidin-1-yl)pyridine-2-carboxylic acid (CAS number 898289-01-5; 66mg, 0.32 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (54 mg, 0.40mmol), EDC (76 mg, 0.40 mmol) and triethylamine (0.111 ml, 0.80 mmol) inDCM (1 ml) was stirred at room temperature overnight. The reaction waspartitioned between DCM and a saturated solution of sodium bicarbonate,filtered through a hydrophobic frit and concentrated in vacuo. Theresulting residue was purified by column chromatography (silica, 40-100%ethyl acetate/petrol) and then further purified by reverse phasepreparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.46-1.63 (m, 2H), 1.65-1.79 (m, 6H),1.83-1.96 (m, 2H), 2.17-2.32 (m, 1H), 2.41-2.56 (m, 1H), 2.88-3.05 (m,4H), 3.91-4.05 (m, 1H), 4.35-4.52 (m, 1H), 6.85 (br. s., 1H), 7.27-7.37(m, 1H), 7.44-7.54 (m, 1H), 7.94 (s, 1H), 8.17-8.27 (m, 2H), 8.86-8.95(m, 1H)

MS ES⁺: 435

Example 525-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for3-(piperidin-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide(Example 51) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 500 mg, 1.77 mmol) and5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 38a; CASnumber 1293284-54-4; 396 mg, 1.77 mmol) except this was purified only bycolumn chromatography (silica, 40-100% ethyl acetate/petrol) to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.41-1.66 (m, 2H), 1.69-1.94 (m, 2H),2.15-2.28 (m, 1H), 2.28-2.41 (m, 1H), 3.89-4.05 (m, 1H), 4.12-4.27 (m,1H), 6.43-6.53 (m, 2H), 7.49-7.58 (m, 2H), 7.61-7.67 (m, 2H), 7.73-7.80(m, 1H), 8.00 (s, 1H), 8.19 (s, 1H)

MS ES⁺: 452

Example 533-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 126 mg, 0.45 mmol) and3-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1293284-51-1;111 mg, 0.54 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.56 (m, 2H), 1.60-1.73 (m, 2H),1.88-2.08 (m, 2H), 4.06-4.09 (m, 1H), 4.15-4.24 (m, 1H), 7.72-7.78 (m,1H), 7.82-7.86 (m, 1H), 7.86-7.92 (m, 1H), 7.94-8.08 (m, 3H), 8.31 (s,1H), 8.39-8.43 (m, 1H), 8.67-8.75 (m, 1H)

MS ES⁺: 436

Example 542-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 126 mg, 0.45 mmol) and2-(1H-1,2,3-triazol-1-yl)-5-(trifluoromethyl)benzoic acid (Intermediate37b; 138 mg, 0.54 mmol) except this was purified by columnchromatography (silica, 40-100% ethyl acetate/petrol) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.36-1.52 (m, 2H), 1.58-1.72 (m, 2H),1.86-2.09 (m, 2H), 3.93-4.07 (m, 1H), 4.07-4.16 (m, 1H), 7.33-7.39 (m,1H), 7.53-7.72 (m, 2H), 7.87-8.03 (m, 4H), 8.37 (s, 1H), 8.45-8.53 (m,1H)

MS ES⁺: 486

Example 555-Chloro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 126 mg, 0.45 mmol) and5-chloro-2-(1H-1,2,3-triazol-1-yl)benzoic acid (Intermediate 38b; 120mg, 0.54 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.39-1.52 (m, 2H), 1.59-1.72 (m, 2H),1.86-2.13 (m, 2H), 3.99-4.10 (m, 1H), 4.10-4.22 (m, 1H), 7.54 (d, J=2.40Hz, 1H), 7.63-7.69 (m, 1H), 7.73 (d, J=2.40 Hz, 1H), 7.79 (d, J=1.01 Hz,1H), 7.90-8.05 (m, 2H), 8.31 (d, J=1.01 Hz, 1H), 8.35 (s, 1H), 8.61-8.66(m, 1H).

MS ES⁺: 452

Example 562,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 126 mg, 0.45 mmol) and2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 39a;120 mg, 0.535 mmol) except this was purified by column chromatography(silica, 40-100% ethyl acetate/petrol) and then further purified byreverse phase preparative HPLC (eluted with acetonitrile/watercontaining 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.50-1.67 (m, 2H), 1.78-1.96 (m, 2H),2.22-2.40 (m, 2H), 4.03-4.15 (m, 1H), 4.19-4.31 (m, 1H), 6.09-6.37 (m,1H), 6.61-6.79 (m, 1H), 7.30-7.42 (m, 1H), 7.56 (s, 2H), 7.66-7.73 (m,1H), 7.96 (s, 1H), 8.13 (s, 1H)

MS ES⁺: 454

Example 575-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A solution of5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 52; 100 mg, 0.22 mmol), cyclopropylboronic acid (CAS number411235-57-9; 29 mg, 0.33 mmol), bis(triphenylphosphine)palladium(II)dichloride (3 mg, 4.43 μmol) and potassium carbonate (31 mg, 0.22 mmol)in 1,4-dioxane (1.3 ml) and water (0.13 ml) was sealed and degassed withnitrogen. The reaction was subjected to microwave irradiation at 130° C.for 30 minutes. To this was then addedbis(di-tert-butyl(4-dimethylaminophenyl)phosphine)-dichloropalladium(II)(157 mg, 0.22 mmol) and the reaction was subjected to microwaveirradiation at 130° C. for a further 1 hour. The reaction mixture waspartitioned between ethyl acetate and water, washed with water andbrine, filtered through a hydrophobic frit and concentrated in vacuo.The resulting residue was purified by reverse phase preparative HPLC(eluted with acetonitrile/water containing 0.1% ammonia) to afford thetitle compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.68-0.81 (m, 2H), 0.99-1.10 (m, 2H),1.38-1.59 (m, 2H), 1.71-1.90 (m, 2H), 1.93-2.02 (m, 1H), 2.09-2.20 (m,1H), 2.28-2.39 (m, 1H), 3.85-3.95 (m, 1H), 4.15-4.26 (m, 1H), 6.24-6.35(m, 1H), 6.40-6.58 (m, 1H), 7.21-7.27 (m, 2H), 7.57-7.64 (m, 3H), 7.95(s, 1H), 8.22 (s, 1H)

MS ES⁺: 458

Example 583-(Trifluoromethoxy)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 70 mg, 0.25 mmol),3-(trifluoromethoxy)pyridine-2-carboxylic acid (CAS number 1221171-81-8;86 mg, 0.42 mmol), EDC (71 mg, 0.37 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (51 mg, 0.37 mmol) andtriethylamine (0.104 ml, 0.74 mmol) in DCM (1 ml) was stirred at roomtemperature overnight. The mixture was partitioned between ethyl acetate(25 ml) and water (10 ml). The organics were washed with water (2×10 ml)and brine (10 ml), dried over sodium sulfate and concentrated in vacuo.The resulting residue was purified by reverse phase chromatography (C18silica, 0-100% water (with 0.05% ammonia)/acetonitrile) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.46-1.82 (m, 4H), 2.01-2.19 (m, 2H),4.15-4.42 (m, 2H), 7.64-7.74 (m, 1H), 7.88-8.13 (m, 3H), 8.29 (s, 1H),8.55-8.67 (m, 1H), 8.74-8.87 (m, 1H)

MS ES⁺: 436

Example 595-Chloro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 37) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and5-chloro-2-(1H-pyrazol-1-yl)benzoic acid (CAS number 1214622-57-7; 120mg, 0.54 mmol) except this was purified by column chromatography(silica, 0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.58 (m, 2H), 1.62-1.74 (m, 2H),1.92-2.09 (m, 2H), 4.07-4.25 (m, 2H), 6.30-6.36 (m, 1H), 7.36-7.42 (m,1H), 7.58-7.66 (m, 3H), 7.90-7.94 (m, 1H), 7.96-8.08 (m, 2H), 8.35 (s,1H) and 8.52-8.60 (m, 1H).

MS ES⁺: 451

Example 603-Ethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 150 mg, 0.53 mmol),3-ethoxypyridine-2-carboxylic acid (CAS number 103878-09-7; 106 mg, 0.64mmol), EDC (153 mg, 0.80 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol(108 mg, 0.80 mmol) and triethylamine (0.222 ml, 1.59 mmol) in DCM (1ml) was stirred at room temperature over the weekend. The mixture waspartitioned between ethyl acetate (50 ml) and water (20 ml). Theorganics were washed with water (2×20 ml) and brine (20 ml), dried oversodium sulfate and concentrated in vacuo. The resulting residue waspurified by column chromatography (basic silica, 30-100% ethylacetate/petrol) and then by reverse phase chromatography (C18 silica,0-100% water (with 0.05% ammonia)/acetonitrile) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.08-1.29 (m, 3H), 1.41-1.63 (m, 2H),1.66-1.80 (m, 2H), 2.01-2.16 (m, 2H), 3.94-4.09 (m, 2H), 4.16-4.34 (m,2H), 7.35-7.44 (m, 1H), 7.46-7.55 (m, 1H), 7.96-8.16 (m, 3H), 8.26-8.46(m, 2H)

MS ES⁺: 396

Example 613,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for3-(piperidin-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide(Example 51) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.27 mmol) and3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 40a; 60mg, 0.27 mmol) except this was purified only by column chromatography(silica, 40-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.38-1.52 (m, 2H), 1.61-1.73 (m, 2H),1.87-2.08 (m, 2H), 3.94-4.04 (m, 1H), 4.07-4.18 (m, 1H), 7.23-7.31 (m,1H), 7.68-7.79 (m, 1H), 7.92 (d, J=7.70 Hz, 1H), 7.97-8.01 (m, 3H), 8.37(s, 1H) and 8.57 (d, J=7.71 Hz, 1H)

MS ES⁺: 454

Example 622-(Trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

To a solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 60 mg, 0.21 mmol) in DMF (3 ml) wasadded 2-(trifluoromethyl)benzoic acid (CAS number 433-97-6; 60 mg, 0.21mmol), TBTU (0.082 g, 0.25 mmol) and DIPEA (0.1 g, 0.84 mmol) and thereaction was stirred at room temperature for 2 hours. The reaction wasdiluted with water (25 ml) and extracted with ethyl acetate (30 ml×3).The organics were washed with water (50 ml), brine (25 ml), dried oversodium sulfate and concentrated in vacuo. The resulting residue waspurified by column chromatography (silica, 0-45% ethyl acetate/n-hexane)to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.23-1.62 (m, 2H), 1.69-1.76 (m, 2H),2.01-2.33 (m, 2H), 4.21-4.24 (m, 2H), 7.39-7.41 (m, 1H), 7.62-75 (m,3H), 8.03-8.07 (m, 2H), 8.35-8.39 (m, 1H), 8.61-8.63 (m, 1H)

MS ES⁺: 419

Example 633-Cyclopropyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

Prepared according to the procedure for2-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 62) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 75 mg, 0.30 mmol) and3-cyclopropylpyridine-2-carboxylic acid (Intermediate 16; 50 mg, 0.31mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 0.62-0.67 (m, 2H), 0.80-0.89 (m, 2H),1.53-1.77 (m, 4H), 2.06-2.10 (m, 2H), 2.51-2.52 (m, 1H), 4.23-4.36 (m,2H), 7.33-7.38 (m, 2H), 8.02-8.09 (m, 2H), 8.32-8.34 (m, 2H), 8.68-8.70(m, 1H)

MS ES⁺: 392

Example 643,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 62) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 60 mg, 0.21 mmol) and3,6-difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 17; 50mg, 0.21 mmol) except this was purified by reverse phase preparativeHPLC (eluted with acetonitrile/water containing 0.1% ammonia) to affordthe title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.43-1.44 (m, 2H), 1.61-1.68 (m, 2H),1.87-2.00 (m, 2H), 4.00-4.07 (m, 2H), 7.56-7.69 (m, 2H), 7.92-7.94 (m,1H), 8.00-8.02 (m, 3H), 8.37 (s, 1H), 8.76-8.78 (m, 1H)

MS ES⁺: 454

Example 652-(Difluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

To a solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 100 mg, 0.35 mmol),2-(difluoromethyl)benzoic acid (CAS number 799814-32-7; 61 mg, 0.35mmol) and triethylamine (0.148 ml, 1.06 mmol) in DCM (2 ml) was added1,3,5,2,4,6-trioxatriphosphorinane, 2,4,6-tripropyl-, 2,4,6-trioxide(CAS number 68957-94-8; 50% in ethyl acetate, 0.417 ml, 0.71 mmol). Thereaction mixture was stirred at room temperature for 3 hours. To thiswas then added further 1,3,5,2,4,6-trioxatriphosphorinane,2,4,6-tripropyl-, 2,4,6-trioxide (CAS number 68957-94-8; 50% in ethylacetate, 0.417 ml, 0.71 mmol) and stirred at room temperature overnight.The reaction was partitioned between DCM and a saturated solution ofsodium bicarbonate, filtered through a hydrophobic frit and concentratedin vacuo. The resulting residue was purified by column chromatography(silica, 0-100% ethyl acetate/petrol) and then triturated with diethylether to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.62-1.74 (m, 2H), 1.84-2.01 (m, 2H),2.30-2.50 (m, 2H), 4.12-4.28 (m, 1H), 4.28-4.40 (m, 1H), 6.06 (br. s.,1H), 6.64-6.86 (m, 1H), 7.09-7.39 (m, 1H), 7.46-7.51 (m, 1H), 7.52-7.58(m, 1H), 7.58-7.65 (m, 1H), 7.71-7.80 (m, 1H), 8.03 (s, 1H), 8.25 (s,1H)

MS ES⁺: 401

Example 662-Cyclopropyl-6-fluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(difluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 65) from(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 100 mg, 0.35 mmol) and2-cyclopropyl-6-fluorobenzoic acid (CAS number 1603213-26-8; 64 mg, 0.35mmol) except to this was added EDC (68 mg, 0.354 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (48 mg, 0.35 mmol) andtriethylamine (0.1 ml, 0.71 mmol) and the reaction was stirred at roomtemperature for a further 1 hour. The reaction mixture was partitionedbetween DCM and water, filtered through a hydrophobic frit andconcentrated in vacuo. The resulting residue was purified by reversephase preparative HPLC (eluted with acetonitrile/water containing 0.1%formic acid) and then triturated with heptane/diethyl ether to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.55-0.69 (m, 2H), 0.70-0.80 (m, 1H),0.81-0.91 (m, 1H), 1.58-1.69 (m, 2H), 1.83-1.94 (m, 3H), 2.24-2.43 (m,2H), 4.06-4.23 (m, 1H), 4.33-4.50 (m, 1H), 6.10 (br. s., 1H), 6.38-6.40(m, 1H), 6.64-6.69 (m, 1H), 6.82-6.91 (m, 1H), 7.23-7.27 (m, 1H), 7.97(s, 1H), 8.20 (s, 1H)

MS ES⁺: 409

Example 675-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-3-yl]amino}cyclopentyl]benzamide

N-[(1S,2S)-2-aminocyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 7; 70 mg, 0.21 mmol),5-bromo-2-(trifluoromethyl)pyridine (CAS number 436799-32-5; 73 mg, 0.32mmol) and cesium carbonate (280 mg, 0.87 mmol) were suspended in toluene(3 ml). The reaction was degassed using nitrogen for 15 minutes. To thiswas then added BINAP (13 mg, 0.021 mmol) andtris(dibenzylideneacetone)dipalladium (0) (19 mg, 0.021 mmol) and theresulting reaction was heated to 100° C. overnight. The reaction masswas poured into water (20 ml) and the organics were extracted with ethylacetate (3×20 ml). The combined organics were dried over sodium sulfateand concentrated in vacuo. This was then purified by reverse phasepreparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.48-1.54 (m, 2H), 1.69-1.75 (m, 2H),1.88-2.03 (m, 2H), 2.38 (s, 3H), 3.73-3.77 (m, 1H), 3.98-4.04 (m, 1H),6.64-6.66 (m, 1H), 7.21-7.24 (m, 2H), 7.40-7.43 (m, 1H), 7.49-7.51 (m,1H), 7.66-7.68 (m, 1H), 8.00 (s, 2H), 8.16 (s, 1H), 8.41-8.43 (m, 1H)

MS ES⁺: 431

Example 68N-Cyclobutyl-2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

To a solution ofN-[(1S,2S)-2-aminocyclopentyl]-N-cyclobutyl-2,6-dimethoxybenzamidehydrochloride (Intermediate 18; 200 mg, 0.56 mmol) in dry DMSO (1.9 ml)was added 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3;153 mg, 0.85 mmol) and DIPEA (295 μl, 1.69 mmol). The reaction subjectedto microwave irradiation at 150° C. for 2 hours and then was partitionedbetween ethyl acetate and water. The organics were washed with water andbrine, dried over magnesium sulfate and concentrated in vacuo. This wasthen purified using column chromatography (silica, 0-100% ethylacetate/petrol) and then further purified by reverse phase preparativeHPLC (eluted with acetonitrile/water containing 0.1% ammonia) to affordthe title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.19-1.36 (m, 1H), 1.39-1.95 (m, 7H),1.96-2.20 (m, 3H), 2.88-3.10 (m, 1H), 3.42-3.54 (m, 3H), 3.59-3.74 (m,3H), 3.76-3.99 (m, 2H), 4.35-5.12 (m, 1H), 6.41-6.79 (m, 3H), 7.21-7.29(m, 1H), 7.30-7.38 (m, 1H), 7.54-7.65 (m, 1H) and 8.12-8.29 (m, 1H)

MS ES⁺: 464

Example 692-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

A solution of N-[(1S,2S)-2-aminocyclopentyl]-2-chlorobenzamidehydrochloride (Intermediate 19; 100 mg, 0.36 mmol),2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 79 mg, 0.44mmol) and DIPEA (190 μl, 1.09 mmol) in dry DMSO (1.2 ml) was sealed andheated at 150° C. for 17 hours. The reaction mixture was filteredthrough cotton wool and purified by reverse phase preparative HPLC(eluted with acetonitrile/water containing 0.1% ammonia) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.64 (m, 2H), 1.65-1.78 (m, 2H),1.99-2.13 (m, 2H), 4.12-4.32 (m, 2H), 6.60-6.69 (m, 1H), 7.25-7.48 (m,5H), 7.58-7.65 (m, 1H), 8.25 (s, 1H) and 8.44-8.54 (m, 1H).

MS ES⁺: 384

Example 702-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 69) from N-[(1S,2S)-2-aminocyclopentyl]-2-chlorobenzamidehydrochloride (Intermediate 19; 100 mg, 0.363 mmol) and2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 80 mg,0.436 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.51-1.64 (m, 2H), 1.65-1.76 (m, 2H),1.96-2.10 (m, 2H), 4.24-4.40 (m, 2H), 7.27-7.46 (m, 4H), 8.09-8.16 (m,1H), 8.44-8.50 (m, 1H) and 8.58 (s, 2H)

MS ES⁺: 385

Example 712-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 69) fromN-[(1S,2S)-2-aminocyclopentyl]-2-fluoro-6-methoxybenzamide hydrochloride(Intermediate 20; 50 mg, 0.17 mmol) and2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 38 mg, 0.21mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.59 (m, 2H), 1.65-1.75 (m, 2H),1.99-2.11 (m, 2H), 3.68 (s, 3H), 4.10-4.21 (m, 2H), 6.63-6.69 (m, 1H),6.74-6.82 (m, 1H), 6.83-6.89 (m, 1H), 7.30-7.39 (m, 2H), 7.58-7.65 (m,1H), 8.24 (s, 1H) and 8.40-8.47 (m, 1H)

MS ES⁺: 398

Example 722,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 69) from N-[(1S,2S)-2-amino cyclopentyl]-2,6-difluorobenzamidehydrochloride (Intermediate 21; 100 mg, 0.36 mmol) and2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 79 mg, 0.43mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.42-1.58 (m, 2H), 1.65-1.76 (m, 2H),2.01-2.13 (m, 2H), 4.12-4.25 (m, 2H), 6.61-6.67 (m, 1H), 7.07-7.15 (m,2H), 7.38-7.43 (m, 1H), 7.44-7.52 (m, 1H), 7.59-7.64 (m, 1H), 8.25 (s,1H) and 8.77-8.84 (m, 1H)

MS ES⁺: 386

Example 73N-[(1S,2S)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A solution of(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 22; 59 mg, 0.23 mmol), 2-(2H-1,2,3-triazol-2-yl)benzoicacid (CAS number 1001401-62-2; 51.5 mg, 0.27 mmol), EDC (65.2 mg, 0.34mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (52.4 mg, 0.34 mmol) andtriethylamine (0.095 ml, 0.68 mmol) in DCM (2 ml) was stirred at roomtemperature for 18 hours. The reaction mixture was diluted with DCM (3ml) and washed with HCl (aq, 1M, 2 ml) then a saturated solution ofsodium bicarbonate (2 ml). The organics were filtered through ahydrophobic frit and concentrated in vacuo. The resulting residue waspurified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.47-1.61 (m, 1H), 1.66-1.78 (m, 3H),1.83-2.03 (m, 2H), 3.03 (s, 3H), 4.32-4.48 (m, 1H), 4.69-4.86 (m, 1H),7.15-7.24 (m, 1H), 7.39-7.48 (m, 1H), 7.53-7.61 (m, 1H), 7.65-7.76 (m,1H), 7.90 (s, 2H), 8.29-8.39 (m, 2H), 8.41-8.49 (m, 1H)

MS ES⁺: 432

Example 745-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 73) from(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 22; 59 mg, 0.23 mmol) and5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 8; 56 mg,0.27 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.48-1.61 (m, 1H), 1.64-1.78 (m, 3H),1.81-2.03 (m, 2H), 3.31 (s, 3H), 4.29-4.45 (m, 1H), 4.70-4.88 (m, 1H),6.95-7.03 (m, 1H), 7.37-7.48 (m, 1H), 7.70-7.80 (m, 1H), 7.90 (s, 2H),8.28-8.34 (m, 1H), 8.41-8.50 (m, 2H)

MS ES⁺: 450

Example 752-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 73) from(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 22; 59 mg, 0.23 mmol) and2-fluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1186050-58-7;56 mg, 0.27 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.43-1.57 (m, 1H), 1.63-1.81 (m, 3H),1.85-1.94 (m, 1H), 1.96-2.07 (m, 1H), 3.07 (s, 3H), 4.39-4.52 (m, 1H),4.66-4.83 (m, 1H), 7.25-7.36 (m, 1H), 7.53-7.64 (m, 1H), 7.66-7.72 (m,1H), 7.95 (s, 2H), 8.33 (s, 1H), 8.43 (s, 1H), 8.56-8.59 (m, 1H)

MS ES⁺: 450

Example 76N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

A solution of(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 23; 60 mg, 0.20 mmol),3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 40 mg, 0.21 mmol), EDC (58 mg, 0.30 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (41 mg, 0.30 mmol) andtriethylamine (0.085 ml, 0.61 mmol) in DCM (1 ml) was stirred at roomtemperature over the weekend. The reaction was concentrated in vacuo andwas then purified by column chromatography (basic silica, 20 to 100%ethyl acetate/petrol) followed by column chromatography (silica, 0 to100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.39-1.84 (m, 4H), 1.95-2.24 (m, 2H),2.31 (s, 3H), 4.17-4.44 (m, 2H), 7.14-7.23 (m, 1H), 7.66-7.75 (m, 1H),7.88 (s, 2H), 8.17-8.33 (m, 2H), 8.62-8.70 (m, 1H), 8.71-8.81 (m, 1H)

MS ES⁺: 433

Example 77N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

A solution of(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 80 mg, 0.31 mmol),3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 70 mg, 0.37 mmol), EDC (177 mg, 0.92 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (126 mg, 0.922 mmol) and DIPEA(161 μl, 0.92 mmol) in dry DCM (1 ml) was stirred at room temperatureovernight. The mixture was partitioned between ethyl acetate (20 ml) andwater (10 ml). The organics were washed with water (2×10 ml), brine (10ml), dried over sodium sulfate and concentrated in vacuo. The residuewas purified by column chromatography (silica, 0 to 100% ethylacetate/petrol) followed by a trituration in pentane/diethyl ether toafford the title compound. ¹H NMR (400 MHz, DCM-d₂) δ ppm 1.43 (s, 3H),1.66-1.99 (m, 4H), 2.14-2.30 (m, 1H), 2.49-2.68 (m, 1H), 4.40-4.55 (m,1H), 7.38-7.48 (m, 1H), 7.56 (br. s., 1H), 7.62-7.67 (m, 1H), 7.69 (br.s., 1H), 7.84 (s, 2H), 8.08-8.14 (m, 1H), 8.23 (br. s., 1H), 8.65-8.70(m, 1H)

MS ES⁺: 433

Example 78N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 76) from(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 23; 60 mg, 0.20 mmol) and2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 40 mg,0.21 mmol) except this was purified only by column chromatography(silica, 0 to 100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.36-1.61 (m, 2H), 1.79-1.93 (m,2H), 2.04-2.20 (m, 1H), 2.38 (s, 3H), 2.49-2.60 (m, 1H), 3.76-3.88 (m,1H), 4.36-4.48 (m, 1H), 6.04-6.17 (m, 1H), 6.66-6.70 (m, 1H), 7.43-7.52(m, 3H), 7.53-7.64 (m, 2H), 7.77-7.82 (m, 1H), 8.20 (s, 1H)

MS ES⁺: 432

Example 79N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 76) from(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 23; 60 mg, 0.20 mmol) and2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 41 mg, 0.20mmol) except this was purified only by column chromatography (silica, 0to 100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.34-1.77 (m, 4H), 1.93-2.06 (m, 1H),2.09-2.27 (m, 4H), 4.08-4.22 (m, 1H), 4.25-4.39 (m, 1H), 7.18-7.26 (m,1H), 7.29-7.42 (m, 2H), 7.44-7.59 (m, 2H), 7.89-7.99 (m, 1H), 8.28 (s,1H), 8.39-8.48 (m, 1H), 8.57-8.63 (m, 2H)

MS ES⁺: 443

Example 805-Fluoro-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 76) from(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 23; 60 mg, 0.20 mmol) and5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 41 mg,0.20 mmol) except this was purified only by column chromatography(silica, 0 to 100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.39-1.82 (m, 4H), 1.94-2.07 (m, 1H),2.09-2.21 (m, 1H), 2.27 (s, 3H), 4.10-4.39 (m, 2H), 7.10-7.20 (m, 1H),7.21-7.32 (m, 2H), 7.34-7.43 (m, 1H), 7.96-8.05 (m, 1H), 8.27 (s, 1H),8.45-8.52 (m, 1H), 8.60-8.67 (m, 2H)

MS ES⁺: 461

Example 81N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 510 mg, 1.96 mmol) and2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 445 mg,2.35 mmol) except this was then partitioned between water (20 ml) andDCM (10 ml). The organics were washed with water (2×20 ml) and brine (20ml), filtered through a hydrophobic frit and concentrated in vacuo. Theresidue was purified by column chromatography (silica, 0-100% ethylacetate/petrol) followed by a trituration with diethyl ether andrecrystallised from IPA/water to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.38 (s, 3H), 1.42-1.53 (m, 1H),1.71-2.00 (m, 3H), 2.02-2.13 (m, 1H), 2.57-2.66 (m, 1H), 4.44-4.52 (m,1H), 6.17-6.24 (m, 1H), 7.54-7.59 (m, 1H), 7.64-7.72 (m, 3H), 7.74-7.77(m, 1H), 7.80 (s, 2H), 7.83-7.88 (m, 1H) and 8.28 (s, 1H)

MS ES⁺: 432

Example 82N-(2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 26; 287 mg, 1.01 mmol) in dry DMSO (3.4 ml)was added 2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2;202 mg, 1.11 mmol) and DIPEA (527 μl, 3.02 mmol). The reaction wasstirred at 140° C. for 1 hour and was then partitioned between ethylacetate and water. The organics were washed with water, brine, filteredthrough a hydrophobic frit and concentrated in vacuo. This was purifiedby column chromatography (silica, 0-100% ethyl acetate/petrol then 0-20%methanol/ethyl acetate) and was then recrystallised from ethyl acetateto afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37 (s, 3H), 1.55-1.74 (m, 3H),1.91-2.02 (m, 2H), 2.13-2.23 (m, 1H), 4.57-4.65 (m, 1H), 7.52-7.59 (m,2H), 7.61-7.67 (m, 1H), 7.73 (s, 1H), 7.78-7.82 (m, 1H), 7.88 (s, 1H),7.98 (s, 2H), 8.36 (s, 1H) and 8.53-8.59 (m, 1H)

MS ES⁺: 432

Example 83N-[(1R,2R)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 82) fromN-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 26; 287 mg, 1.01 mmol) and2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 202 mg,1.11 mmol) except this was then chirally separated using SFC (Watersprep30/MS system using 20% Ethanol, column AY) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.56-1.75 (m, 4H), 1.92-2.03 (m, 4H),2.14-2.24 (m, 1H), 4.56-4.66 (m, 1H), 7.52-7.59 (m, 2H), 7.61-7.68 (m,1H), 7.75 (s, 1H), 7.79-7.83 (m, 1H), 7.88 (s, 1H), 7.99 (s, 2H), 8.37(s, 1H), 8.55-8.62 (m, 1H)

MS ES⁺: 432

Example 845-Fluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 80 mg, 0.31 mmol) and5-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 8; 76 mg,0.37 mmol) except this was purified by column chromatography (0 to 50%ethyl acetate/petrol) followed by a trituration in pentane/diethyl etherto afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.36 (s, 3H), 1.53-1.75 (m, 3H),1.87-2.02 (m, 2H), 2.17-2.30 (m, 1H), 4.60-4.63 (m, 1H), 7.38-7.46 (m,1H), 7.46-7.56 (m, 1H), 7.65 (s, 1H), 7.80-7.87 (m, 1H), 7.90 (s, 1H),7.99 (s, 2H), 8.36 (s, 1H), 8.54-8.63 (m, 1H)

MS ES⁺: 450

Example 85N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(1H-pyrazol-1-yl)pyridine-2-carboxamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 80 mg, 0.31 mmol) and3-(1H-pyrazol-1-yl)pyridine-2-carboxylic acid (CAS number 1521232-19-8;70 mg, 0.37 mmol) except this was purified by column chromatography(silica, 50-100% ethyl acetate/petrol then 0-10% methanol/ethyl acetate)followed by reverse phase chromatography (C18 silica, 0-100% water (with0.05% ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33 (s, 3H), 1.54-1.78 (m, 3H),1.83-2.04 (m, 2H), 2.18-2.31 (m, 1H), 4.64-4.78 (m, 1H), 6.43-6.51 (m,1H), 7.61-7.71 (m, 3H), 7.91 (s, 1H), 8.06-8.13 (m, 2H), 8.37 (s, 1H),8.58-8.63 (m, 1H), 8.64-8.70 (m, 1H)

MS ES⁺: 432

Example 863-Ethoxy-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 80 mg, 0.31 mmol) and 3-ethoxypyridine-2-carboxylicacid (CAS number 103878-09-7; 51 mg, 0.31 mmol) except this was purifiedby column chromatography (silica, 0-100% ethyl acetate/petrol) followedby reverse phase chromatography (C18 silica, 0-100% water (with 0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.24-1.34 (m, 3H), 1.40 (s, 3H),1.54-1.78 (m, 3H), 1.85-1.96 (m, 1H), 2.00-2.11 (m, 1H), 2.22-2.36 (m,1H), 4.05-4.14 (m, 2H), 4.69-4.77 (m, 1H), 7.41-7.47 (m, 1H), 7.52-7.58(m, 1H), 7.82 (s, 1H), 8.01 (s, 1H), 8.12-8.17 (m, 1H), 8.30-8.46 (m,2H)

MS ES⁺: 410

Example 872-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 63 mg, 0.24 mmol) and2-chloro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 15; 65 mg,0.29 mmol) except this was purified by column chromatography (silica,0-30% ethyl acetate/petrol) followed by trituration with diethylether/pentane to afford the title compound.

¹H NMR (400 MHz, DCM-d2) δ ppm 1.43 (s, 3H), 1.44-1.57 (m, 1H),1.68-2.18 (m, 4H), 2.52-2.67 (m, 1H), 4.45-4.58 (m, 1H), 6.06-6.16 (m,1H), 7.47-7.56 (m, 2H), 7.75 (s, 2H), 7.83 (br. s., 1H), 7.89-8.01 (m,1H), 8.25 (s, 1H)

MS ES⁺: 466

Example 882,6-Difluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 63 mg, 0.24 mmol) and 2,6-difluorobenzoic acid (CASnumber 385-00-2; 46 mg, 0.29 mmol) except this was purified by columnchromatography (silica, 0-20% ethyl acetate/petrol) followed by reversephase chromatography (C18 silica, 0-100% water (with 0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.39 (s, 3H), 1.50-1.87 (m, 4H),1.98-2.15 (m, 1H), 2.30-2.44 (m, 1H), 4.80-4.90 (m, 1H), 7.12-7.22 (m,2H), 7.52 (s, 1H), 7.70 (s, 1H), 8.00-8.06 (m, 1H), 8.38 (s, 1H),8.69-8.76 (m, 1H)

MS ES⁺: 401

Example 893-Cyclopropyl-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 48 mg, 0.15 mmol), 3-cyclopropylpyridine-2-carboxylicacid (Intermediate 16; 33 mg, 0.20 mmol) and triethylamine (0.077 ml,0.55 mmol) except this was purified by column chromatography (silica,0-50% ethyl acetate/petrol) followed by column chromatography (silica,0-2.5% methanol/DCM) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 0.58-0.80 (m, 2H), 1.05-1.17 (m,2H), 1.39 (s, 3H), 1.61-2.08 (m, 4H), 2.12-2.24 (m, 1H), 2.63 (s, 1H),3.28-3.43 (m, 1H), 4.46-4.59 (m, 1H), 7.31-7.37 (m, 2H), 7.78-7.89 (m,2H), 8.23-8.33 (m, 2H), 8.33-8.38 (m, 1H)

MS ES¹: 406

Example 90N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(trifluoromethoxy)pyridine-2-carboxamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 48 mg, 0.15 mmol),3-(trifluoromethoxy)pyridine-2-carboxylic acid (CAS number 1221171-81-8;42 mg, 0.20 mmol) and triethylamine (0.077 ml, 0.55 mmol) except thiswas purified by column chromatography (silica, 0-50% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.38 (s, 3H), 1.60-2.04 (m, 4H),2.14-2.27 (m, 1H), 2.56-2.70 (m, 1H), 4.46-4.62 (m, 1H), 7.48-7.62 (m,2H), 7.74-7.80 (m, 1H), 7.83-7.89 (m, 1H), 7.92-8.01 (m, 1H), 8.25 (s,1H), 8.54-8.60 (m, 1H)

MS ES⁺: 450

Example 91N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 48 mg, 0.15 mmol), 2-(pyrimidin-2-yl)benzoic acid (CASnumber 400892-62-8; 41 mg, 0.20 mmol) and triethylamine (0.077 ml, 0.55mmol) except this was purified by column chromatography (silica, 0-100%ethyl acetate/petrol)) followed by reverse phase chromatography (C18silica, 0-100% water (with 0.05% ammonia)/acetonitrile) to afford thetitle compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.45 (s, 3H), 1.48-1.57 (m, 1H),1.72-1.99 (m, 3H), 2.04-2.12 (m, 1H), 2.63-2.70 (m, 1H), 4.46-4.58 (m,1H), 6.16-6.26 (m, 1H), 7.14-7.22 (m, 1H), 7.49-7.70 (m, 4H), 7.87 (s,1H), 8.09-8.17 (m, 1H), 8.27 (s, 1H), 8.64-8.70 (m, 2H)

MS ES⁺: 443

Example 925-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 77) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 90 mg, 0.35 mmol) and5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 38a; CASnumber 1293284-54-4; 93 mg, 0.42 mmol) except this was purified bycolumn chromatography (silica, 0-50% ethyl acetate/petrol) followed byrecrystallisation from diethyl ether/pentane to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37 (s, 3H), 1.51-1.77 (m, 3H),1.86-2.04 (m, 2H), 2.19-2.31 (m, 1H), 4.63-4.66 (m, 1H), 7.57-7.76 (m,3H), 7.81-7.88 (m, 1H), 7.91 (s, 1H), 8.03 (s, 2H), 8.37 (s, 1H),8.58-8.68 (m, 1H)

MS ES⁺: 466

Example 93N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 82) fromN-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 26; 200 mg, 0.70 mmol) and2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 141 mg,0.77 mmol) except this was purified by column chromatography (silica,0-100% ethyl acetate/petrol) followed by reverse phase chromatography(C18 silica, 0-100% water (with 0.05% ammonia)/acetonitrile) to affordthe title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.33 (s, 3H), 1.58-1.74 (m, 3H),1.84-2.01 (m, 2H), 2.25-2.34 (m, 1H), 4.42-4.51 (m, 1H), 7.52-7.59 (m,2H), 7.62-7.68 (m, 1H), 7.81-7.85 (m, 1H), 7.90 (s, 1H), 7.95 (s, 2H),8.54-8.66 (m, 2H) and 8.68-8.73 (m, 1H)

MS ES⁺: 432

Example 94N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 93) fromN-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 26; 200 mg, 0.70 mmol) and2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4; 141 mg,0.77 mmol) except this was then chirally separated using SFC(acetonitrile with diethylamine modifier, column Lux A2) to afford thetitle compound as a single enantiomer.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34 (s, 3H), 1.58-1.77 (m, 3H),1.84-2.03 (m, 2H), 2.25-2.36 (m, 1H), 4.42-4.53 (m, 1H), 7.50-7.61 (m,2H), 7.62-7.70 (m, 1H), 7.81-7.85 (m, 1H), 7.91 (s, 1H), 7.96 (s, 2H),8.54-8.67 (m, 2H), 8.68-8.73 (m, 1H)

MS ES⁺: 432

Example 95N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 82) fromN-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 26; 95 mg, 0.30 mmol) and2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 100 mg,0.55 mmol) except this was heated at 140° C. for 17 hours and thenpurified by column chromatography (basic silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.34 (s, 3H), 1.37-1.51 (m, 1H),1.68-1.90 (m, 2H), 1.90-2.00 (m, 1H), 2.02-2.14 (m, 1H), 2.39-2.52 (m,1H), 4.37-4.47 (m, 1H), 6.19 (br. s., 1H), 6.34-6.55 (m, 1H), 6.92-7.23(m, 1H), 7.44-7.56 (m, 2H), 7.57-7.69 (m, 2H), 7.76 (s, 2H), 7.78-7.84(m, 1H), 8.24 (s, 1H)

MS ES⁺: 431

Example 96N-(2-Methyl-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

A solution ofN-(2-amino-2-methylcyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 26; 150 mg, 0.47 mmol),2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 118 mg,0.49 mmol), BINAP (29 mg, 0.047 mmol),tris(dibenzylideneacetone)dipalladium(0) (21.34 mg, 0.023 mmol) andsodium tert-butoxide (63 mg, 0.65 mmol) in dry toluene (1.6 ml) wassealed, evacuated and purged with nitrogen. The reaction was heated at140° C. for 17 hours and was then partitioned between ethyl acetate andwater, washing with water, brine, dried over sodium sulfate andconcentrated in vacuo. The residue was purified by column chromatography(silica, 0-70% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.31 (s, 3H), 1.45-1.78 (m, 3H),1.80-2.14 (m, 3H), 4.39-4.50 (m, 1H), 6.39-6.47 (m, 1H), 6.78 (s, 1H),7.35-7.44 (m, 1H), 7.49-7.59 (m, 2H), 7.59-7.70 (m, 1H), 7.77-7.85 (m,1H), 7.92-8.02 (m, 3H), 8.47-8.58 (m, 1H)

MS ES⁺: 447

Example 975-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

To a solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 50 mg, 0.20 mmol) in DMF (3 ml) was added5-chloro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 38a; CASnumber 1293284-54-4; 45 mg, 0.204 mmol), TBTU (78 mg, 0.245 mmol) andDIPEA (40 mg, 0.306 mmol). The reaction was stirred at room temperaturefor 2 hours and was then diluted with water (25 ml) and extracted withethyl acetate (3×30 ml). The organics were washed with water (25 ml),brine (20 ml), dried over sodium sulfate and concentrated in vacuo. Theresidue was then purified by column chromatography (silica, 0-45% ethylacetate/n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.50-1.60 (m, 4H), 1.66-2.08 (m, 2H),4.03-4.10 (m, 1H), 4.18-4.22 (m, 1H), 6.65-6.67 (m, 1H), 7.33-7.35 (m,1H), 7.43-7.44 (m, 1H) 7.62-7.70 (m, 2H) 7.80-7.82 (m, 1H), 7.99 (s,2H), 8.29 (s, 1H), 8.53-8.55 (m, 1H)

MS ES⁺: 451

Example 983-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 97) from(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 50 mg, 0.20 mmol) and3-fluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1293284-51-1;42 mg, 0.20 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.41-1.44 (m, 2H), 1.61-1.68 (m, 2H),1.89-2.03 (m, 2H), 3.93-3.96 (m, 1H), 4.02-4.06 (m, 1H), 6.59-6.62 (m,1H) 7.31-7.36 (m, 2H) 7.59-7.68 (m, 3H), 8.01 (s, 2H), 8.28 (s, 1H),8.49-8.51 (m, 1H)

MS ES⁺: 435

Example 993,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 97) from(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 50 mg, 0.20 mmol) and3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)benzoic acid (Intermediate 40a; 46mg, 0.20 mmol) except this was purified by column chromatography(silica, 0-30% ethyl acetate/n-hexane) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.41-1.48 (m, 2H), 1.61-1.69 (m, 2H),1.88-1.93 (m, 2H), 3.91-3.96 (m, 1H), 4.04-4.08 (m, 1H), 7.58-7.61 (m,1H), 7.24-7.31 (m, 2H) 7.62-7.64 (m, 1H) 7.72-7.77 (m, 1H), 8.02 (s,2H), 8.28 (s, 1H), 8.56-8.58 (m, 1H)

MS ES⁺: 453

Example 1003-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

Prepared according to the procedure for5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 97) from(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 50 mg, 0.20 mmol) and3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 39 mg, 0.20 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.46-1.77 (m, 4H), 2.01-2.09 (m, 2H),4.07-4.21 (m, 2H), 6.65-6.67 (m, 1H), 7.38-7.40 (m, 1H), 7.62-7.65 (m,1H), 7.71-7.73 (m, 1H), 8.04 (s, 2H), 8.23-8.28 (m, 2H), 8.66-8.68 (m,1H), 8.68-8.76 (m, 1H)

MS ES⁺: 418

Example 1013-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide

Prepared according to the procedure for5-chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide(Example 97) from(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 50 mg, 0.20 mmol) and3-(1H-pyrazol-1-yl)pyridine-2-carboxylic acid (CAS number 1521232-19-8;38 mg, 0.20 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.41-1.71 (m, 4H), 1.99-2.05 (m, 2H),4.11-4.23 (m, 2H), 6.35-6.36 (m, 1H), 6.64-6.66 (m, 1H), 7.42-7.44 (m,1H), 7.63-7.68 (m, 3H), 7.96-7.96 (m, 1H), 8.08-8.10 (m, 1H), 8.27 (s,1H), 8.57-8.58 (m, 1H), 8.80-8.82 (m, 1H)

MS ES⁺: 417

Example 1022-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

To a solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 1; 1.09 g, 3.87 mmol) in DCM (13 ml) wasadded 2-fluoro-6-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number1186050-58-7; 0.802 g, 3.87 mmol), DIPEA (2.027 ml, 11.61 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (0.579 g, 4.26 mmol) and EDC(0.816 g, 4.26 mmol). The reaction was stirred at room temperature for17 hours and was then partitioned between DCM and a saturated solutionof sodium bicarbonate, filtered through a hydrophobic fit andconcentrated in vacuo. The residue was purified by column chromatography(basic silica, 0-100% ethyl acetate/petrol) and recrystallised from IPAto afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.41-1.59 (m, 2H), 1.59-1.76 (m, 2H),1.95-2.10 (m, 2H), 4.06-4.20 (m, 2H), 6.68 (d, J=8.8 Hz, 1H), 7.29-7.41(m, 2H), 7.57-7.66 (m, 2H), 7.71-7.75 (m, 1H), 8.00 (s, 2H), 8.25-8.28(m, 1H), 8.63 (d, J=6.8 Hz, 1H)

MS ES⁺: 435

Example 103N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

A solution of1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine(Intermediate 28; 57 mg, 0.21 mmol),3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 51 mg, 0.27 mmol), EDC (51 mg, 0.27 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (36 mg, 0.27 mmol) andtriethylamine (0.086 ml, 0.62 mmol) in DCM (3 ml) was stirred at roomtemperature for 18 hours. The reaction was then diluted with DCM (20 ml)and a saturated solution of sodium bicarbonate (10 ml), filtered througha hydrophobic frit and concentrated in vacuo. The residue was purifiedby column chromatography (silica, 0-100% ethyl acetate/petrol) to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.47 (s, 3H), 1.62-1.74 (m, 1H),1.78-1.89 (m, 2H), 1.91-2.01 (m, 1H), 2.15-2.26 (m, 1H), 2.68-2.78 (m,1H), 4.45-4.55 (m, 1H), 7.23-7.28 (m, 1H), 7.38 (br. s., 1H), 7.41-7.49(m, 1H), 7.61-7.66 (m, 1H), 8.08-8.11 (m, 1H), 8.13 (s, 1H) and8.65-8.70 (m, 1H).

MS ES⁺: 450

Example 105N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A solution ofN-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 4; 100 mg, 0.33 mmol),2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 65 mg,0.36 mmol) and DIPEA (42 mg, 0.33 mmol) in dry DMSO (1.1 ml) wassubjected to microwave irradiation at 140° C. for 1 hour. The reactionwas filtered through cotton wool before being purified by reverse phasepreparative HPLC (eluted with acetonitrile/water containing 0.1%ammonia) to afford the title compound.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.41-1.77 (m, 4H), 1.91-2.15 (m, 2H),4.17-4.40 (m, 2H), 7.32-7.44 (m, 2H), 7.44-7.54 (m, 1H), 7.54-7.66 (m,1H), 7.68-7.81 (m, 2H), 7.82-7.92 (m, 2H), 8.14-8.22 (m, 1H), 8.35-8.46(m, 1H)

MS ES⁺: 435

Example 106N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 105) from N-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride(Intermediate 4; 100 mg, 0.33 mmol) and3-chloro-2-fluoro-5-(trifluoromethyl)pyridine (CAS number 72537-17-8; 71mg, 0.36 mmol) except this was then further purified using columnchromatography (basic silica, 0-100% ethyl acetate/petrol) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.46-1.63 (m, 2H), 1.63-1.77 (m, 2H),1.91-2.05 (m, 1H), 2.11-2.23 (m, 1H), 4.15-4.25 (m, 1H), 4.26-4.39 (m,1H), 7.17-7.20 (m, 1H), 7.38-7.45 (m, 1H), 7.46-7.52 (m, 1H), 7.56-7.64(m, 1H), 7.77 (d, J=7.6 Hz, 1H), 7.82 (s, 2H), 7.95-7.99 (m, 1H),8.32-8.37 (m, 1H), 8.48 (d, J=7.6 Hz, 1H)

MS ES⁺: 451

Example 107N-[(1S,2S)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 105) fromN-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 4; 100 mg, 0.33 mmol) and3-bromo-2-chloro-5-(trifluoromethyl)pyridine (CAS number 71701-92-3; 93mg, 0.36 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40-1.62 (m, 2H), 1.62-1.78 (m, 2H),1.91-2.03 (m, 1H), 2.14-2.27 (m, 1H), 4.08-4.19 (m, 1H), 4.27-4.39 (m,1H), 7.01-7.03 (m, 1H), 7.39-7.45 (m, 1H), 7.46-7.52 (m, 1H), 7.57-7.65(m, 1H), 7.75-7.79 (m, 1H), 7.81 (s, 2H), 8.08-8.12 (m, 1H), 8.36-8.40(m, 1H), 8.47-8.50 (m, 1H)

MS ES⁺: 495, 497

Example 108N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A mixture ofN-[(1S,2S)-2-{[3-bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 107; 67 mg, 0.14 mmol), methylboronic acid (CAS number13061-96-6; 24 mg, 0.41 mmol), tetrakis(triphenylphosphine)palladium (16mg, 0.014 mmol) and potassium carbonate (aq. 2 M, 271 μl, 0.54 mmol) in1,4-dioxane (450 μl) was sealed, evacuated and purged with nitrogen andthen subjected to microwave irradiation at 140° C. for 30 minutes. Thereaction was partitioned between ethyl acetate and water, washing withwater, brine, dried over magnesium sulfate and concentrated in vacuo.This was then purified by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.38-1.51 (m, 1H), 1.52-1.62 (m, 1H),1.63-1.76 (m, 2H), 1.91-2.03 (m, 1H), 2.05 (s, 3H), 2.14-2.27 (m, 1H),4.06-4.18 (m, 1H), 4.21-4.33 (m, 1H), 6.60-6.64 (m, 1H), 7.37-7.45 (m,1H), 7.45-7.55 (m, 2H), 7.57-7.65 (m, 1H), 7.71-7.80 (m, 3H), 8.19-8.22(m, 1H), 8.49-8.52 (m, 1H)

MS ES⁺: 431

Example 109N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A mixture ofN-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 29; 170 mg, 0.38 mmol), cyclopropylboronic acid (CASnumber 411235-57-9; 97 mg, 1.13 mmol), potassium carbonate (aq. 2 M, 752μl, 1.51 mmol) and tetrakis(triphenylphosphine)palladium (44 mg, 0.038mmol) in 1,4-dioxane (1.3 ml) was sealed, purged and evacuated withnitrogen and then subjected to microwave irradiation 120° C. for 1 hour.The reaction was partitioned between ethyl acetate and water, washedwith water, brine, dried over magnesium sulfate and concentrated invacuo. This was then purified by reverse phase preparative HPLC (elutedwith acetonitrile/water containing 0.1% ammonia) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.81-0.89 (m, 1H), 0.89-1.05 (m, 3H),1.45-1.64 (m, 2H), 1.65-1.77 (m, 2H), 1.96-2.07 (m, 1H), 2.10-2.23 (m,2H), 4.15-4.25 (m, 1H), 4.29-4.40 (m, 1H), 7.41-7.46 (m, 1H), 7.47-7.54(m, 2H), 7.57-7.64 (m, 1H), 7.74-7.78 (m, 1H), 7.81 (s, 2H), 8.20 (s,1H), 8.50-8.53 (m, 1H)

MS ES⁺: 458

Example 110N-[(1S,2S)-2-{[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 109) fromN-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 29; 170 mg, 0.38 mmol) and4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (CAS number126726-62-3; 190 mg, 1.13 mmol) except this was then dissolved inmethanol (1.4 ml) and to this was then added palladium on carbon (10%wt, 50% wet) (15 mg, 0.014 mmol) and the resulting mixture was stirredunder a balloon of hydrogen gas for 2 hours. The reaction was filteredthrough diatomaceous earth (commercially sold under the trade mark“Celite”) and concentrated in vacuo to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.11-1.15 (m, 3H), 1.14-1.17 (m, 3H),1.42-1.63 (m, 2H), 1.63-1.77 (m, 2H), 1.93-2.05 (m, 1H), 2.10-2.22 (m,1H), 3.11-3.22 (m, 1H), 4.14-4.26 (m, 1H), 4.30-4.41 (m, 1H), 7.27-7.29(m, 1H), 7.36-7.43 (m, 1H), 7.44-7.52 (m, 1H), 7.56-7.65 (m, 1H),7.73-7.82 (m, 3H), 8.27 (s, 1H), 8.48-8.51 (m, 1H)

MS ES⁺: 460

Example 111N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 109) fromN-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 29; 170 mg, 0.38 mmol) and2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS number75927-49-0; 174 mg, 1.13 mmol) except this was then dissolved inmethanol (1.4 ml) and to this was then added palladium on carbon (10%wt, 50% wet) (15 mg, 0.014 mmol) and the resulting mixture was stirredunder a balloon of hydrogen gas for 2 hours. The reaction was filteredthrough diatomaceous earth (commercially sold under the trade mark“Celite”) and concentrated in vacuo to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.15-1.19 (m, 3H), 1.42-1.65 (m, 2H),1.64-1.77 (m, 2H), 1.93-2.05 (m, 1H), 2.10-2.22 (m, 1H), 2.55-2.70 (m,2H), 4.12-4.23 (m, 1H), 4.28-4.40 (m, 1H), 7.21-7.25 (m, 1H), 7.40-7.45(m, 1H), 7.46-7.53 (m, 1H), 7.57-7.65 (m, 1H), 7.72-7.80 (m, 3H), 8.28(s, 1H), 8.51-8.55 (m, 1H)

MS ES⁺: 446

Example 112N-[(1S,2S)-2-[(5-Cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A mixture ofN-[(1S,2S)-2-[(5-bromopyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamideandN-[(1S,2S)-2-[(5-chloropyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 30a and 30b; 100 mg, 0.23 mmol), cyclopropylboronic acid(CAS number 411235-57-9; 60 mg, 0.70 mmol), sodium carbonate (aq. 2 M,350 μl, 0.70 mmol) and tetrakis(triphenylphosphine)palladium (27 mg,0.023 mmol) in 1,4-dioxane (778 μl) was sealed, purged and evacuatedwith nitrogen and then subjected to microwave irradiation at 100° C. for1 hour. To this was then added further cyclopropylboronic acid (CASnumber 411235-57-9; 60 mg, 0.70 mmol) andtetrakis(triphenylphosphine)palladium (27 mg, 0.023 mmol). The reactionwas sealed, purged and evacuated with nitrogen and again subjected tomicrowave irradiation at 140° C. for 20 minutes. The reaction waspartitioned between ethyl acetate and water, washed with water, brine,dried over magnesium sulfate and concentrated in vacuo. The resultingresidue was purified by column chromatography (silica, 0-100% ethylacetate/petrol) and then purified by reverse phase preparative HPLC(eluted with acetonitrile/water containing 0.1% formic acid) and furtherpurified by column chromatography (basic silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 0.77-0.92 (m, 4H), 1.40-1.60 (m, 2H),1.68-1.94 (m, 3H), 2.14-2.29 (m, 2H), 3.80-3.91 (m, 1H), 3.99-4.10 (m,1H), 6.65-6.73 (m, 1H), 7.43-7.59 (m, 4H), 7.64 (s, 2H), 7.68-7.72 (m,1H), 7.74-7.78 (m, 1H) and 7.84 (br. s., 1H).

MS ES⁺: 390

Example 113N-[(1S,2S)-2-{[5-(Propan-2-yl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-[(5-cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 112) fromN-[(1S,2S)-2-[(5-bromopyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamideandN-[(1S,2S)-2-[(5-chloropyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 30a and 30b; 100 mg, 0.23 mmol) and4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (CAS number126726-62-3; 165 mg, 0.98 mmol) except this was purified only by columnchromatography (silica, 0-100% ethyl acetate/petrol) and then wasdissolved in ethanol (2.5 ml). To this was then added palladium oncarbon (10% wt, 50% wet) (26 mg, 0.025 mmol) and the resulting mixturewas stirred under a balloon of hydrogen gas for 2 hours. The reactionwas filtered through diatomaceous earth (commercially sold under thetrade mark “Celite”) and concentrated in vacuo. This was purified bycolumn chromatography (basic silica, 0-100% ethyl acetate/petrol) toafford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.13-1.20 (m, 6H), 1.37-1.57 (m, 2H),1.58-1.72 (m, 2H), 1.93-2.07 (m, 2H), 2.81-2.91 (m, 1H), 3.95-4.09 (m,2H), 6.72-6.78 (m, 1H), 7.40-7.44 (m, 1H), 7.46-7.51 (m, 1H), 7.57-7.62(m, 1H), 7.75-7.78 (m, 1H), 7.80-7.82 (m, 1H), 7.92-7.93 (m, 1H), 7.94(s, 2H), 8.35-8.39 (m, 1H).

MS ES⁺: 392

Example 114N-[(1S,2S)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-[(5-cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 112) fromN-[(1S,2S)-2-[(5-bromopyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamideandN-[(1S,2S)-2-[(5-chloropyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 30a and 30b; 100 mg, 0.23 mmol) and2-ethenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (CAS number75927-49-0; 151 mg, 0.98 mmol) except this was purified only by columnchromatography (silica, 0-100% ethyl acetate/petrol) and then wasdissolved in ethanol (1.4 ml). To this was then added palladium oncarbon (10% wt, 50% wet) (15 mg, 0.014 mmol) and the resulting mixturewas stirred under a balloon of hydrogen gas for 2 hours. The reactionwas filtered through diatomaceous earth (commercially sold under thetrade mark “Celite”) and concentrated in vacuo. This was purified bycolumn chromatography (basic silica, 0-100% ethyl acetate/petrol) toafford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.17-1.25 (m, 3H), 1.42-1.67 (m, 2H),1.68-1.94 (m, 3H), 2.15-2.29 (m, 2H), 2.59-2.68 (m, 2H), 3.95 (br. s.,1H), 4.02-4.13 (m, 1H), 6.77 (br. s., 1H), 7.43-7.69 (m, 6H), 7.74-7.80(m, 1H) and 8.07 (br. s., 1H).

MS ES⁺: 378

Example 1152-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide

A mixture ofN-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 4; 75 mg, 0.24 mmol),2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 59 mg,0.24 mmol), BINAP (15 mg, 0.024 mmol),tris(dibenzylideneacetone)dipalladium(0) (11 mg, 0.012 mmol) and sodiumtert-butoxide (33 mg, 0.34 mmol) in dry toluene (2.4 ml) was sealed,evacuated and purged with nitrogen and heated at 110° C. for 17 hours.The reaction was partitioned between ethyl acetate and water, washingwith water, brine, filtered through a hydrophobic frit and concentratedin vacuo. The residue was purified by column chromatography (silica,0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.37-1.58 (m, 2H), 1.59-1.73 (m, 2H),1.92-2.08 (m, 2H), 3.96-4.08 (m, 2H), 6.58-6.65 (m, 1H), 6.81-6.90 (m,1H), 7.40-7.46 (m, 2H), 7.46-7.53 (m, 1H), 7.56-7.65 (m, 1H), 7.74-7.81(m, 1H), 7.93-8.01 (m, 3H), 8.33-8.42 (m, 1H)

MS ES⁺: 433

Example 1175-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide

A solution ofN-[(1S,2S)-2-aminocyclopentyl]-5-chloro-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 31; 120 mg, 0.35 mmol),2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 127 mg,0.53 mmol) and potassium tert-butoxide (118 mg, 1.05 mmol) in toluene(10 ml) was degassed under a nitrogen atmosphere for 15 minutes. To thiswas then added BINAP (22 mg, 0.035 mmol) andtris(dibenzylideneacetone)dipalladium(0) (32 mg, 0.035 mmol) and thereaction mixture was again degassed for 15 minutes. The reaction mixturewas heated at 120° C. for 15 hours and then was diluted with water,filtered through diatomaceous earth (commercially sold under the trademark “Celite”) and extracted with ethyl acetate. The organics werewashed with water, brine, dried over sodium sulfate and concentrated invacuo. The crude product was purified by column chromatography (silica,0-2.5% methanol/DCM) to afford the title compound.

¹H NMR (400 MHz, DMSO-d) δ ppm 1.42-1.57 (m, 2H), 1.64-1.67 (m, 2H),1.96-2.04 (m, 2H), 4.00-4.07 (m, 2H), 6.60-6.63 (m, 1H), 6.91-6.92 (m,1H), 7.44-7.48 (m, 2H), 7.67-7.70 (m, 1H), 7.81-7.83 (m, 1H), 7.99-8.01(m, 3H), 8.56-8.57 (m, 1H)

MS ES⁺: 468

Example 118N-[(1S,2S)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A mixture ofN-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 4; 300 mg, 0.98 mmol),5-bromo-2-chloropyridine (CAS number 53939-30-3; 225 mg, 1.17 mmol),sodium tert-butoxide (150 mg, 1.56 mmol), BINAP (24 mg, 0.039 mmol) andtris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.019 mmol) in toluene(4 ml) was heated at 85° C. overnight. The mixture was partitionedbetween ethyl acetate (10 ml) and water (10 ml). The aqueous layer wasfurther extracted ici with ethyl acetate (3×20 ml). The combinedorganics were washed with water (2×20 ml), filtered through ahydrophobic frit and concentrated in vacuo. The crude product waspurified by column chromatography (silica, 0-100% ethyl acetate/petrol)to afford the title compound.

¹H NMR (300 MHz, DCM-d₂) δ ppm 1.40-1.52 (m, 2H), 1.66-1.88 (m, 2H),2.08-2.30 (m, 2H), 3.72-3.90 (m, 1H), 3.94-4.12 (m, 1H), 5.00-5.19 (m,1H), 6.34-6.45 (m, 1H), 6.59-6.79 (m, 1H), 7.39-7.61 (m, 4H), 7.66 (s,2H), 7.73-7.79 (m, 1H), 7.92-7.96 (m, 1H).

MS ES⁺: 427, 429

Example 119N-[(1S,2S)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-[(5-bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 118) from N-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide hydrochloride(Intermediate 4; 300 mg, 0.98 mmol) and5-bromo-2-chloro-3-methoxypyridine (CAS number 286947-03-3; 260 mg, 1.17mmol) except after heating overnight, to this was then added further5-bromo-2-chloro-3-methoxypyridine (CAS number 286947-03-3; 260 mg, 1.17mmol), sodium tert-butoxide (150 mg, 1.56 mmol), BINAP (24 mg, 0.039mmol) and tris(dibenzylideneacetone)dipalladium(0) (18 mg, 0.019 mmol)and the reaction was heated at 100° C. for 3 hours. The mixture waspartitioned between ethyl acetate (10 ml) and water (10 ml). The aqueouslayer was further extracted with ethyl acetate (3×10 ml). The combinedorganics were washed with brine, filtered through a hydrophobic frit andconcentrated in vacuo. The crude product was purified by columnchromatography (silica, 0-100% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.43-1.52 (m, 1H), 1.55-1.60 (m, 1H),1.73-1.84 (m, 2H), 2.12-2.23 (m, 1H), 2.29-2.40 (m, 1H), 3.82 (s, 3H),3.84-3.94 (m, 1H), 3.97-4.09 (m, 1H), 5.23-5.30 (m, 1H), 6.90-6.94 (m,1H), 7.25-7.35 (m, 1H), 7.41-7.49 (m, 3H), 7.51-7.59 (m, 1H), 7.65 (s,2H), 7.73-7.78 (m, 1H)

MS ES⁺: 457, 459

Example 1212-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure forN-[(1S,2S)-2-[(5-bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 118) fromN-[(1S,2S)-2-aminocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 4; 200 mg, 0.65 mmol) and2-bromo-4-(trifluoromethyl)pyridine (CAS number 175205-81-9; 147 mg,0.650 mmol) except this was heated to 140° C. for 17 hours to afford thetitle compound.

¹H NMR (300 MHz, DMSO-d₆) δ ppm 1.38-1.59 (m, 2H), 1.60-1.73 (m, 2H),1.92-2.10 (m, 2H), 3.96-4.15 (m, 2H), 6.71 (d, J=5.20 Hz, 1H), 6.85 (s,1H), 7.03-7.11 (m, 1H), 7.39-7.54 (m, 2H), 7.55-7.64 (m, 1H), 7.73-7.80(m, 1H), 7.94 (s, 2H), 8.17 (d, J=5.20 Hz, 1H), 8.33-8.43 (m, 1H)

MS ES⁺: 417

Example 122N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

A solution of(1S,2S)-1-N-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 33; 100 mg, 0.32 mmol),3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 66 mg, 0.35 mmol), EDC (91 mg, 0.47 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (65 mg, 0.47 mmol) andtriethylamine (0.132 ml, 0.95 mmol) in DCM (1 ml) was stirred at roomtemperature overnight. The reaction was partitioned between water (5 ml)and DCM (5 ml), filtered through a hydrophobic frit and concentrated invacuo. The resulting residue was purified by column chromatography(silica, 0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.49-1.73 (m, 2H), 1.80-1.91 (m, 2H),2.26-2.44 (m, 2H), 4.11-4.21 (m, 1H), 4.26-4.37 (m, 1H), 6.04-6.12 (m,1H), 7.54-7.60 (m, 1H), 7.61-7.64 (m, 1H), 7.76 (s, 2H), 7.97-8.02 (m,1H), 8.07-8.14 (m, 1H), 8.21-8.25 (m, 1H), 8.62-8.66 (m, 1H)

MS ES⁺: 452

Example 123N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 122) from(1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 34; 100 mg, 0.33 mmol) and3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 66 mg, 0.35 mmol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.48-1.73 (m, 2H), 1.77-1.93 (m, 2H),2.23-2.47 (m, 2H), 4.11-4.21 (m, 1H), 4.26-4.35 (m, 1H), 5.75-5.84 (m,1H), 7.27-7.34 (m, 1H), 7.55-7.62 (m, 1H), 7.77 (s, 2H), 7.97-8.03 (m,1H), 8.03-8.09 (m, 1H), 8.12 (s, 1H), 8.61-8.66 (m, 1H)

MS ES⁺: 436

Example 124N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 122) from(1S,2S)-1-N-[3-methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 35; 100 mg, 0.34 mmol) and3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 71 mg, 0.37 mmol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.34-1.55 (m, 1H), 1.57-1.79 (m, 3H),1.94-2.10 (m, 4H), 2.15-2.28 (m, 1H), 4.15-4.37 (m, 2H), 6.52-6.65 (m,1H), 7.42-7.58 (m, 1H), 7.67-7.78 (m, 1H), 7.87 (s, 2H), 8.15-8.31 (m,2H), 8.60-8.72 (m, 1H), 8.77-8.89 (m, 1H)

MS ES⁺: 432

Example 125N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

Prepared according to the procedure for N-[(1S,2S)-2-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide(Example 122) from(1S,2S)-1-N-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 41; 266 mg, 0.86 mmol) and3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 179 mg, 0.94 mmol) except this was further purified byreverse phase chromatography (C18 silica, 5-100% water (with 0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.20-1.27 (m, 3H), 1.39-1.52 (m, 1H),1.63-1.76 (m, 1H), 1.81-1.92 (m, 2H), 2.18-2.29 (m, 1H), 2.42-2.59 (m,3H), 4.00-4.11 (m, 1H), 4.26-4.37 (m, 1H), 6.38-6.47 (m, 1H), 7.55-7.61(m, 1H), 7.70 (s, 2H), 7.75-7.83 (m, 1H), 7.97-8.02 (m, 1H), 8.15 (s,1H), 8.61-8.67 (m, 1H).

MS ES⁺: 447

Example 126N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

A microwave vial was charged withN-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 42; 65 mg, 0.19 mmol),2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 38 mg,0.21 mmol) and DIPEA (99 μl, 0.57 mmol) in dry DMSO (630 μl). Thereaction was subjected to microwave irradiation at 140° C. for 30minutes. The reaction was partitioned between ethyl acetate and water.The organics were washed with water and brine, dried over magnesiumsulfate, filtered and concentrated in vacuo. The crude material waspurified by column chromatography (basic silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.00-2.22 (m, 2H), 2.56-2.76 (m, 2H),4.35-4.53 (m, 2H), 7.38-7.42 (m, 1H), 7.47-7.52 (m, 1H), 7.59-7.65 (m,1H), 7.76-7.81 (m, 1H), 7.93 (s, 2H), 8.05-8.08 (m, 1H), 8.16-8.25 (m,1H), 8.40 (s, 1H), 8.62-8.69 (m, 1H).

MS ES⁺: 454

Example 127N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 42; 120 mg, 0.39 mmol) in dry DMSO (1.2 ml)was added 2-chloro-5-(trifluoromethyl)pyrimidine (CAS number 69034-12-4;70 mg, 0.384 mmol) and DIPEA (183 μl, 1.047 mmol). The reaction mixturewas heated in a sealed vial at 140° C. for 17 hours then partitionedbetween ethyl acetate and water. The organics were washed with water,filtered through a hydrophobic frit and concentrated in vacuo. The crudematerial was purified by column chromatography (basic silica, 0-100%ethyl acetate/petrol) then was chirally separated using SFC (Watersprep30/MS system using 20% Isopropanol, Daicel AD 10 mm id×250 mm longcolumns at 30 ml/min, 40° C. and 100 bar) to afford the title compoundas a single enantiomer.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 2.06-2.25 (m, 2H), 2.56-2.70 (m, 2H),4.42-4.59 (m, 2H), 7.36-7.42 (m, 1H), 7.46-7.52 (m, 1H), 7.58-7.65 (m,1H), 7.76-7.81 (m, 1H), 7.93 (s, 2H), 8.20-8.24 (m, 1H), 8.60-8.70 (m,3H)

MS ES⁺: 454

Example 128N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 42; 120 mg, 0.349 mmol) in dry DMSO (1.2 ml)was added 2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3;70 mg, 0.38 mmol) and DIPEA (183 μl, 1.05 mmol). The reaction mixturewas heated in a sealed vial at 140° C. for 17 hours then partitionedbetween ethyl acetate and water. The organics were washed with water,filtered through a hydrophobic frit and concentrated in vacuo. The crudematerial was purified by column chromatography (basic silica, 0-100%ethyl acetate in petrol) and then was chirally separated using SFC(Waters prep30/MS system using 10% Ethanol, Daicel AD 10 mm id×250 mmlong columns at 30 ml/min, 40° C. and 100 bar) to afford the titlecompound as a single enantiomer.

¹H NMR (400 MHz, DCM-d₂) δ ppm 2.02-2.23 (m, 2H), 2.73-2.94 (m, 2H),4.23-4.39 (m, 2H), 5.90 (br. s, 1H), 6.56-6.63 (m, 1H), 6.84-6.96 (m,1H), 7.42-7.53 (m, 2H), 7.53-7.67 (m, 4H), 7.78-7.83 (m, 1H), 8.21 (s,1H)

MS ES⁺: 453

Example 129N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

Prepared according to the procedure forN-(4,4-difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 128) fromN-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 42; 120 mg, 0.349 mmol) and2-chloro-5-(trifluoromethyl)pyridine (CAS number 52334-81-3; 70 mg, 0.38mmol) and this was then chirally separated using SFC to afford the titlecompound as a single enantiomer.

¹H NMR (400 MHz, DCM-d₂) δ ppm 2.01-2.22 (m, 2H), 2.74-2.92 (m, 2H),4.25-4.39 (m, 2H), 6.06 (br. s, 1H), 6.54-6.65 (m, 1H), 6.81-6.94 (m,1H), 7.42-7.53 (m, 2H), 7.54-7.67 (m, 4H), 7.77-7.83 (m, 1H), 8.20 (s,1H)

MS ES⁺: 453

Example 130N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide

Method 1:

Prepared according to the procedure forN-(4,4-difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide(Example 126) fromN-(2-amino-4,4-difluorocyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamidehydrochloride (Intermediate 42; 65 mg, 0.19 mmol) and2-chloro-5-(trifluoromethyl)pyrazine (CAS number 799557-87-2; 38 mg,0.21 mmol) and this was then chirally separated using SFC (Watersprep30/MS system using 16% Isopropanol, Phenomenex Lux-C-4 10 mm id×250mm long columns at 30 ml/min, 40° C. and 100 bar) to afford the titlecompound as a single enantiomer.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.98-2.27 (m, 2H), 2.58-2.78 (m, 2H),4.32-4.57 (m, 2H), 7.36-7.45 (m, 1H), 7.46-7.54 (m, 1H), 7.58-7.69 (m,1H), 7.75-7.84 (m, 1H), 7.94 (s, 2H), 8.03-8.12 (m, 1H), 8.16-8.29 (m,1H), 8.41 (s, 1H), 8.67 (s, 1H)

MS ES⁺: 454

Method 2:

To a mixture of4,4-difluoro-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 45; 35 mg, 0.12 mmol) in dry DCM (400 μl) was added2-(2H-1,2,3-triazol-2-yl)benzoic acid (CAS number 1001401-62-2; 28 mg,0.15 mmol), EDC (71 mg, 0.37 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (51 mg, 0.38 mmol) and DIPEA (65μl, 0.37 mmol). The reaction was stirred at room temperature for 72hours then partitioned between ethyl acetate and water. The organicswere washed with water and brine, dried over sodium sulfate, filteredand concentrated in vacuo. The crude material was purified by columnchromatography (silica, 0-100% ethyl acetate in petrol) then this wasthen chirally separated using SFC (Waters prep30/MS system using 16%Isopropanol, Phenomenex Lux-C-4 10 mm id×250 mm long columns at 30ml/min, 40° C. and 100 bar) to afford the title compound as a singleenantiomer.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.98-2.27 (m, 2H), 2.58-2.78 (m, 2H),4.32-4.57 (m, 2H), 7.36-7.45 (m, 1H), 7.46-7.54 (m, 1H), 7.58-7.69 (m,1H), 7.75-7.84 (m, 1H), 7.94 (s, 2H), 8.03-8.12 (m, 1H), 8.16-8.29 (m,1H), 8.41 (s, 1H), 8.67 (s, 1H)

MS ES⁺: 454

Example 131N-[(1S,2S)-4,4-Difluoro-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-[(1S,2S)-2-amino-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 46; 50 mg, 0.16 mmol) in dry toluene (1.6 ml) was added2-bromo-5-(trifluoromethoxy)pyridine (CAS number 888327-36-4; 40 mg,0.17 mmol), BINAP (10 mg, 0.016 mmol),tris(dibenzylideneacetone)dipalladium(0) (8 mg, 8.74 μmol) and sodiumtert-butoxide (22 mg, 0.23 mmol). The reaction was placed under anatmosphere of nitrogen, sealed and heated at 120° C. for 17 hours thenpartitioned between ethyl acetate and water. The organics were washedwith water and brine, dried over sodium sulfate, filtered andconcentrated in vacuo. The crude material was purified by columnchromatography (silica, 10-70% ethyl acetate/petrol) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.87-2.22 (m, 2H), 2.53-2.78 (m, 2H),4.23-4.43 (m, 2H), 6.52-6.66 (m, 1H), 7.07-7.16 (m, 1H), 7.34-7.41 (m,1H), 7.45-7.53 (m, 2H), 7.57-7.64 (m, 1H), 7.77-7.82 (m, 1H), 7.95 (s,2H), 8.00-8.06 (m, 1H), 8.58-8.66 (m, 1H)

MS ES⁺: 469

Example 132N-[(1S,2S)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

A microwave vial was charged withN-[(1S,2S)-2-amino-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 46; 50 mg, 0.15 mmol),2,3-difluoro-5-(trifluoromethyl)pyridine (CAS number 89402-42-6; 29 mg,0.16 mmol) and DIPEA (26 μl, 0.15 mmol) in dry DMSO (485 μl). Thereaction mixture was subjected to microwave irradiation at 120° C. for30 minutes then partitioned between ethyl acetate and water. Theorganics were washed with water and brine, dried over sodium sulfate,filtered and concentrated in vacuo. The crude material was purified bycolumn chromatography (silica, 0-60% ethyl acetate/petrol) to afford thetitle compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 2.06-2.28 (m, 2H), 2.53-2.76 (m, 2H),4.46-4.69 (m, 2H), 7.32-7.38 (m, 1H), 7.42-7.51 (m, 1H), 7.55-7.65 (m,2H), 7.74-7.85 (m, 2H), 7.89 (s, 2H), 8.21 (s, 1H), 8.60-8.68 (m, 1H)

MS ES⁺: 471

Example 1352-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 116 mg, 0.41 mmol),2-(5-ethoxypyrimidin-2-yl)benzoic acid (Intermediate 47; 100 mg, 0.41mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (84 mg, 0.61 mmol), EDC(118 mg, 0.61 mmol) and triethylamine (0.171 ml, 1.23 mmol) in dry DCM(4 ml) was stirred at room temperature for 4 hours. The reaction waspartitioned between DCM and water, filtered through a hydrophobic fritand concentrated in vacuo. The crude product was purified by reversephase preparative HPLC (eluted with acetonitrile/water with 0.1%ammonia) and then by reverse phase preparative HPLC (eluted withacetonitrile/water containing 0.1% formic acid) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d2) δ ppm 1.40-1.43 (m, 3H), 1.46-1.91 (m, 4H),2.14-2.23 (m, 1H), 2.35-2.44 (m, 1H), 3.86-4.06 (m, 3H), 4.25-4.34 (m,1H), 6.38-6.42 (m, 1H), 6.67-6.72 (m, 1H), 7.40-7.55 (m, 3H), 7.83-7.87(m, 1H), 7.98-8.02 (m, 1H), 8.16-8.25 (m, 3H)

MS ES⁺: 473

Example 1362-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A solution of(1S,2S)-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 14; 14 mg, 0.05 mmol),2-fluoro-6-methoxybenzoic acid (CAS number 137654-21-8; 8.5 mg, 0.05mmol), TOTU (20 mg, 0.06 mmol) and 4-methylmorpholine (0.008 ml, 0.075mmol) in DMF (0.25 ml) was stirred at room temperature for 1 hour. Thereaction was then diluted with methanol and concentrated in vacuo. Theresulting residue was purified by reverse phase preparative HPLC (elutedwith acetonitrile/water with 0.1% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-d2) δ ppm 1.51-1.67 (m, 2H), 1.82-1.95 (m, 2H),2.20-2.32 (m, 1H), 2.32-2.43 (m, 1H), 3.70 (s, 3H), 4.05-4.17 (m, 1H),4.28-4.45 (m, 1H), 6.20 (br. s., 1H), 6.35-6.53 (m, 1H), 6.66-6.76 (m,2H), 7.24-7.36 (m, 1H), 7.98 (s, 1H), 8.21 (s, 1H)

MS ES⁺: 399

Example 137N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

To a solution of 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CASnumber 1228431-21-7; 155 mg, 0.77 mmol), DIPEA (0.27 ml, 1.54 mmol) and(1S,2S)-1-N-[3-methyl-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 35; 200 mg, 0.68 mmol) in DCM (3 ml) andacetonitrile (5 ml) was added HATU (293 mg, 0.77 mmol). The reaction wasstirred at room temperature for 16 hours and then concentrated in vacuo.The residue was purified by reverse phase column chromatography (C18silica, 0-100% water (0.1% formic acid)/acetonitrile) and then byreverse phase column chromatography (C18 silica, 5-95% water (0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d6) δ ppm 1.41-1.55 (m, 1H), 1.59-1.77 (m, 3H),1.99 (s, 3H), 2.00-2.11 (m, 1H), 2.13-2.27 (m, 1H), 4.12-4.35 (m, 2H),6.60-6.68 (m, 1H), 7.31-7.38 (m, 1H), 7.47-7.53 (m, 1H), 7.59-7.67 (m,1H), 8.15-8.26 (m, 2H), 8.62-8.71 (m, 3H), 8.78-8.86 (m, 1H)

MS ES⁺: 443

Example 138N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide

Prepared according to the procedure for2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 135) from(1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 34: 263 mg, 1.00 mmol) and2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 200 mg, 1.00mmol) except after the reaction was complete it was concentrated invacuo and the residue was purified by column chromatography (silica,0-50% ethyl acetate/petrol) and then was purified by reverse phasecolumn chromatography (C18 silica, 0-100% water (0.05%ammonia)/methanol) and triturated with DCM/petrol. The product wasfurther purified by reverse phase column chromatography (C18 silica,0-100% water (0.1% ammonia)/acetonitrile to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.49-1.66 (m, 2H), 1.73-1.92 (m,2H), 2.29-2.48 (m, 2H), 4.09-4.30 (m, 2H), 5.80-5.97 (m, 1H), 6.68-6.80(m, 1H), 6.99-7.11 (m, 1H), 7.28-7.33 (m, 1H), 7.40-7.58 (m, 3H),7.95-8.03 (m, 1H), 8.03-8.10 (m, 1H), 8.54-8.65 (m, 2H)

MS ES⁺: 446

Example 1395-Fluoro-N-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide

Prepared according to the procedure for2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 135) from(1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 34: 200 mg, 0.76 mmol) and5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number 1293284-57-7; 166mg, 0.76 mmol) except after the reaction was complete it wasconcentrated in vacuo and the residue was purified by reverse phasecolumn chromatography (C18 silica, 0-100% water (0.05%ammonia)/methanol), then by column chromatography (silica, 0-50% ethylacetate/petrol) and then triturated with DCM/petrol to afford the titlecompound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.50-1.66 (m, 2H), 1.77-1.94 (m,2H), 2.27-2.46 (m, 2H), 4.05-4.23 (m, 2H), 5.64-5.81 (m, 1H), 6.89-6.98(m, 1H), 7.02-7.07 (m, 1H), 7.11-7.17 (m, 1H), 7.18-7.24 (m, 1H),7.24-7.30 (m, 1H), 7.94-8.00 (m, 1H), 8.09-8.17 (m, 1H), 8.56-8.62 (m,2H)

MS ES⁺: 464

Example 140N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide

Prepared according to the procedure for2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 135) from(1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 34: 450 mg, 1.71 mmol) and2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2;349 mg, 1.71 mmol) except after the reaction was complete it waspartitioned between DCM and a saturated solution of sodium bicarbonate,filtered through a hydrophobic frit. The organics were loaded directlyon to a cation/anion mixed mode cartridge, eluted with DCM andconcentrated in vacuo. The resulting residue was purified by columnchromatography (silica, 0-100% ethyl acetate/petrol) and then purifiedby reverse phase column chromatography (C18 silica, 0-100% water (0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DCM-d2) δ ppm 1.57-1.72 (m, 2H), 1.82-1.94 (m, 2H),2.27-2.46 (m, 5H), 4.10-4.37 (m, 2H), 5.69-5.82 (m, 1H), 7.18-7.27 (m,1H), 7.28-7.37 (m, 1H), 7.40-7.50 (m, 1H), 7.53-7.64 (m, 2H), 7.88-8.00(m, 2H)

MS ES⁺: 450

Example 1412-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure for2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 135) from(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 23; 452 mg, 1.74 mmol) and2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2;355 mg, 1.74 mmol) except after the reaction was complete it waspartitioned between DCM and a saturated solution of sodium bicarbonate,filtered through a hydrophobic frit. The organics were loaded directlyon to a cation/anion mixed mode cartridge, eluted with DCM andconcentrated in vacuo. The resulting residue was purified by columnchromatography (silica, 0-100% ethyl acetate/petrol) and thenrecrystallised from MTBE/heptane to afford the title compound.

¹H NMR (400 MHz, CHLOROFORM-d) δ ppm 1.48-1.70 (m, 2H), 1.82-1.95 (m,2H), 2.24 (s, 3H), 2.26-2.37 (m, 1H), 2.42 (s, 3H), 2.49-2.62 (m, 1H),3.98-4.12 (m, 1H), 4.38-4.52 (m, 1H), 6.43-6.52 (m, 1H), 6.65-6.74 (m,1H), 7.50-7.65 (m, 3H), 7.97-8.05 (m, 1H), 8.12 (s, 1H)

MS ES⁺: 447

Example 142N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

Prepared according to the procedure for2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 135) from(1S,2S)-1-N-[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 48; 105 mg, 0.33 mmol) and3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 74 mg, 0.39 mmol) except after work-up, the organics wereloaded directly on to a cation/anion mixed mode cartridge, eluted withDCM, then methanol and 2M ammonia in methanol and concentrated in vacuo.The resulting residue was purified by column chromatography (silica,0-100% ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.79-1.05 (m, 4H), 1.45-1.80 (m, 4H),2.00-2.24 (m, 3H), 4.24-4.43 (m, 2H), 7.48-7.54 (m, 1H), 7.68-7.73 (m,1H), 7.90 (s, 2H), 8.18-8.21 (m, 1H), 8.22-8.26 (m, 1H), 8.65-8.69 (m,1H), 8.72-8.83 (m, 1H)

MS ES⁺: 459

Example 143N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

Prepared according to the procedure for2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide(Example 135) from(1S,2S)-1-N-[3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 48; 105 mg, 0.33 mmol) and3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7;79 mg, 0.39 mmol) except after work-up, the organics were loadeddirectly on to a cation/anion mixed mode cartridge, eluted with DCM,then methanol and 2M ammonia in methanol and concentrated in vacuo. Theresulting residue was purified by column chromatography (silica, 0-100%ethyl acetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 0.81-1.03 (m, 4H), 1.47-1.59 (m, 1H),1.63-1.79 (m, 3H), 2.02-2.15 (m, 2H), 2.16-2.26 (m, 1H), 4.28-4.39 (m,2H), 7.34-7.38 (m, 1H), 7.53-7.59 (m, 1H), 7.61-7.66 (m, 1H), 8.19-8.21(m, 1H), 8.22-8.26 (m, 1H), 8.64-8.68 (m, 1H), 8.68-8.71 (m, 2H),8.72-8.77 (m, 1H)

MS ES⁺: 470

Example 144N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

A solution of(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 50 mg, 0.192 mmol),3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7;46 mg, 0.231 mmol), triethylamine (80 ul, 0.576 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (34 mg, 0.250 mmol) and EDC (48mg, 0.250 mmol) in DCM (5 ml) was stirred at room temperature for 18hours. The reaction was partitioned between DCM (20 ml) and a saturatedsolution of sodium bicarbonate (10 ml). The aqueous layer was furtherextracted with DCM (20 ml) and the combined organics were filteredthrough a hydrophobic frit and concentrated in vacuo. The resultingresidue was purified by column chromatography (silica, 0-100% ethylacetate/petrol) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.42 (s, 3H), 1.64-1.99 (m, 4H),2.13-2.23 (m, 1H), 2.52-2.60 (m, 1H), 4.41-4.49 (m, 1H), 7.30-7.34 (m,1H), 7.55-7.67 (m, 4H), 8.08-8.12 (m, 1H), 8.22 (s, 1H), 8.64-8.67 (m,1H), 8.73-8.76 (m, 2H)

MS ES⁺: 444

Example 1452-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

Prepared according to the procedure forN-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide(Example 144) from(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 190 mg, 0.73 mmol) and2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2;179 mg, 0.88 mmol). After work-up, the crude material was loadeddirectly on to a cation/anion mixed mode cartridge, eluted with DCM andconcentrated in vacuo. This was then recrystallised from MTBE to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.41 (s, 3H), 1.50-1.63 (m, 1H),1.72-2.04 (m, 3H), 2.10-2.24 (m, 1H), 2.31 (s, 3H), 2.56-2.66 (m, 1H),4.46-4.65 (m, 1H), 6.34-6.52 (m, 1H), 7.59-7.74 (m, 4H), 7.82 (br. s.,1H), 8.01-8.09 (m, 1H), 8.21-8.31 (m, 1H)

MS ES⁺: 447

Example 146N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide

To a solution of1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]-1-methylcyclopentane-1,2-diamine(Intermediate 28; 0.225 g, 0.81 mmol) and 4-methylmorpholine (0.134 ml,1.217 mmol) in acetonitrile (5 ml) was added TOTU (0.399 g, 1.23 mmol)and 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number1228431-21-7; 0.163 g, 0.81 mmol). The reaction was stirred at roomtemperature for 1 hour and then was diluted with DCM and washed withbrine. The organics were dried over magnesium sulfate, concentrated invacuo and purified by SCX chromatography (2M ammonia in methanol). Theresulting residue was purified by column chromatography (silica, 0-10%methanol/DCM) and further purified by reverse phase chromatography (C18silica, 5-95% water (0.05% ammonia)/acetonitrile) to afford the titlecompound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.45 (s, 3H), 1.65-1.98 (m, 5H),2.52-2.59 (m, 1H), 4.38-4.48 (m, 1H), 7.36-7.41 (m, 1H), 7.64-7.70 (m,2H), 7.78-7.83 (m, 1H), 8.19 (s, 1H), 8.34-8.39 (m, 1H), 8.67-8.73 (m,3H), 8.94-9.00 (m, 1H)

MS ES⁺: 461

Example 147N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

A solution of(1S,2S)-1-N-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 34; 379 mg, 1.44 mmol),3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7;290 mg, 1.44 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (34 mg, 0.250mmol) (294 mg, 2.16 mmol), EDC (415 mg, 2.16 mmol) and triethylamine(0.604 ml, 4.32 mmol) in DCM (1 ml) was stirred at room temperature for16 hours. The reaction was added partitioned between DCM and assaturated solution of sodium bicarbonate. The organics were filteredthrough a hydrophobic frit and loaded directly on to a cation/anionmixed mode cartridge, eluted with DCM and concentrated in vacuo. Theresulting residue was purified by reverse phase chromatography (C18silica, 0-100% water (0.1% ammonia)/acetonitrile) to afford the titlecompound.

¹H NMR (400 MHz, DCM-d2) δ ppm 1.42-1.74 (m, 2H), 1.76-1.94 (m, 2H),2.21-2.33 (m, 1H), 2.33-2.49 (m, 1H), 4.06-4.34 (m, 2H), 5.93 (br. s.,1H), 7.18-7.34 (m, 2H), 7.47-7.58 (m, 1H), 7.94-8.04 (m, 1H), 8.11-8.31(m, 2H), 8.57-8.67 (m, 1H), 8.66-8.76 (m, 2H).

MS ES⁺: 447

Example 148N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

A solution of(1S,2S)-1-N-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 33; 327 mg, 1.03 mmol),3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7;250 mg, 1.24 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (211 mg, 1.55mmol), EDC (297 mg, 1.55 mmol) and triethylamine (0.432 ml, 3.10 mmol)in DCM (4 ml) was stirred at room temperature for 18 hours. The reactionwas partitioned between DCM (10 ml) and water (10 ml), filtered througha hydrophobic frit and concentrated in vacuo. The resulting residue waspurified by column chromatography (0-100% ethyl acetate/petrol) and wasthen by reverse phase chromatography (C18 silica, 5-95% water (0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.44-1.57 (m, 1H), 1.63-1.78 (m, 3H),1.95-2.10 (m, 1H), 2.14-2.27 (m, 1H), 4.27-4.36 (m, 2H), 7.21-7.25 (m,1H), 7.36-7.40 (m, 1H), 7.61-7.66 (m, 1H), 7.95-7.97 (m, 1H), 8.21-8.24(m, 1H), 8.34-8.37 (m, 1H), 8.64-8.67 (m, 1H), 8.69-8.72 (m, 3H)

MS ES⁺: 463, 465

Example 149N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide

A solution of(1S,2S)-1-N-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 41; 450 mg, 1.64 mmol),2-(3-methyl-1,2,4-oxadiazol-5-yl)benzoic acid (CAS number 475105-77-2;335 mg, 1.64 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (335 mg, 2.46mmol), EDC (472 mg, 2.46 mmol) and triethylamine (0.687 ml, 4.92 mmol)in DCM (5 ml) was stirred at room temperature for 16 hours. The reactionwas partitioned between DCM and a saturated solution of sodiumbicarbonate, filtered through a hydrophobic frit and loaded directly onto a cation/anion mixed mode cartridge, eluted with DCM and concentratedin vacuo. The resulting residue was purified by reverse phasechromatography (C18 silica, 0-100% water (0.1% ammonia)/acetonitrile)and recrystalised from MTBE/heptane to afford the title compound.

¹H NMR—(400 MHz, METHANOL-d4) δ ppm 1.25-1.32 (m, 3H), 1.55-1.96 (m,4H), 2.14-2.28 (m, 4H), 2.32-2.44 (m, 1H), 2.64-2.75 (m, 2H), 4.23-4.34(m, 1H), 4.40-4.51 (m, 1H), 7.45-7.51 (m, 1H), 7.61-7.71 (m, 2H),7.99-8.06 (m, 1H), 8.11 (s, 1H).

MS ES⁺: 461

Example 150N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

Prepared according to the procedure forN-[(1S,2S)-2-{[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide(Example 149) from(1S,2S)-1-N-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 41; 450 mg, 1.64 mmol) and3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7;330 mg, 1.64 mmol) to afford the title compound.

¹H NMR—(400 MHz, METHANOL-d4) δ ppm 1.18-1.28 (m, 3H), 1.54-1.95 (m,4H), 2.17-2.30 (m, 1H), 2.32-2.45 (m, 1H), 2.49-2.70 (m, 2H), 4.23-4.42(m, 2H), 7.29-7.36 (m, 1H), 7.62-7.71 (m, 1H), 8.17 (s, 1H), 8.28-8.35(m, 1H), 8.62-8.75 (m, 3H).

MS ES⁺: 458

Example 151N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide

Prepared according to the procedure forN-[(1S,2S)-2-{[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide(Example 149) from(1S,2S)-1-N-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 41; 450 mg 1.64 mmol) and2-(pyrimidin-2-yl)benzoic acid (CAS number 400892-62-8; 328 mg, 1.64mmol) to afford the title compound.

¹H NMR (400 MHz, METHANOL-d4) δ ppm 1.19-1.29 (m, 3H), 1.52-1.96 (m,4H), 2.12-2.23 (m, 1H), 2.29-2.44 (m, 1H), 2.47-2.71 (m, 2H), 4.16-4.28(m, 1H), 4.28-4.42 (m, 1H), 7.11-7.20 (m, 1H), 7.40-7.47 (m, 1H),7.50-7.64 (m, 2H), 8.00-8.06 (m, 1H), 8.14 (s, 1H), 8.50-8.59 (m, 2H).

MS ES⁺: 457

Example 153N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide

A solution of 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number1228431-21-7; 80 mg, 0.40 mmol),1-methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine(Intermediate 50; 103 mg, 0.40 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (81 mg, 0.60 mmol), EDC (114 mg,0.60 mmol) and DIPEA (0.208 ml, 1.19 mmol) in DCM (4 ml) was stirred atroom temperature for 4 days. The reaction was diluted with DCM (5 ml)and a saturated solution of sodium bicarbonate (5 ml), filtered througha hydrophobic frit and concentrated in vacuo. The crude product waspurified by reverse phase chromatography (C18 silica, 5-95% water (0.05%ammonia)/acetonitrile) to afford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.40 (s, 3H), 1.61-1.84 (m, 3H),1.87-2.00 (m, 2H), 2.29-2.42 (m, 1H), 4.43-4.54 (m, 1H), 7.38-7.43 (m,1H), 7.63-7.69 (m, 1H), 7.99 (s, 1H), 8.34-8.39 (m, 1H), 8.51-8.66 (m,2H), 8.68-8.71 (m, 1H), 8.72-8.75 (m, 2H), 8.80-8.86 (m, 1H)

MS ES⁺: 444

Example 154N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide(Example 153) from1-methyl-1-N-[5-(trifluoromethyl)pyrimidin-2-yl]cyclopentane-1,2-diamine(Intermediate 50; 150 mg, 0.58 mmol) and3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 110 mg, 0.58 mmol) and then triturated with heptane toafford the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ ppm 1.36 (s, 3H), 1.62-1.79 (m, 3H),1.88-2.05 (m, 2H), 2.24-2.35 (m, 1H), 4.47-4.58 (m, 1H), 7.72-7.76 (m,1H), 7.83 (s, 1H), 8.04 (s, 2H), 8.30-8.34 (m, 1H), 8.53-8.67 (m, 2H),8.68-8.72 (m, 1H), 8.86-8.92 (m, 1H)

MS ES⁺: 433

Example 155N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide(Example 153) from1-methyl-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine(Intermediate 51; 85 mg, 0.33 mmol),3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid (CAS number1252907-86-0; 75 mg, 0.33 mmol) and triethylamine (0.14 ml, 0.98 mmol)except this was then recrystallised from diisopropyl ether/pentane andthen triturated with diethyl ether to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.44 (s, 3H), 1.59-1.73 (m, 1H),1.74-2.05 (m, 3H), 2.13-2.27 (m, 1H), 2.49 (br. s., 1H), 4.43-4.52 (m,1H), 6.33 (br. s., 1H), 6.85 (br. s., 1H), 7.39-7.52 (m, 2H), 7.60-7.66(m, 1H), 7.84 (s, 2H), 8.07-8.12 (m, 1H), 8.25 (br. s., 1H), 8.65-8.70(m, 1H)

MS ES⁺: 432

Example 156N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide

Prepared according to the procedure forN-(2-methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide(Example 153) from1-methyl-1-N-[5-(trifluoromethyl)pyridin-2-yl]cyclopentane-1,2-diamine(Intermediate 51; 91 mg, 0.35 mmol),3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number 1228431-21-7;85 mg, 0.42 mmol) and triethylamine (0.147 ml, 1.06 mmol) except afterwork-up the organics were loaded directly on to a cation/anion mixedmode cartridge, eluted with DCM then with 2M ammonia in methanol andconcentrated in vacuo. The resulting residue was purified by reversephase chromatography (C18 silica, 5-100% water (0.05%ammonia)/acetonitrile) then recrystallised from MTBE/heptane to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.44 (s, 3H), 1.60-1.74 (m, 1H),1.75-2.02 (m, 3H), 2.12-2.23 (m, 1H), 2.47-2.58 (m, 1H), 4.38-4.48 (m,1H), 6.23 (br. s., 1H), 6.97 (br. s., 1H), 7.24-7.29 (m, 1H), 7.40-7.47(m, 1H), 7.53-7.60 (m, 2H), 8.08-8.12 (m, 1H), 8.25 (br. s., 1H),8.63-8.66 (m, 1H), 8.71-8.75 (m, 2H)

MS ES⁺: 443

Example 157N-[(1S,2S)-2-{[5-(Difluoromethoxy)pyridin-2-yl]amino}-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide

To a solution ofN-[(1S,2S)-2-amino-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide(Intermediate 46; 100 mg, 0.33 mmol) in dry toluene (3 ml) was added2-bromo-5-(difluoromethoxy)pyridine (CAS number 845827-14-7; 89 mg, 0.33mmol), BINAP (20 mg, 0.033 mmol),tris(dibenzylideneacetone)dipalladium(0) (15 mg, 0.016 mmol) and sodiumtert-butoxide (44 mg, 0.46 mmol). The reaction was placed under anatmosphere of nitrogen, sealed and heated at 110° C. for 2.5 hours thenfiltered through a thiol cartridge, eluting with ethyl acetate andwater. The filtrate was diluted with further ethyl acetate and water andthen partitioned. The organics were washed with water, dried overmagnesium sulfate, filtered and concentrated in vacuo. The crudematerial was purified by column chromatography (silica, 0-100% ethylacetate/petrol) then triturated with heptane and diethyl ether to affordthe title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.88-2.23 (m, 2H), 2.71-2.95 (m, 2H),4.07-4.32 (m, 2H), 6.19-6.69 (m, 2H), 7.12-7.20 (m, 1H), 7.23-7.31 (m,1H), 7.43-7.53 (m, 2H), 7.55-7.61 (m, 1H), 7.64 (s, 2H), 7.75-7.82 (m,2H)

MS ES⁺: 451

Example 158N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-5-fluoro-2-(pyrimidin-2-yl)benzamide

To a solution of 5-fluoro-2-(pyrimidin-2-yl)benzoic acid (CAS number1293284-57-7; 53 mg, 0.24 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol(33 mg, 0.24 mmol), EDC (46.3 mg, 0.241 mmol) and triethylamine (0.067ml, 0.48 mmol) in DCM (5 ml) was added(1S,2S)-1-N-[3-ethyl-5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 41; 50 mg, 0.161 mmol). The reaction mixturewas stirred at room temperature for 88 hours and then partitionedbetween DCM and a saturated solution of sodium bicarbonate, passingthrough a hydrophobic frit. The organics were loaded directly on to acation/anion mixed mode cartridge, eluted with DCM and concentrated invacuo. This was then purified by reverse phase chromatography (C18silica, 0-100% acetonitrile/water with 0.1% ammonia). The resultingaqueous was concentrated in vacuo and extracted with DCM. The organicswere concentrated in vacuo to afford the title compound.

¹H NMR (400 MHz, METHANOL-d₄) δ ppm 1.18-1.29 (m, 3H), 1.55-1.73 (m,2H), 1.77-1.90 (m, 2H), 2.07-2.26 (m, 1H), 2.29-2.41 (m, 1H), 2.45-2.72(m, 2H), 4.16-4.42 (m, 2H), 6.99-7.05 (m, 1H), 7.08-7.20 (m, 2H),7.22-7.36 (m, 1H), 8.03-8.18 (m, 2H), 8.42-8.57 (m, 2H)

MS ES⁺: 475

Example 159N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide

To a solution of(1S,2S)-1-N-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diaminehydrochloride (Intermediate 23; 100 mg, 0.34 mmol) in DCM (1.2 ml) wasadded 3-(pyrimidin-2-yl)pyridine-2-carboxylic acid (CAS number1228431-21-7; 81 mg, 0.40 mmol), 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol(69 mg, 0.51 mmol), EDC (97 mg, 0.51 mmol) and triethylamine (0.14 ml,1.01 mmol). The reaction was stirred at room temperature for 18 hoursand then partitioned between water and DCM, passing through ahydrophobic frit. The organics were concentrated in vacuo and thenpurified by column chromatography (0-100% ethyl acetate/petrol) toafford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.42-1.54 (m, 1H), 1.72-1.85 (m, 1H),1.86-1.97 (m, 2H), 2.20 (s, 3H), 2.21-2.31 (m, 1H), 2.52-2.64 (m, 1H),3.95-4.09 (m, 1H), 4.26-4.42 (m, 1H), 6.66-6.76 (m, 1H), 7.24-7.31 (m,1H), 7.52-7.62 (m, 1H), 7.98-8.08 (m, 2H), 8.21 (s, 1H), 8.64-8.72 (m,3H)

MS ES⁺: 444

Example 1602-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide

A solution of 2-(5-methyl-1,3,4-oxadiazol-2-yl)benzoic acid (CAS number898289-64-0; 82 mg, 0.40 mmol),(1S,2S)-1-methyl-1-N-[5-(trifluoromethyl)pyrazin-2-yl]cyclopentane-1,2-diamine(Intermediate 25; 80 mg, 0.31 mmol),3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (54 mg, 0.40 mmol), EDC (77 mg,0.40 mmol) and triethylamine (0.13 ml, 0.92 mmol) in DCM (3 ml) wasstirred at room temperature for 72 hours. The reaction was diluted withDCM and washed with a saturated solution of sodium bicarbonate, passingthrough a hydrophobic frit and concentrated in vacuo. The crude productwas purified by reverse phase chromatography (C18 silica, 5-100%acetonitrile/water with 0.05% ammonia) to afford the title compound.

¹H NMR (400 MHz, DCM-d₂) δ ppm 1.36 (s, 3H), 1.51-1.65 (m, 1H),1.71-1.92 (m, 2H), 1.94-2.05 (m, 1H), 2.10-2.20 (m, 1H), 2.49-2.53 (m,3H), 2.55-2.65 (m, 1H), 4.55-4.64 (m, 1H), 6.46-6.58 (m, 1H), 7.51 (br.s., 1H), 7.59-7.67 (m, 3H), 7.90-7.95 (m, 1H), 7.96-7.99 (m, 1H), 8.23(s, 1H)

MS ES⁺: 447

3. Biological Efficacy of Compounds of the Invention

Orexin antagonist activity was determined by measuring changes inintracellular calcium levels using a Ca²⁺ sensitive fluorescent dye. Thechanges in fluorescent signal were monitored by Fluorescent ImagingPlate Reader (FLIPR™) technology available from Molecular Devices, LLC,U.S.A. Orexin mediated increases in intracellular Ca²⁺ concentrationwere readily detected upon activation with orexin-A. Twenty-four hoursprior to the assay, RBL-2H3 cells stably expressing either human orexinreceptor 1 or human orexin receptor 2 were seeded in cell culture mediumin black, clear-bottom 384-well plates (commercially available fromCorning Inc., U.S.A.) and grown overnight at 37° C., 5% CO₂. On the dayof the assay, cell culture media was removed and cells were loaded withCalcium 5 Dye (commercially sold by Molecular Devices, LLC, U.S.A.) for1 hour at 37° C., 5% CO₂. Test compounds (at 10 point half logconcentration response curves from 10 μM) were added to cells for 15minutes prior to the addition of orexin-A to all wells, to achieve afinal concentration that produces approximately an 80% maximal response.The IC₅₀ values were determined from ten point concentration responsecurves. Curves were generated using the average of two wells for eachdata point. The results obtained are shown in the table below.

Results Human Orexin1R Human Orexin2R Example Number IC₅₀ (nM) IC₅₀ (nM)1 240 >10,000 2 870 >10,000 3 58 >10,000 4 520 >10,000 5 270 >10,000 651 >10,000 7 51 >10,000 8 110 >10,000 9 340 >10,000 10 59 >10,000 11170 >10,000 12 65 >10,000 13 99 >10,000 14 89 >10,000 15 49 >10,000 1654 >10,000 17 53 >10,000 18 57 >10,000 19 757 6105 20 875 >10,000 21 5766421 22 665 6160 23 792 3800 24 766 >10,000 25 472 >10,000 26622 >10,000 27 726 2000 28 776 >10,000 29 279 >10,000 30 370 >10,000 31122 >10,000 32 32 >10,000 33 890 >10,000 34 523 >10,000 35 693 >10,00036 207 >10,000 37 340 >10,000 38 49 >10,000 39 81 >10,000 40 35 >10,00041 644 >10,000 42 261 >10,000 43 289 >10,000 44 199 >10,000 45241 >10,000 46 172 >10,000 47 445 >10,000 48 88 >10,000 49 367 >10,00050 80 >10,000 51 301 >10,000 52 69 >10,000 53 93 >10,000 54 950 >10,00055 761 >10,000 56 166 >10,000 57 38 >10,000 58 934 >10,000 59161 >10,000 60 852 >10,000 61 321 >10,000 62 457 >10,000 63 450 >10,00064 57 >10,000 65 797 >10,000 66 180 >10,000 67 891 >10,000 68 297 161069 321 >10,000 70 678 >10,000 71 722 7600 72 479 >10,000 73 248 >10,00074 308 >10,000 75 279 >10,000 76 33 >10,000 77 12 >10,000 78 19 >10,00079 35 >10,000 80 35 >10,000 81 7 >10,000 82 21 7541 83 2500 1400 8422 >10,000 85 18 >10,000 86 129 >10,000 87 8 >10,000 88 166 >10,000 89140 >10,000 90 68 >10,000 91 6 >10,000 92 8 5569 93 35 >10,000 9428 >10,000 95 19 1067 96 86 1356 97 122 >10,000 98 160 >10,000 99153 >10,000 100 128 >10,000 101 310 >10,000 102 46 >10,000 103 8 7897105 39 >10,000 106 29 >10,000 107 27 >10,000 108 24 >10,000 10921 >10,000 110 43 3549 111 34 >10,000 112 476 >10,000 113 67 >10,000 114997 >10,000 115 175 >10,000 117 406 >10,000 118 368 >10,000 119 22 7800121 822 >10,000 122 32 >10,000 123 18 >10,000 124 21 >10,000 12514 >10,000 126 119 >10,000 127 68 >10,000 128 33 >10,000 129 633 8753130 77 >10,000 131 39 >10,000 132 12 >10,000 135 94 >10,000 136830 >10,000 137 34 >10,000 138 30 >10,000 139 32 >10,000 140 35 >10,000141 62 >10,000 142 12 8827 143 49 >10,000 144 13 >10,000 145 11 >10,000146 7 >10,000 147 24 >10,000 148 19 >10,000 149 25 >10,000 15043 >10,000 151 29 >10,000 153 66 >10,000 154 42 >10,000 155 8 >10,000156 11 >10,000 157 236 >10,000 158 5 >10,000 159 25 >10,000 160 29>10,000

The invention claimed is:
 1. A compound of formula

wherein R¹ represents a 5- or 6-membered heteroaryl group optionallysubstituted by at least one substituent selected from halogen, cyano,hydroxyl, C₃-C₆ cycloalkyl, C₁-C₃ alkyl, C₁-C₃ alkoxy, C₁-C₃alkoxycarbonyl, C₁-C₃ alkoxycarbonylamino, C₁-C₃ haloalkyl, C₁-C₃haloalkoxy, —NR⁴R⁵, C₃-C₆ cycloalkylamino, C₁-C₃ alkylcarbonyloxy, C₁-C₃alkylcarbonylamino, sulphonamido, C₁-C₃ alkylsulphonyl, C₁-C₃alkylsulphonylamino and —C(O)NR⁶R⁷; L represents a bond, CH₂, O or NR¹²;R^(a) represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃ haloalkylgroup; R^(b) represents a hydrogen atom or a C₁-C₃ alkyl or C₁-C₃haloalkyl group; X represents CH₂, CHF or CF₂; R² represents a hydrogenatom or a C₁-C₆ alkyl or C₃-C₆ cycloalkyl group; R³ represents a phenylgroup or a 5- or 6-membered heteroaryl group, all optionally substitutedby at least one substituent independently selected from halogen,hydroxyl, cyano, C₁-C₃ alkyl, C₁-C₃ haloalkyl, C₁-C₃ hydroxyalkyl, C₁-C₃alkoxy, C₁-C₃ haloalkoxy, C₂-C₄ alkenyl, C₁-C₃ alkylcarbonyloxy, C₁-C₃alkoxycarbonyl, —NR⁸R⁹, —C(O)NR¹⁰R¹¹, C₃-C₆ cycloalkyl, C₃-C₆cycloalkyloxy, C₃-C₆ cycloalkylmethyl or a 5- or 6-membered heteroarylgroup, the heteroaryl group itself being optionally substituted by atleast one substituent independently selected from C₁-C₆ alkyl, C₁-C₆alkoxy and C₁-C₆ haloalkoxy; R⁴ and R⁵ each independently represent ahydrogen atom or a C₁-C₃ alkyl or C₃-C₆ cycloalkyl group, or R⁴ and R⁵may together with the nitrogen atom to which they are attached form a 4-to 7-membered saturated heterocyclic ring optionally substituted by atleast one substituent independently selected from halogen, hydroxyl andC₁-C₃ alkoxy; R⁶ and R⁷ each independently represent a hydrogen atom ora C₁-C₃ alkyl or C₃-C₆ cycloalkyl group, or R⁶ and R⁷ may together withthe nitrogen atom to which they are attached form a 4- to 7-memberedsaturated heterocyclic ring optionally substituted by at least onesubstituent independently selected from halogen and hydroxyl; R⁸ and R⁹each independently represent a hydrogen atom or a C₁-C₃ alkyl or C₃-C₆cycloalkyl group, or R⁸ and R⁹ may together with the nitrogen atom towhich they are attached form a 4- to 7-membered saturated heterocyclicring optionally substituted by at least one substituent independentlyselected from halogen, hydroxyl and C₁-C₃ alkoxy; R¹⁰ and R¹¹ eachindependently represent a hydrogen atom or a C₁-C₃ alkyl or C₃-C₆cycloalkyl group, or R¹⁰ and R¹¹ may together with the nitrogen atom towhich they are attached form a 4- to 7-membered saturated heterocyclicring optionally substituted by at least one substituent independentlyselected from halogen and hydroxyl; and R¹² represents a hydrogen atom,methyl group or a C₂-C₃ alkylene chain that links to R¹ to form a 5- or6-membered ring; or a pharmaceutically acceptable salt thereof.
 2. Acompound according to claim 1, wherein R¹ represents a 5- or 6-memberedheteroaryl group containing one or two ring heteroatoms independentlyselected from nitrogen, oxygen and sulphur, the heteroaryl group beingoptionally substituted by one or two substituents independently selectedfrom halogen, C₁-C₃ alkyl and C₁-C₃ haloalkyl.
 3. A compound accordingto claim 1, wherein R¹ represents a 5- or 6-membered heteroaryl groupselected from pyridinyl, pyrimidinyl and pyrazinyl, all optionallysubstituted as defined in claim
 1. 4. A compound according to claim 3,wherein R¹ represents a group selected from: (i)4-(trifluoromethyl)pyridin-2-yl, (ii) 5-(trifluoromethyl)pyridin-2-yl,(iii) 5-(trifluoromethoxy)pyridin-2-yl, (iv)6-(trifluoromethyl)pyridin-2-yl, (v) 6-(trifluoromethyl)pyridin-3-yl,(vi) 5-chloropyridin-2-yl, (vii) 5-bromopyridin-2-yl, (viii)3-fluoro-5-(trifluoromethyl)pyridin-2-yl, (ix)3-chloro-5-(trifluoromethyl)pyridin-2-yl, (x)3-bromo-5-(trifluoromethyl)pyridin-2-yl, (xi)5-bromo-3-methoxypyridin-2-yl, (xii)3-methyl-5-(trifluoromethyl)pyridin-2-yl, (xiii)5-(trifluoromethyl)pyrimidin-2-yl, (xiv) 5-ethylpyrimidin-2-yl, (xv)5-(trifluoromethyl)pyrazin-2-yl, (xvi) 5-chloropyrazin-2-yl, (xvii)5-(ethyl)pyrazin-2-yl, (xviii) 5-(cyclopropyl)pyrazin-2-yl, (xix)5-(isopropyl)pyrazin-2-yl, (xx)3-methyl-5-(trifluoromethyl)pyrazin-2-yl, (xxi)3-ethyl-5-(trifluoromethyl)pyrazin-2-yl, (xxii)3-cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl, and (xxiii)3-isopropyl-5-(trifluoromethyl)pyrazin-2-yl.
 5. A compound according toclaim 1, wherein X represents CH₂.
 6. A compound according to claim 1,wherein L represents NH.
 7. A compound according to claim 1, wherein R²represents a hydrogen atom.
 8. A compound according to claim 1, whereinR³ represents a 5- or 6-membered heteroaryl group selected frompyridinyl, pyrimidinyl and pyrazinyl, all optionally substituted asdefined in claim
 1. 9. A compound according to claim 1, wherein R³represents a phenyl group optionally substituted by at least onesubstituent independently selected from fluorine, chlorine, C₁-C₃ alkyl,C₁-C₃ alkoxy or a 5- or 6-membered heteroaryl group, the heteroarylgroup itself being optionally substituted by one or two substituentsindependently selected from C₁-C₂ alkyl, C₁-C₂ alkoxy and C₁-C₂haloalkoxy.
 10. A compound according to claim 1, wherein R³ represents agroup selected from: (i) 2-fluorophenyl, (ii) 2-chlorophenyl, (iii)2-methylphenyl, (iv) 2-cyclopropylphenyl, (v) 2-methoxyphenyl, (vi)2-ethoxyphenyl, (vii) 2-(difluoromethoxy)phenyl, (viii) 3-methylphenyl,(ix) 3-methoxyphenyl, (x) 2,6-difluorophenyl, (xi) 2,6-dichlorophenyl,(xii) 2,6-dimethoxyphenyl, (xiii) 2,6-diethoxyphenyl, (xiv)2-ethoxy-5-methylphenyl, (xv) 2,5-dimethoxyphenyl, (xvi)2-fluoro-6-methoxyphenyl, (xvii) 5-fluoro-2-methoxyphenyl, (xviii)3-fluoro-2-methoxyphenyl, (xix) 2-(1H-1,2,4-triazol-1-yl)phenyl, (xx)2-(2H-1,2,3-triazol-2-yl)phenyl, (xxi)5-methyl-2-(1H-1,2,3-triazol-1-yl)phenyl, (xxii)5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl, (xxiii)5-fluoro-2-(1H-1,2,3-triazol-1-yl)phenyl, (xxiv)5-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (xxv)2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl, (xxvi)2-(pyrimidin-2-yl)phenyl, (xxvii) 5-fluoro-2-(pyrimidin-2-yl)phenyl,(xxviii) 2-(1H-pyrazol-1-yl)phenyl, (xxix) 2-(1H-imidazol-1-yl)phenyl,(xxx) 2-(1H-1,2,3-triazol-1-yl)phenyl, (xxxi)2-(pyrimidin-2-yl)-5-fluorophenyl, (xxxii)2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl, (xxxiii)2-methoxy-5-methylphenyl, (xxxiv)2-chloro-6-(2H-1,2,3-triazol-2-yl)phenyl, (xxxv)2-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl, (xxxvi)5-trifluoromethyl-2-(2H-1,2,3-triazol-2-yl)phenyl, (xxxvii)2-fluoro-6-(pyrazol-1-yl)phenyl, (xxxviii)5-fluoro-2-(pyrazol-1-yl)phenyl, (xxxix)5-methyl-2-(pyrazol-1-yl)phenyl, (xl) 2-bromo-6-methoxyphenyl, (xli)2-methoxy-6-(pyrazol-1-yl)phenyl, (xlii)5-chloro-2-(2H-1,2,3-triazol-2-yl)phenyl, (xliii)3-fluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (xliv)5-trifluoromethyl-2-(1H-1,2,3-triazol-1-yl)phenyl, (xlv)5-chloro-2-(1H-1,2,3-triazol-1-yl)phenyl, (xlvi)2,3-difluoro-6-(2H-1,2,3-triazol-2-yl)phenyl, (xlvii)5-cyclopropyl-2-(2H-1,2,3-triazol-2-yl)phenyl, (xlviii)5-chloro-2-(pyrazol-1-yl)phenyl, (xlix)3,5-difluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (l)2-(difluoromethyl)phenyl, (li) 2-(trifluoromethyl)phenyl, (lii)3,6-difluoro-2-(2H-1,2,3-triazol-2-yl)phenyl, (liii)2-cyclopropyl-6-fluorophenyl, (liv) 2-(5-ethoxypyrimidin-2-yl)phenyl,(lv) 3-(pyrimidin-2-yl)pyridin-2-yl, (lvi)3-ethoxy-6-methylpyridin-2-yl, (lvii) 3-(pyrazol-1-yl)pyridin-2-yl,(lviii) 3-(piperidin-1-yl)pyridin-2-yl, (lix)3-(trifluoromethoxy)pyridin-2-yl, (lx) 3-(ethoxy)pyridin-2-yl, (lxi)3-(cyclopropyl)pyridin-2-yl, (lxii) 3-chloropyridin-2-yl, (lxiii)3-bromopyridin-2-yl, (lxiv) 3-methoxypyridin-2-yl, (lxv)3-(propan-2-yloxy)pyridin-2-yl, (lxvi) 6-bromo-3-methoxypyridin-2-yl,(lxvii) 3-methoxy-6-methylpyridin-2-yl, and (lxviii)3-(2H-1,2,3-triazol-2-yl)pyridin-2-yl.
 11. A compound of formula (I) asdefined in claim 1 selected from the group consisting of:2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-[(5-Ethylpyrimidin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-[(5-Chloropyridin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-[(5-Chloropyrazin-2-yl)amino]cyclopentyl]-5-methyl-2-(2H-1,2,3-triazol-2-yl)benzamide;5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;5-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2R)-2-{[5-(trifluoromethyl)pyrazin-2-yl]oxy}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;2,6-Dimethoxy-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]oxy}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-(2-{[4-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-(2-{[5-(trifluoromethyl)pyridin-2-yl]methyl}cyclopentyl)benzamide;2,6-Dimethoxy-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;3-Bromo-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;2-Ethoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-Ethoxy-6-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;2-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2,6-Dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(1H-1,2,3-Triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Methoxy-5-methyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(Pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Fluoro-2-(pyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Chloro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Fluoro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Methyl-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;2-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(2H-1,2,3-Triazol-2-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Fluoro-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Fluoro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Methyl-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Bromo-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Methoxy-6-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-(Piperidin-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(1H-1,2,3-Triazol-1-yl)-5-(trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Chloro-2-(1H-1,2,3-triazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2,3-Difluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Cyclopropyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-(Trifluoromethoxy)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;5-Chloro-2-(1H-pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-Ethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(Trifluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-Cyclopropyl-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;3,6-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-(Difluoromethyl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Cyclopropyl-6-fluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;5-Methyl-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[6-(trifluoromethyl)pyridin-3-yl]amino}cyclopentyl]benzamide;N-Cyclobutyl-2,6-dimethoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2-Chloro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl]benzamide;2-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;2,6-Difluoro-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-{Methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;5-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;2-Fluoro-N-[(1S,2S)-2-{methyl[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;5-Fluoro-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1R,2R)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;5-Fluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(1H-pyrazol-1-yl)pyridine-2-carboxamide;3-Ethoxy-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide,2-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-6-(2H-1,2,3-triazol-2-yl)benzamide;2,6-Difluoro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;3-Cyclopropyl-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(trifluoromethoxy)pyridine-2-carboxamide;N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;5-Chloro-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;N-(2-Methyl-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;3-Fluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;3,5-Difluoro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;3-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;3-(1H-Pyrazol-1-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]pyridine-2-carboxamide;2-Fluoro-6-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Bromo-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-(Propan-2-yl)-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-[(5-Cyclopropylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[5-(Propan-2-yl)pyrazin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-[(5-Ethylpyrazin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;5-Chloro-2-(2H-1,2,3-triazol-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-[(5-Bromopyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-[(5-Bromo-3-methoxypyridin-2-yl)amino]cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;2-(2H-1,2,3-Triazol-2-yl)-N-[(1S,2S)-2-{[4-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;N-(4,4-Difluoro-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-4,4-Difluoro-2-{[5-(trifluoromethoxy)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-4,4-Difluoro-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;2-(5-Ethoxypyrimidin-2-yl)-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;2-Fluoro-6-methoxy-N-[(1S,2S)-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;5-Fluoro-N-[(1S,2S)-2-{[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-{[3-methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Cyclopropyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;2-(3-Methyl-1,2,4-oxadiazol-5-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;N-(2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}-2-methylcyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Fluoro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Chloro-5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(3-methyl-1,2,4-oxadiazol-5-yl)benzamide;N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-2-(pyrimidin-2-yl)benzamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyrimidin-2-yl]amino}cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide;N-(2-Methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]amino}cyclopentyl)-3-(pyrimidin-2-yl)pyridine-2-carboxamide;N-[(1S,2S)-2-{[5-(Difluoromethoxy)pyridin-2-yl]amino}-4,4-difluorocyclopentyl]-2-(2H-1,2,3-triazol-2-yl)benzamide;N-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-5-fluoro-2-(pyrimidin-2-yl)benzamide;N-[(1S,2S)-2-{[3-Methyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(pyrimidin-2-yl)pyridine-2-carboxamide;2-(5-Methyl-1,3,4-oxadiazol-2-yl)-N-[(1S,2S)-2-methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]benzamide;enantiomers thereof and pharmaceutically acceptable salts of any of theforegoing.
 12. A process for the preparation of a compound of formula(I) or a pharmaceutically acceptable salt thereof as defined in claim 1,which comprises (i) reacting a compound of formula

wherein L, X, R^(a), R^(b), R¹ and R² are as defined in formula (I),with a compound of formula

wherein R²⁰ represents a halogen atom or a hydroxyl group and R³ is asdefined in formula (I), or a salt thereof; or (ii) when L represents NHor N(CH₃), reacting a compound of formula

wherein R²⁵ represents a hydrogen atom or methyl group and X, R^(a),R^(b), R² and R³ are as defined in formula (I), with a compound offormula (V), R¹-LG¹, wherein LG¹ represents a leaving group and R¹ is asdefined in formula (I); and optionally thereafter carrying out one ormore of the following procedures: converting a compound of formula (I)into another compound of formula (I) removing any protecting groupsforming a pharmaceutically acceptable salt.
 13. A pharmaceuticalcomposition comprising a compound of formula (I) or a pharmaceuticallyacceptable salt thereof as claimed in claim 1, in association with apharmaceutically acceptable adjuvant, diluent or carrier, and optionallyone or more other therapeutic agents.
 14. A composition according toclaim 13, wherein the one or more other therapeutic agents are selectedfrom carbamazepine, olanzapine, quetiapine, verapamil, lamotrigine,oxcarbazepine, risperidone, aripiprazole, ziprasidone and lithium.
 15. Acompound of formula (I) or a pharmaceutically acceptable salt thereof asclaimed in claim 1 for use in treating schizophrenia, schizophreniformdisorder, schizoaffective disorder, cognitive disorders or pain.
 16. Acompound of formula (I) or a pharmaceutically acceptable salt thereof asclaimed in claim 1 for use in treating post-traumatic stress disorder,panic disorders or addiction.
 17. A compound of formula (I) as definedin claim 1, wherein the compound isN-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide,enantiomers thereof and pharmaceutically acceptable salts of any of theforegoing.
 18. A compound of formula (I) as defined in claim 1, whereinthe compound isN-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamide,enantiomers thereof and pharmaceutically acceptable salts of any of theforegoing.
 19. A compound of formula (I) as defined in claim 1, whereinthe compound isN-[(1S,2S)-2-Methyl-2-{[5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamideand pharmaceutically acceptable salts thereof.
 20. A compound of formula(I) as defined in claim 1, wherein the compound isN-[(1S,2S)-2-{[3-Ethyl-5-(trifluoromethyl)pyrazin-2-yl]amino}cyclopentyl]-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxamideand pharmaceutically acceptable salts thereof.